{"title": "PDF", "author": "PDF", "url": "http://geb.uni-giessen.de/geb/volltexte/2002/745/pdf/d020045.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": " \n \n \nAus dem Institut f\u00fcr Veterin\u00e4r-Pathologie \nder Justus-Liebig-Universit\u00e4t Gie\u00dfen \n \n \n \n \n \n \n \n \n \n \n \nUntersuchung der Wirksamkeit eines Impfstoffes \ngegen die Feline Infekti\u00f6se Peritonitis \nunter Tierheimbedingungen  \n \n \n \n \n \n \n \nINAUGURAL-DISSERTATION \nzur Erlangung des Doktorgrades beim \nFachbereich Veterin\u00e4rmedizin \nder Justus-Liebig-Universit\u00e4t Gie\u00dfen \n \n \n \n \n \n \nEingereicht von \nWOLF LEUKERT \n \n \n \n \nGie\u00dfen 2002  \n \n \nAus dem Institut f\u00fcr Veterin\u00e4r-Pathologie \nder Justus-Liebig-Universit\u00e4t Gie\u00dfen \n \nBetreuer: Prof. Dr. M. Reinacher \n \n \n \n \n \n \nUntersuchung der Wirksamkeit eines Impfstoffes \ngegen die Feline Infekti\u00f6se Peritonitis \nunter Tierheimbedingungen  \n \n \n \n \n \n \n \nINAUGURAL-DISSERTATION \nzur Erlangung des Doktorgrades beim \nFachbereich Veterin\u00e4rmedizin \nder Justus-Liebig-Universit\u00e4t Gie\u00dfen \n \n \n \n \n \n \nEingereicht von \nWOLF LEUKERT \nTierarzt aus Leipzig \n \n \n \nGie\u00dfen 2002  \n \n \n \n \n \n \n \nMit Genehmigung des Fachbereichs Veterin\u00e4rmedizin \nder Justus-Liebig-Universit\u00e4t Gie\u00dfen \n \n \n \n \nDekan:     Prof. Dr. Dr. h. c. B. Hoffmann    \n \n \n             \n \n \n \n1. Berichterstatter:    Prof. Dr. M. Reinacher     \n \n \n2. Berichterstatter:    H Doz Dr. A. Moritz      \n \n \n \n \n \n \n \n \nTag der m\u00fcndlichen Pr\u00fcfung:   12.02.2002       \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nMeinen Eltern  Inhalt \n Inhaltsverzeichnis \n \n                 S e i t e  \n \n1  Einleitung         1 \n2  Literatur\u00fcbersicht        2 \n2.1  Allgemeines und Historie       2 \n2.2  Erreger der Felinen Infekti\u00f6sen Peritonitis (FIP)    3 \n2.2.1  Coronaviren (CoV)        3 \n2.2.1.1  Morphologie         3 \n2.2.1.2  Chemisch-physikalische Eigenschaften     4 \n2.2.1.3  Antigenverwandschaft und Klassifizierung     4 \n2.2.1.4  Feline Coronaviren (FCoV)       5 \n2.2.1.4.1 Pr\u00e4valenz von FCoV-Infektionen      7 \n2.2.1.4.2 Epizootiologie der FCoV-Infektion      8 \n2.3  Epizootiologie der FIP        9 \n2.4  Pathogenese der FIP         10 \n2.5  Klinik und Krankheitsformen der FIP      11 \n2.6  Diagnostik der FIP        14 \n2.6.1  H\u00e4matologie und Serologie       15 \n2.6.1.1  Antik\u00f6rper-Bestimmung       16 \n2.6.1.1.1 Indirekte Immunfluoreszenztechnik (IFT)     16 \n2.6.1.2  Kompetitiver ELISA zum Nachweis von CoV-Immunkomplexen  17 \n2.6.2  Punktat          18 \n2.6.3  Virusnachweis         19 \n2.6.4  Zerebrospinalfl\u00fcssigkeit       19 \n2.6.5  Diagnoseschl\u00fcssel        20 \n2.6.6  Differentialdiagnosen der FIP       20 \n2.6.6.1  Differentialdiagnosen der effusiven FIP     20 \n2.6.6.2  Differentialdiagnosen der nichteffusiven FIP     21 \n2.7  Pr\u00e4vention         21 \n2.7.1  Vakzination         22 \n2.7.1.1  Primucell\u00ae F I P          2 4  \n2.8  Therapie         28 \n2.9  Prognose         30 Inhalt \n3  Material und Methoden       31 \n3.1  Versuchsaufbau        31 \n3.2  Versuchsdurchf\u00fchrung        33 \n3.2.1  Randomisierung        33 \n3.2.2  Zeitliches Management und Impfregime     36 \n3.2.3  Haltung der Tiere        37 \n3.2.3.1  Beschreibung der Versuchstierst\u00e4lle      38 \n3.2.4  Erforderliche Genehmigungen       39 \n3.2.4.1  Beh\u00f6rdliche Kontrollen       40 \n3.3  Versuchstiere         40 \n3.3.1  Spezifisch pathogenfreie (SPF) Tiere      40 \n3.3.2  Tierheimkatzen        41 \n3.4  Impfstoffe         42 \n3.4.1  Die Vakzine Primucell\u00aeF I P        4 2  \n3.4.2  Andere eingesetzte Impfstoffe       44 \n3.5  Angewandte Tests und Labormethoden     44 \n3.5.1  Kompetitiver ELISA zum Nachweis l\u00f6slicher Immunkomplexe \n  in Seren und Exsudaten FIP-verd\u00e4chtiger Katzen    44 \n3.5.1.1  Antigenbeschichtung der Mikrotiterplatten     44 \n3.5.1.2  Aufbereitung der Serum- und Exsudatproben     45 \n3.5.1.3  Probenvorbereitung        45 \n3.5.1.4  Durchf\u00fchrung des Tests       46 \n3.5.1.5  Auswertung der Me\u00dfergebnisse      47 \n3.5.2  Immunfluoreszenztest (IFT)       47 \n3.5.2.1  Testdurchf\u00fchrung        48 \n3.5.3  Reverse Transkriptase-Polymerase-Ketten-Reaktion (RT-PCR)  48 \n3.5.3.1  Isolierung und Kultivierung der Monozyten     49 \n3.5.3.2  RNA-Extraktion        49 \n3.5.3.3  DNase-Behandlung zur Entfernung kontaminierender genomischer DNA 50 \n3.5.3.4  Synthese der cDNA (RT-Reaktion)      51 \n3.5.3.5  Oligonukleotid-Primer        51 \n3.5.3.6  Polymerase-Ketten-Reaktion       52 \n3.5.3.7  Nachweis der PCR-Produkte mittels Agarosegel-Elektrophorese und  \n  Ethidiumbromid-F\u00e4rbung       53 \n3.5.3.8  Quantifizierung der PCR-Produkte      54 Inhalt \n3.5.3.9  Best\u00e4tigung der Spezifit\u00e4t der Banden      54 \n3.5.4  Fixierung der Gewebe        54 \n3.5.5  Histopathologische Pr\u00e4paration      55 \n3.5.6  Nachweis des Coronavirus-Antigens      55 \n4  Ergebnisse         57 \n4.1  Gewichtsentwicklung der SPF-Tiere      57 \n4.2  Serologische und andere Testergebnisse     58 \n4.3  Klinisch unauff\u00e4llige Tiere       59 \n4.4  Andere Todesursachen als FIP       59 \n4.5  Chronologische \u00dcbersicht der Todesf\u00e4lle     60 \n4.6  FIP-F\u00e4lle         61 \n4.7  Preventable fraction        63 \n4.8  Formen der FIP        65 \n4.8.1  Augenver\u00e4nderungen        65 \n4.9  FIP und andere Erkrankungen in der Population    67 \n4.10  Rohdaten in Tabellenform       67 \n5  Diskussion         71 \n5.1  Versuchsbedingungen        71 \n5.2  Infektionsstatus der SPF-Katzen und der Tierheimkatzen vor Beginn des  \n  V e r s u c h s          7 2  \n5.3  Impfung         73 \n5.4  FCoV/FIPV-Infektionsdruck       73 \n5.5  Nachweis der FCoV-Infektion       75 \n5.6  FIP-F\u00e4lle         75 \n5.7  Beurteilung anderer pathogenetischer relevanter Faktoren   76 \n5.7.1  Psychischer und sozialer Stre\u00df       77 \n5.7.2  Koinfektionen         77 \n5.7.3  Immunsuppression durch andere Ursachen     77 \n5.8  Beurteilung der Serologie       78 \n5.9  \u00dcberleben einer klinisch manifesten FIP     79 \n5.10  FIPV-Infektion ohne Entwicklung einer FIP     80 \n5.11  Auswertbarkeit des Versuchs       81 \n5.12  Beurteilung der Wirksamkeit des FIP-Impfstoffes    81 \n5.13  Abschlie\u00dfende Bemerkungen       83 \n6  Zusammenfassung        84 Inhalt \n7   S u m m a r y          8 6  \n8   L i t e r a t u r v e r z e i c h n i s         8 8  \n9  Anhang                  113 \n9.1  Abbildungen                  113 \n9.2  Diagramme                  120 \n9.3  L\u00f6sungen, Puffer und Bezugsquellen             137  \n9.3.1  ELISA                  137 \n9.3.2  PCR                  138 \n9.3.4  Bezugsquellen                139 \n9.5  Abk\u00fcrzungen                 142 Einleitung   1 \n1. Einleitung \n \nDie Feline Infekti\u00f6se Peritonitis (FIP) ist eine fatale systemische Erkrankung der Feliden, die \ndurch ein Coronavirus (CoV) hervorgerufen wird. Der klinische Verlauf ist nach Auftreten der \nSymptome progresssiv, die Prognose infaust, der Ausgang fast immer letal (Horzinek und \nOsterhaus, 1979a, b; Kriegleder und Geyer, 1984; Pedersen, 1987; Weiss, 1991; Lutz, 1992; Suter et al., 1993). Die Infektion betrifft vorra ngig Hauskatzen, die in gr\u00f6\u00dferen Populationen \nauf begrenztem Raum leben. Dementsprechend stellt die FIP haupts\u00e4chlich in Tierheimen, Zuchten und anderen Mehrfachhaltungen ein erhebliches Problem dar. Neben dem Katzenschnupfenkomplex und der Felinen Leuk\u00e4mievirus (FeLV)-Infektion ist die FIP eine \nder wichtigsten Infektionskrankheiten der Katze (Cotter et al., 1973; Lutz et al., 1985, 1990). \nF\u00fcr den praktischen Tierarzt und den Katzenz\u00fcchter ist die FIP ein schwer erfa\u00dfbares und frustrierendes Problem (Olsen, 1993). Eine wirksame Therapie wurde bisher nicht gefunden (Hoskins, 1991; Lutz, 1992). Eine entscheidende Rolle dabei spielt auch der unzureichende \nErkenntnisstand \u00fcber die immunvermittelte Pathoge nese (Lutz et al., 1986). Die Diagnostik ist \nf\u00fcr den praktischen Tierarzt ein Problem, wenn die typischen K\u00f6rperh\u00f6hlenerg\u00fcsse fehlen (Kersten, 1985; Rohrer, 1992; Rohrer et al., 1993). Praxisreife Schnelltests f\u00fcr den \nRoutinebetrieb mit ausreichender diagnostischer Sicherheit gibt es nicht (Pedersen, 1976a; Osterhaus et al., 1977; Lange et al., 1987; Sparke s et al., 1990; Lutz et al., 1996; Troy et al., \n1996). In den letzten Jahren hat die PCR zum Nachweis feliner Coronaviren zunehmend an \nBedeutung gewonnen (Fehr et al., 1996). Sero logische Untersuchungsergebnisse k\u00f6nnen nur \nals diagnostisches Hilfsmittel neben anderen Parametern dienen (Rohrer, 1992; Rohrer et al., \n1993). Jahrelang wurde versucht, eine sichere FI P-Vakzine herzustellen (Baldwin, 1986; Scott, \n1987). In den USA wurde 1991 von \u201cSmithKline Beecham\u201c, der Bereich Tiergesundheit ist heute zu \u201cPfizer\u201c geh\u00f6rig, eine praxisreife Vakzine entwickelt. Der Einsatz dieser Vakzine wird kontrovers diskutiert und ist umstritten (Wolf, 1997). In den vergangenen Jahren gab es \neine Vielzahl von Untersuchungen, in denen experimentelle FIP-Vakzinen getestet wurden \n(Escobar et al., 1992; Fehr et al., 1995; Gerber , 1995; McArdle et al., 1995; Postorino Reeves \net al., 1992; Postorino Reeves, 1995; Baldwin und Scott, 1997; Fehr et al., 1997). Ziel der \nvorliegenden Arbeit war es, die Wirksamkeit der Vakzine Primucell\n\u00aeFIP im Tierversuch unter \nden Bedingungen eines Tierheimes zu testen. Literatur\u00fcbersicht \n 2 \n2. Literatur\u00fcbersicht \n \n2.1 Allgemeines und Historie \n \nBereits Anfang der vierziger Jahre beschrie b Bonaduce (1942) in Neapel eine Erkrankung, \ndie der pleuritischen Form der FIP \u00e4hnelt. Ein vergleichbares Krankheitsbild konstatierten \nkurze Zeit sp\u00e4ter Holzworth (1963) sowie Fe ldmann und Jortner (1964). Robinson et al. \n(1971) datierten das erste Auftreten der Erkrankung in ihrem Sektionsgut sogar auf 1953 \nzur\u00fcck. Als einheitliches Krankheitsbild und mit ihrer heutigen g\u00fcltigen Bezeichnung \nFeline Infekti\u00f6se Peritonitis (FIP) wu rde die Erkrankung 1966 von Wolfe und Griesemer \nbeschrieben. Sie erbrachten auch durch die experimentelle Infektion gesunder Katzen mit Organmaterial erkrankter Tiere den Nachweis  der Infektiosit\u00e4t. Urspr\u00fcnglich sollte der \nName FIP nur solange gelten, bis genauere Kenntnisse \u00fcber die Krankheitsprozesse vorliegen. Obwohl heute verschiedene Manife stationsformen bekannt sind, hat sich der \nName behauptet. Die Virus\u00e4tiologie wurde von Zook et al. (1968) und Ward et al. (1968) \nunabh\u00e4ngig voneinander nachgewiesen. Hardy et al. (1971) fanden in experimentell \ninfizierten Katzen virus\u00e4hnliche Partikel bei elektronenmikroskopischen Untersuchungen. Bereits 1970 formulierte Ward die Hypothese, da\u00df es sich um ein Coronavirus handeln \nmu\u00df. Diese Vermutung wurde durch die Isolie rung von Coronavirus-\u00e4hnlichen Partikeln \naus Aszites und Leberhomogenat infizierter Kat zen best\u00e4tigt (Osterhaus et al., 1976). Den \nNachweis daf\u00fcr erbrachten Hoshino und Sco tt (1978) und O`Reilly et al. (1979) mit der \nVirusisolierung. Aufgrund morphologischer und physikochemischer Eigenschaften wurde das FIPV als Coronavirus klassifiziert (Ost erhaus et al., 1976; Pedersen, 1976b; Horzinek \net al., 1977). \nIm deutschsprachigen Raum (Schweiz) beri chteten St\u00fcnzi und Grevel (1973) erstmals von \nder FIP. Generell k\u00f6nnen bei Katzen auf der ganzen Welt gegen feline Coronavirus gerichtete Antik\u00f6rper nachgewiesen werden  (Horzinek und Osterhaus, 1979a). Im Laufe \nder Zeit hat die H\u00e4ufigkeit der FIP enorm zugenommen (Lutz et al., 1984). Literatur\u00fcbersicht \n 3 \n2.2  Erreger der Felinen Infekti\u00f6sen Peritonitis (FIP) \n \n2.2.1  Coronaviren (CoV) \n \n2.2.1.1  Morphologie \n \nCoronaviren (CoV) sind beh\u00fcllte pleomorphe Einzelstrang RNA-Viren mit einem \nDurchmesser von 60-220 Nanometer. Die Lipopr oteinh\u00fclle entsteht durch Budding an \nspezifischen intrazellul\u00e4ren Membranen, den sogenannten \"budding compartments\" (Petterson, 1991; Griffiths und Rottier, 1992; Holmes und Lai, 1996). Sie enth\u00e4lt zwei \nGlykoproteine: das die H\u00fclle durchdringende Membranprotein M (ehemals E1), das die \nVerbindung zum Kapsid herstellt, und das Spikeprotein S (ehemals E2), das die Bildung von Antik\u00f6rpern und die zellvermittelte Immunit\u00e4 t beim Wirt induziert. Die Spikeproteine \nsind keulenf\u00f6rmige 12-24 nm lange, kranzartig angeordnete Peplomere, die auch f\u00fcr die \nNamensgebung (corona = Krone) verant wortlich sind. Das dritte virale \nHauptstrukturprotein ist das Nukleokapsidprotein N. Das N-Protein bildet zusammen mit der 27-32 kDa gro\u00dfen, polyadenylierten einstr \u00e4ngigen Plus-Strang-RNA das flexible, \nhelikale Nukleokapsid (Holmes und Lai, 1996). Ein Teil der CoV, jedoch nicht das feline \nCoV (FCoV), weist ein viertes Strukturprotein auf, das H\u00e4ma gglutinations-Esterase-Protein \nHE (Cavanagh et al., 1990; Holmes und Lai, 1996). \nDer Viruseintritt in die Zelle erfolgt nach Bindung des Virions mittels des S-Proteins an \nRezeptorglykoproteine der zellul\u00e4ren Plasmamembran und anschlie\u00dfender Fusion von Virush\u00fclle und Plasmamembran. Der gesamt e Vermehrungszyklus der CoV l\u00e4uft im \nZytoplasma der infizierten Wirtszelle ab. Nach direkter Translation der viralen RNA-\nabh\u00e4ngigen RNA-Polymerase an der genomis chen RNA erfolgt die Synthese einer \nNegativstrang-RNA an der genomischen Pos itivstrang-RNA. Der Negativstrang dient als \nTemplate f\u00fcr die diskontinuierliche Transkri ption der verschiedenen viralen mRNA, deren \ngenauer Mechanismus bislang noch nicht gekl\u00e4rt ist, und der Transkription der \ngenomischen RNA (Holmes und Lai, 1996). S- Proteine werden am endoplasmatischen \nRetikulum (RER) gebildet und als glykosylie rte Homotrimere in den Golgi-Komplex \ntransportiert. Nach ihrer Translation an Membran-gebundene Polysomen im RER akkumulieren M-Proteine im Golgi-Komplex. Di e N-Proteine werden dagegen an freien \nPolysomen translatiert und im Zytosol phosphoryliert; sie binden anschlie\u00dfend an die genomische RNA. Der Zusammenbau des Virions erfolgt durch die Bindung der Literatur\u00fcbersicht \n 4 \nNukleokapside an M-Protein enthaltende intr azellul\u00e4re Membranen. Die S-Proteine werden \nw\u00e4hrend des Buddings, das im \"budding compar tment\" zwischen RER und Golgi-Komplex \nliegt (Klumperman et al., 1994), in das Viri on eingebaut. Die Virionen akkumulieren in \ngro\u00dfen Vesikeln, die zur Freisetzung der Viren aus der Zelle mit der Plasmamembran \nverschmelzen (Siddell et al., 1982; Liebermann, 1992; Holmes und Lai 1996). \n \n2.2.1.2  Chemisch-physikalische Eigenschaften \n \nCoronaviren haben eine Dichte von 1,18 g/ml in  Rohrzucker. Ihr pH-Optimum liegt bei 6-\n7, die S\u00e4urelabilit\u00e4t (pH 3) ist variabel. Sie sind hitzelabil, bei 56\u00b0C werden sie inaktiviert, bei niedrigen Temperaturen in geeigneten Medien sind sie jedoch infekti\u00f6s. Bei Raumtemperatur erfolgt der Verlust der Infektiosit\u00e4t nach 24-48 Stunden (Grahn, 1991), \ngegen\u00fcber Austrocknung besteht allerdings eine  Resistenz (Pedersen, 1976b; Lutz et al., \n1985). Formaldehyd und quartern\u00e4re Ammoniumve rbindungen zerst\u00f6ren die Viren, Phenol \ndagegen nicht. Coronaviren sind \u00e4therempfindlich und k\u00f6nnen mit den meisten Detergentien und Desinfektionsmitteln sowie Chloroform zerst\u00f6rt werden (Barlough und \nWeiss, 1983). UV-Strahlung wirkt inaktivierend (Siddell et al., 1983). Durch die Lipidh\u00fclle \nerkl\u00e4rt sich die relativ kurze \u00dcberlebenszeit in der Au\u00dfenwelt. Die Tenazit\u00e4t ist gering. \n \n2.2.1.3  Antigenverwandtschaft und Klassifizierung \n \nDie Gattung Coronavirus bildet zusammen mit der Gattung Torovirus die Familie \nCoronaviridae, die wiederum mit der Familie  Arteriviridae die Ordnung Nidovirales bildet \n(Snijder et al., 1991; Holmes und Lai, 1996). \nCoV kommen bei vielen S\u00e4ugetieren, V\u00f6geln und beim Menschen vor. Sie erzeugen bei \ndiesen verschiedene Krankheitsbilder, rufe n jedoch nur bei den Feliden ein komplexes \nKrankheitsbild wie die FIP hervor (Holmes und Lai, 1996). CoV gelten als wirtsspezifisch \nund zeigen einen Tropismus zu Epithelzellen de s Intestinal- und Respirationstraktes sowie \nzum ZNS. Die Tabelle 1, modifiziert nach  Holmes und Lai (1996), gibt einen kurzen \n\u00dcberblick \u00fcber die aktuelle Klassifizi erung der CoV und die von ihnen verursachten \nKrankheiten. Zwischen den Antigengruppen besteht keine Kreuzreaktivit\u00e4t. Innerhalb einer Antigengruppe gibt es verschiedene Serotypen. Experimentell ist eine Infektion anderer Spezies als der originalen Wirtsspezies durch  bestimmte Serotypen m\u00f6glich (Witte et al., \n1977; Yaling et al., 1988). Literatur\u00fcbersicht \n 5 \nNeutralisierende Antik\u00f6rper werden gegen da s Spikeprotein (S) gebildet. Aufgrund der \nUnterschiede im S-Gen ist eine Differenzie rung verschiedener CoV mittels spezifischer \ncDNA-Sonden m\u00f6glich (Bae et al., 1991). \n \nTabelle 1: Coronavirus-Spezies (adaptiert von Holmes und Lai, 1996) \nAntigen-Gruppe Virusspezies Wirtsspezies Krankheit/Infektionstyp \n I HCV-229E \nTGEV \nCCV \nFECV \nFIPV \nRbCV Mensch \nSchwein \nHund \nKatze \nKatze \nKaninchen respiratorische Infektion \nporzine transmissible Gastroenteritis \ngastrointestinale Infektion \nenterale Infektion \nFIP  \nkeine Angaben \n II HCV-OC43 \nMHV \n \nSDAV \nHEV \nBCV \nRECV \nTCV Mensch \nMaus \n \nRatte \nSchwein \nRind \nKaninchen \nPute respiratorische Infektion \nHepatitis, Enzephalomyelitis; \nrepiratorische und enterale Infektion \nSialodakryadenitisvirus \nVomitus, K\u00fcmmern, Enzephalomyelitis \nenterale Infektion \nenterale Infektion \nenterale Infektion \n III IBV Huhn infekti\u00f6se Tracheobronchitis \n \n2.2.1.4  Feline Coronaviren (FCoV) \n \nFeline Coronaviren (FCoV) lassen sich ents prechend ihrer Virulenz in verschiedene \nBiotypen oder Pathotypen einteilen: feline en terale CoV (FECV) und feline infekti\u00f6se \nPeritonitis-Viren (FIPV) (Tupper et al ., 1987). Letzteres ist eine pathogene \nDeletionsmutante des niedrig virulenten FE CV: FIPV weisen Deletionen in den open \nreading frames des 3c- und des 7b-Gens, die beide f\u00fcr Nichtstrukturpoteine unbekannter \nFunktion kodieren, auf (Herrewegh et al., 1995c ; Hickman et al., 1995; Poland et al., 1996; \nVennema et al., 1998). Eine serologische ode r morphologische Unterscheidung der beiden \nBiotypen ist nicht m\u00f6glich (Vennema, 1999). Im Unterschied zur hohen Pr\u00e4valenz der FECV-Infektion in der Katzenpopoulation ist di e Pr\u00e4valenz der klinischen FIP nur gering Literatur\u00fcbersicht \n 6 \n(Pedersen et al., 1981b, Pedersen 1995); es ist davon auszugehen, dass das FIPV in der \nRegel nicht von einem Tier auf das andere \u00fcbe rtragen wird, sondern als Mutante des FECV \nin der Katze auftritt, die an FIP erkrankt (Evermann et al., 1991; Herrewegh et al., 1995c; Poland et al., 1996; Vennema et al., 1998). Da f\u00fcr spricht, dass in FECV-infizierten, \ngeschlossenen Katzen-Populationen sporadisch FIP-F\u00e4lle auftreten (Hickman et al., 1995; \nFoley et al., 1997a). Desweiteren findet sich in Best\u00e4nden mit Tieren, die massiv FCoV \nausscheiden, eine erh\u00f6hte FIP-Inzidenz (Foley  et al., 1997a). Die FIP-Inzidenz-Rate ist \ndementsprechend relativ zur Mutationsrate des Biotyps FECV in den Biotyp FIPV: Die \naktuelle Mutationsrate wird von folgenden Faktoren beeinflu\u00dft: 1) der FECV-Replikationsrate (Poland et al., 1996), 2) der angeborenen oder erworbenen Resistenz einer \nRasse, Katzenlinie oder individuellen Katze ge gen\u00fcber dem mutierten Virus (Foley et al., \n1997a, b; Poland et al., 1996), 3) dem FECV-Stamm und der Leichtigkeit, mit dem er \nmutiert (Vennema et al., 1998). FECV-Tr\u00e4ger w\u00fcrden dementsprechend als Reservoir f\u00fcr \ndas jeweilige Neuentstehen von FIPV dien en (Pedersen, 1995; Vennema et al., 1998). \nEine andere Einteilung der FCoV erfolgt unabh\u00e4ngig von der Virulenz auf der Basis der \nKreuzreaktivit\u00e4t mit dem caninen CoV (CCV) in Virusneutralisationstests und aufgrund der Kultivierbarkeit in vitro: man unterscheidet  Serotyp I und Serotyp II (Pedersen et al., \n1984a, b; Vennema, 1999)(Tab. 2). Der Serotyp I zeigt keine Neutralisation mit CCV-Antiseren und schlechtes Wachstum in der Zell kultur, dominiert aber bei Feldinfektionen \n(Pedersen et al., 1984a, b; Hohdatsu et al ., 1992; Vennema et al., 1999). Der Serotyp II \ndagegen ist relativ leicht zu kultivieren und zeigt Neutralisation durch CCV-Antiseren. Er \nist vermutlich das Produkt einer doppelten Rekombination von FCoV Serotyp I und CCV: das S-Protein entspricht dem CCV, woge gen das 7b-Gen bei FCoV Serotyp I und II \nidentisch sind (Motokawa et al., 1996;  Herrewegh et al., 1998; Vennema, 1999). Literatur\u00fcbersicht \n 7 \nTabelle 2:  FIPV-St\u00e4mme  (modifiziert nach Kai et al., 1987) \nFIPV-Stamm Zitat Serotyp Infektiosit\u00e4t \nUCD 1 O`Reilly et al., 1979 I mittel bis gering \nUCD 2 Pedersen und Floyd, 1985 I hoch \nUCD 3 Pedersen und Floyd, 1985 I hoch \nUCD 4 Pedersen und Floyd, 1985 I hoch \nUCD 8 Vennema et al., 1995 I keine Angaben \nNOR 15 (DF 2) Evermann et al., 1981 II hoch \nWellcome Horzinek et al., 1995 k. A. keine Angaben \nDahlberg Horzinek et al., 1995 k. A. keine Angaben \n79-1146 McKeirnan et al., 1981 II hoch \nTN 406 (Black) Black, 1980 I mittel bis tief \nHR Kai et al., 1987 k. A. keine Angaben \nCVR 1036 McArdle et al., 1992,1995 k. A. hoch \nk. A. = keine Angaben \n \n2.2.1.4.1 Pr\u00e4valenz von FCoV-Infektionen \n \nIn der Hauskatzenpopulation ist die FCoV-Infek tion sehr h\u00e4ufig. Einzeln gehaltene Katzen \nweisen zu 10-50% FCoV-Antik\u00f6rper auf, in  gr\u00f6\u00dferen Haltungen (Tierheime und Zuchten) \nliegen die Zahlen bei 80-90% (Pedersen, 1976a; Loeffler et al., 1978; Pedersen et al., \n1981b; Pedersen, 1983b; Sparkes et al., 1992). Ka i et al. (1995) vermuten, dass die FECV \nf\u00fcr die h\u00e4ufige Serokonversion verantwortlich sind, da lokale FECV-Infektion niedrige und \nsystemische FECV-Infektion hohe Antik\u00f6rpertiter verursachen. \nAnders als experimentelle Infektionen mit FECV-St\u00e4mmen (Pedersen et al., 1981a, b), die \nerst ab einer Infektionsdosis von > 103 plaque forming units (PFU) zur klinischen \nManifestation (Fieber, Leukopenie, Diarrhoe) f \u00fchren (Kai et al., 1995), verlaufen nat\u00fcrliche \nenterale FECV-Infektionen meist klinisch inapparent. Es gibt nur einzelne Berichte \u00fcber \nletale Coronavirus-Enteritiden (McKeirnan et al., 1981; Dea et al., 1982; Hayashi et al., \n1982; Kipar et al., 1998).  Literatur\u00fcbersicht \n 8 \n2.2.1.4.2 Epizootiologie der FCoV-Infektion  \n \nInfizierte Tiere scheiden Virus mit den F \u00e4zes aus; der Nachweis erfolgte mittels \nElektronenmikroskopie oder PCR (Herrewegh et  al., 1995a,b; Addie et  al., 1996; Poland et \nal., 1996; Foley et al., 1997b; Kennedy et al ., 1998; Kipar et al., 1999b). In den F\u00e4zes \ngesunder Katzen k\u00f6nnen sich auch \u201ecoronavirus-like particles\u201c (Toroviren) befinden \n(Hoshino und Scott, 1980). Nach experimentelle r Infektion wurde mittels Virusisolierung \nauch eine oropharyngeale Ausscheidung nachgewi esen, die ab dem 2. Tag post infectionem \n(p.i.) unabh\u00e4ngig vom Infektionsweg (intrave n\u00f6s, intraperitoneal, oral) bis zum 9. oder 10. \nTag p.i. vorlag (Stoddart et al., 1988b). Desw eiteren f\u00fchrte die orale Verabreichung von \nUrin an FIP erkrankter Katzen bei eine r von 3 Katzen zu FIP (Hardy und Hurvitz, 1971), \nwas auf die Ausscheidung mit dem Urin hinde utet. H\u00f6k (1993a, b) gelangen auch der \nFCoV-Antigen-Nachweis und die Virusisolierung aus der Membrana nictitans, so dass eine \nVirussausscheidung mit Augensekreten m\u00f6glich zu sein scheint. \nBei nat\u00fcrlich infizierten Tieren wurden detailliertere Untersuchungen zur Virusausscheidung mit den F\u00e4zes gemacht: infi zierte Katzen scheiden das Virus \u00fcber \nl\u00e4ngere Zeitr\u00e4ume (Untersuchungszeitr\u00e4ume bi s zu 13 Monaten) intermittierend aus (Foley \net al., 1997b, Harpold et al., 1999). Anders als be i experimentell infizierten Tieren ist bei \nnat\u00fcrlichen FIP-F\u00e4llen eine Virusausscheidung bis zum Tod m\u00f6glich (Pedersen et al., 1984b; Stoddart et al., 1988a,b; Addie et  al., 1996). Serum-Antik\u00f6rpertiter und \nVirusausscheidung waren nicht signifikant ko rreliert (Harpold et al., 1999). Stre\u00df, Geburt \nund Laktation scheinen die Virusausscheidung nicht zu induzieren (Foley et al., 1997b). \nAngaben zum Beginn der Virusausscheidung (Nachweis mittels RT-PCR) bei Welpen \ndifferieren: W\u00e4hrend in einer Untersuchung eine Ausscheidung nicht vor einem Alter von \n10 Wochen beobachtet wurde (Foley et al., 1997b), wurde in einer anderen Untersuchung die Virusausscheidung ab einem Alter von ca. 7 Wochen, d.h. vor oder zum Zeitpunkt der Serokonversion, nachgewiesen (Harpold et al., 1999). Es ist davon auszugehen, dass in \nMehrkatzenhaltungen ein gro\u00dfer Anteil an Tieren zu jeder Zeit Virus ausscheidet, das Einzeltier jedoch Zyklen von Infekti on und Ausscheidung, Erholung und Reinfektion \ndurchmacht (Foley et al., 1997b). Das Viru s-Reservoir scheinen zumindest u.a. \nEpithelzellen des Kolons zu sein (Herrewegh et al., 1997). Literatur\u00fcbersicht \n 9 \n2.3  Epizootiologie der FIP \n \nDie FIP ist eine Erkrankung der Feliden, \u00fcberw iegend aber ein Problem der domestizierten \nKatzen. Empf\u00e4nglich sind vorrangig junge (6-17 Monate) oder sehr alte (>10 Jahre) Tiere \n(Kaas und Dent, 1995), prinzipiell k\u00f6nnen Katzen jedoch in jedem Alter erkranken (Lutz et \nal., 1986; Nicolaysen et al., 1990; Wolf, 1997). Epizootiologische Studien werden \nwesentlich erschwert durch die Unspezifit\u00e4t der zur Verf\u00fcgung stehenden serologischen \nTests (Weiss, 1991). Nach der Katzenseuche und der FeLV-Infektion ist die FIP aber eine \nder h\u00e4ufigsten letalen Infektionskrankheiten de r Katzen (Suter et al., 1993). Bez\u00fcglich der \nAssoziation zwischen FIP und anderen Infek tionskrankheiten finden sich unterschiedliche \nAngaben. In einer umfangreichen Studie wa ren 22% der FeLV-positiven Katzen und 7% \nder FIV-Katzen zus\u00e4tzlich an FIP erkrankt , 19% der FIP-Katzen waren FeLV-positiv \n(Reinacher, 1993a, b). Roiko et al. (1985) fanden bei FIP-Katzen eine 50%ige FeLV-\nInfektionsrate, bei zwei weiteren Untersuc hungen liegt der Anteil der FeLV-Infektion von \nFIP-Katzen bei 45% bzw. 62% (Hardy und Hurvitz, 1971; Essex et al., 1975). Unter \nFeldbedingungen scheinen FeLV- und FIPV-In fektionen nicht geh\u00e4uft gemeinsam \nvorzukommen, sie beg\u00fcnstigen aber einander (L utz, 1992). Addie et al. (2000) gehen davon \naus, da\u00df eine gleichzeitige Infektion mit Retroviren nicht die Wahrscheinlichkeit erh\u00f6ht, \neine FIP zu entwickeln. Die Morbidit\u00e4t der FIP ist als niedrig einzustufen, die Mortalit\u00e4t als sehr hoch (Pedersen et al., 1981a; Ford, 1982). Die H\u00e4ufigkeit der FIP ist territorial verschieden, sie kommt jedoch weltweit vor (Barlough et al., 1982). Im Pathologischen \nInstitut der Universit\u00e4t Glasgow (GB) wurde di e FIP bei nur ca. 4% der sezierten Katzen \ndiagnostiziert (Addie und Jarrett, 1994), in Z\u00fcri ch lag die Quote dagegen bei 16% und in \nLeipzig bei 14% (Reinacher, 1994). In M\u00fcnche n betrug der FIP-Anteil bei Sektionskatzen \nin den Jahren 1969-1982 nur 6% (Landes et al ., 1984), in der Katzenzucht des Zentralen \nTierlaboratoriums der Medizinischen Ho chschule Hannover (MHH) in der Zeit von 1982-\n1984 nur 1-4% (Maess, 1985). Bei reinrassigen Ka tzen tritt die FIP h\u00e4ufiger auf als bei \nanderen Katzen (Hoskins, 1991). Die Literaturangaben \u00fcber m\u00f6gliche Rassedispositionen sind uneinheitlich. W\u00e4hrend Horzinek und Oste rhaus (1979b) sowie Timoney (1976) eine \nRassedisposition verneinen, sehen Schalm ( 1971) sowie Wolfe und Griesemer (1971) eine \nDisposition bei Siamkatzen. Eine Geschlech tsdisposition konnte bisher nicht eindeutig \nnachgewiesen werden, auch wenn in einige n Untersuchungen m\u00e4nnliche Tiere h\u00e4ufiger \nerkrankten (Neu und Pfeifer, 1985). Dies kann jedoch durchaus darauf zur\u00fcckzuf\u00fchren sein, \nda\u00df Kater h\u00e4ufig mehr Kontakt zu a nderen Katzen haben, wodurch sich das Literatur\u00fcbersicht \n 10 \nInfektionsrisiko erh\u00f6ht (Lutz et  al., 1985). Bei einer Studie an exotischen Feliden stellten \nEverman et al. (1988) bei Geparden eine ge nerell hohe Empf\u00e4nglichkeit f\u00fcr FIP fest. L\u00f6we, \nTiger, Puma und Amerikanischer Luchs scheinen resistenter gegen das FIPV zu sein. \nBeschrieben sind FIP-Erkrankungen bei einer Vielzahl von Wildfeliden, z.B. beim L\u00f6wen \n(Robinson et al., 1971; Colly, 1973; Wisser, 1984), Bergl\u00f6wen (Theobald, 1978; Scott, \n1993), Jaguar (Robinson et al., 1971; Fransen, 1972; Colly, 1973), Leoparden (Robinson et \nal., 1971; Colly, 1973; Tuch et  al., 1974), Schneeleoparden (Wallach und Boever, 1983), \nGeparden (Horzinek und Osterhaus, 1979a; Pfei ffer et al., 1983), Nordluchs (Poelma et al., \n1974), Luchs (Barlough und Stoddart, 1990), Ka rakal (Poelma et al., 1974), Sandkatze \n(Barlough und Stoddart, 1990) und Pallaskatze (Pedersen, 1987).  \n \n2.4  Pathogenese der FIP \n \nDie Infektion mit dem FCoV erfolgt oronasal,  prim\u00e4r \u00fcber die f\u00e4kal-orale Route. Nach \noraler Infektion sind Viruspartikel in Entero zyten nachweisbar, jedoch nicht in der Lunge \n(Stoddart et al., 1988b; Weiss und Scott, 1981a, b). Virulente, d.h. mutierte FCoV erlangen \ndie F\u00e4higkeit zur massiven Replikation in Ma krophagen (Stoddart und Scott, 1989), so dass \nsich eine zellassoziierte Vir\u00e4mie entwic kelt. Deren Folge ist die Infektion von \nMakrophagen im region\u00e4ren, d.h. Mesenteria l-Lymphknoten (Stoddart et al., 1984, 1988a, \nb), der \u00fcber eine Infektion von Monozyten und deren Ausbreitung \u00fcber das Blut eine \nsystemische Infektion folgt (Pedersen, 1995). Die schnelle Replikation des Virus in den \nMakrophagen bewirkt die Zellyse, Freisetz ung von Viruspartikeln und Phagozytose durch \nweitere Makrophagen. Virus-infizierte Monozyten scheinen aus Venolen in den verschiedenen Geweben und subser\u00f6s auszuwandern und \u00fcber die Freisetzung von Virus weitere Makrophagen zu rekrutieren (Pederse n, 1995). Desweiteren entstehen bei der FIP \nim Blut zirkulierende Immunkomplexe (Jac obse-Geels et al., 1980, 1982; Weiss und Scott, \n1981a, b; Hayashi, 1983; August, 1984; Barlough, 1984), deren Ablagerung als m\u00f6gliche Ursache f\u00fcr die Entstehung der proteinreichen  K\u00f6rperh\u00f6hlenerg\u00fcsse angesehen wird. In \nGef\u00e4\u00dfw\u00e4nden abgelagert Immunkomplexe f\u00fchr en \u00fcber die Freisetzung vasoaktiver Amine \nzur Endothelzellretraktion und somit zum Austritt von Plasmaproteinen (Addie und Jarrett, 1998). Makrophagen in den L\u00e4sionen synthetisieren Interleukin 1 (IL-1) (Hasegawa und Hasegawa, 1991). Es wird vermutet, dass IL-1 \u00fcber eine m\u00f6gliche Endothelzell-\nAktivierung, seine chemotaktische Wirkung und die Induktion der Freisetzung anderer \nZytokine eine Rolle bei der Entstehung de r entz\u00fcndlichen Prozesse hat (Hasegawa und Literatur\u00fcbersicht \n 11 \nHasegawa, 1991). Desweiteren wurden bei Ka tzen mit FIP Apoptosen von T- und B-Zellen \nohne deren FCoV-Infektion beobachtet, was auf eine indirekte Wirkung des Virus \u00fcber eine \nFreisetzung von l\u00f6slichen Faktoren aus den in fizierten Makrophagen hindeutet (Haagmans \net al., 1996).  \nExperimentelle Infektionen ergaben bei seropositiven Katzen einen fulminanteren \nKrankheitsverlauf als bei seronegativen, was als Antik\u00f6rper-abh\u00e4ngige Verst\u00e4rkung (antibody-dependent enhancement; ADE) bezeichnet wird und in einer erleichterten Phagozytose von Antik\u00f6rper-beladenen Viru spartikeln durch die Makrophagen begr\u00fcndet \nzu sein scheint (Hohdatsu et al., 1991; Olsen et al., 1992; Corapi et al., 1992, 1995; Scott et \nal., 1995). Bekannt ist die ADE auch beim Humanen Immundefizienzvirus (HIV), dem \nDengue Virus und anderen Viren (Porterfield, 1986) . Allerdings gibt es keine Berichte \u00fcber \ndas Vorkommen einer ADE bei nat\u00fcrlichen FI P-F\u00e4llen. Stattdessen scheinen seropositive \nKatzen unter nat\u00fcrlichen Bedingungen zumindest  zum Teil resistent gegen FIP zu sein \n(Addie et al., 1995b). \n \n2.5  Klinik / Krankheitsformen der FIP \n \nNur bei 1-5% der Katzen kommt es nach  einer FCoV-Infektion zur klinischen \nManifestation einer FIP (Lut z et al., 1985). Die Symptomatik der FIP allerdings ist \nvielf\u00e4ltig. An FIP erkrankte Katzen sind i mmunsupprimiert (Haagmans et al., 1996). Die \nklinischen Symptome entwickeln sich parallel zu den pathologischen Ver\u00e4nderungen (Osterhaus, 1979). Der Krankheitsverlauf is t progressiv und meist fatal. Anf\u00e4nglich \nherrschen unspezifische Allgemeinsympt ome vor (Hirschberger et al., 1995), wie \nverminderter Appetit, Abgeschlagenhe it (Rohrer et al., 1993) und verringertes \nK\u00f6rperpflegeverhalten. Das fluktuierende Fieber ist therapieresistent, im Anfangsstadium wird es meist nicht erfa\u00dft. Hinzu kommen h\u00e4 ufig Vomitus und Diarrhoe oder Kotverhalten, \nDehydratation und Anorexie. Rhinitis, Ikterus, An\u00e4mie und Ur\u00e4mie sind m\u00f6glich (Rohrer et al., 1993; Hirschberger et al., 1995). Das fortge schrittene Krankheitsbild richtet sich nach \nder Verlausform. \nMan unterscheidet die effusive  oder feuchte (nasse) Form und die nichteffusive  oder \ntrockene (granulomat\u00f6se) Form. H\u00f6k (1993a, b) vermutet, da\u00df f\u00fcr die unterschiedlichen \nVerlaufsformen unterschiedliche Virust\u00e4mme me hr als andere Faktoren eine Rolle spielen \nk\u00f6nnten. Die feuchte Form tritt 4x h\u00e4ufiger als die trockene auf (Grahn, 1991; Rohrer et al., \n1993). Die beiden Formen k\u00f6nnen kombiniert auftreten (Lutz et al., 1985). Literatur\u00fcbersicht \n 12 \nBei der klassischen feuchten Form steht eine  exsudative Peritonitis und/oder Pleuritis im \nVordergrund. Neu und Pfeifer (1985) fanden die feuchte Form bei 94% ihrer untersuchten \nF\u00e4lle, 70% hatten einen deutlichen Ba uchh\u00f6hlenergu\u00df. Die Erg\u00fcsse k\u00f6nnen wenige \nMilliliter, \u00fcber 700 ml (Toolan, 1993) oder sogar bis ca. zwei Liter betragen (Gerbig und \nKraft, 1979). Die Umfangsvermehrung des A bdomens ist nicht oder bei Palpation nur \ngeringgradig schmerzhaft. Bei hochgrad igem Aszites ist Fluktuation vorhanden. \nResultierend treten Atembeschwerden (Dyspnoe ), in Extremf\u00e4llen auch Maulatmung und \nZyanose auf. Die Atemnot wird vom Besit zer h\u00e4ufig anamnestisch als Hauptsymptom \nangegeben. Thoraxerg\u00fcsse (10-20 ml) verst\u00e4rken  diese Symptomatik, treten aber nur in 30 \nbis 50% (Barlough und Stoddart, 1990) der exsudativen FIP-F\u00e4lle auf. Eine Kombination \nvon Bauchh\u00f6hlen- und Brusth\u00f6hlenergu\u00df konnten Neu und Pfeifer (1985) sogar nur bei \netwa 5% der F\u00e4lle finden. Selten ist die FIP mit einer Perikarditis vergesellschaftet, die bei \nausgepr\u00e4gter Form zur Herz-Kreislauf-Insuffizienz, bedingt durch perikardiale Effusion (Madron, 1986; Vacirca et al. 1989), f\u00fchren kann. Bei 10% der effusiven Form treten ZNS-\n, bei 4% klinisch wahrnehmbare Auge nver\u00e4nderungen auf (Pedersen, 1983a). Weber \n(2000) fand bei 40% der Sektionskatzen mit effusiver FIP eine Beteiligung der Augen. \nDie FIP in ihrer exsudativen Verlaufsform  ist eine ausgesprochene Jungtierkrankheit \n(Hirschberger et al., 1995). Die trockene Form tritt mehr bei \u00e4lteren Katzen und nach l\u00e4ngerer Latenzzeit auf (Hayashi et al., 1980). \nDie trockene Form ist klinisch oft nur unter  Vorbehalt zu diagnostizieren. Auf\u00e4llig sind die \nAbmagerung bei z. T. gutem Appetit und die z.T. vorhandenen Augenl\u00e4sionen. Bei 40% \nder F\u00e4lle treten ZNS-, bei 35% Augenver\u00e4 nderungen auf (Pedersen, 1983a). Weber (2000) \nfand bei 60% der Sektionskatzen mit trockener FIP Augenl\u00e4sionen. Oft sind nur die Augenbefunde klinisch erfa\u00dfbar. Charak teristisch sind pyogranulomat\u00f6se Entz\u00fcndungen \nzahlreicher innerer Organe. Mitunter gelingt es dem erfahrenen Praktiker, \npyogranulomat\u00f6se Herde als Vorw\u00f6lbungen an Nieren oder Mesenteriallymphknoten zu \npalpieren, die einen Hinweis geben k\u00f6nnen (Lutz et al., 1985). Dabei handelt es sich um grauwei\u00dfe Areale, die auch bei der effusive n, vorrangig aber bei der trockenen Form in \nverschiedenen Organen (z. B. Milz, Leber, Nieren, Netz, Peritoneum) zu beobachten sind. Histologisch handelt es sich um dichte  Ansammlungen von Makrophagen, neutrophilen \nGranulozyten, Lymphozyten und Plasmazellen, we lche meistens eine zentrale Nekrose mit \nFibrineinlagerung umschlie\u00dfen. Eine Vergr \u00f6\u00dferung der Mesenteriallymphknoten kann die \nvorrangige oder alleinige Ver\u00e4nderungen eine r FIP sein. Dabei handelt es sich um \ngranulomat\u00f6s-nekrotisierende Lymphadenitiden (Kipar et al., 1999a). Auskultatorisch oder Literatur\u00fcbersicht \n 13 \nr\u00f6ntgenologisch erfa\u00dfbar sind lediglich Entz \u00fcndungen im Bereich der Pleura, der Lunge \noder des Herzens. In F\u00e4llen, bei denen Nierenversagen auftritt, ist dieses meistens auf eine \ninterstitielle Nephritis zur\u00fcckzuf\u00fchren (Reinacher, 1994), nicht, wie man bei einer Immunkomplexkrankheit annehmen k\u00f6nnte, auf eine Glomerulonephritis. \nSchwer zu diagnostizieren ist die ZNS-Form der FIP mit pyogranulomat\u00f6sen Hirnver\u00e4nderungen, da an den viszeralen Organen keine typischen Befunde erhoben \nwerden k\u00f6nnen. Meningoenzephalitis und Panophthalmitis sind h\u00e4ufig miteinander vergesellschaftet (Slauson und Finn, 1972). Durc h eine Vaskulitis im Gehirn (Entz\u00fcndung \ndisseminierter kleiner Gef\u00e4\u00dfe, oft mit Bildung von Abscheidungsthromben) k\u00f6nnen H\u00e4morrhagien und akute schwere neurologisc he Erscheinungen auftreten (Reinacher, \n1994). Prim\u00e4r f\u00fchrt die FIP nicht zu eine r Enzephalitis, sondern zu einer Meningitis \n(Reinacher, 1994). Die neurologische Symptomatik ist vielf\u00e4ltig und kann durch Inkoordination, Paresen, Nystagmus, Konvulsionen, Tremor, Nervenl\u00e4hmungen \n[schwankender Gang, L\u00e4hmungen der Vorde r- und/oder Hinterextremit\u00e4ten, L\u00e4hmungen \ndes N. trigeminus und des N. facialis], Hype r\u00e4sthesie, generalisierte Ataxien, Schiefhalten \ndes Kopfes, Verhaltensst\u00f6rungen und Harni nkontinenz gekennzeichnet sein (Kornegay, \n1978). \n\u00dcber ein Drittel der Katzen mit neurologi scher Symptomatik zeigen keine anderen \nAnzeichen der FIP (Shell, 1997). Fankhauser und Fatzer (1977) berichten \u00fcber vier Katzen \nim Alter von 5 Monaten bis 2 Jahren mit granulomat\u00f6ser Meningitis und Chorioependymitis im Zusammenhang mit der FI P. Krum et al. (1975) erw\u00e4hnen bei der \nnichteffusiven Form einen assoziierten Hydr ocephalus bei einer jungen Katze. Neben dem \nHydrocephalus ist die Hydromyelie bei einer einj\u00e4hrigen kastrierten Katze beschrieben \n(Tamke et al., 1988). \nDie FIP kann an allen Geweben des Auges zu L\u00e4sionen f\u00fchren (Slauson und Finn, 1972; \nWeber, 2000). In der Regel stellen sich die Augenver\u00e4nderungen aber als Uveitiden dar, \nwelche aus der hohen immunulogischen Sensibilit\u00e4t der Uvea resultieren (Schmidt, 1998). Bereits 1971 diagnostizierte Doherty bei 3 Katzen mit FIP eine bilaterale Uveitis. Gelatt (1973) erw\u00e4hnt das Vorkommen bilateraler A ugenver\u00e4nderungen bei einer 6 Monate alten \nKatze mit FIP. Er diagnostizierte eine Pa nophthalmitis und Iridozyklitis mit Pr\u00e4zipitaten an \nder Hornhauthinterfl\u00e4che. \nCharakteristische Augenver\u00e4nderungen sind Iritis, Irisatrophie, Uveitis (Shell, 1997), Tr\u00fcbung des Augenkammerwassers, keratitische Pr\u00e4zipitate (= Hypopyon: Neutrophile Granulozyten, wenige Lymphozyten, Zelldeb ris), entz\u00fcndliche Niederschl\u00e4ge auf dem Literatur\u00fcbersicht \n 14 \nHornhautendothel, Hornhautendotheldegener ationen, Hornhaut\u00f6dem, Hornhautgeschw\u00fcr, \nLinsenkatarakt, Glask\u00f6rpertr\u00fcbungen, Retinitis , Netzhautblutungen und Phthisis bulbi \n(Krebiel et al., 1974; Kellner und Litschi,  1989; Weber 2000). Eine durch das FIPV \nbedingte Iritis ist nicht zu unterscheiden von einer FeLV-bedingten Uveitis (Kellner und \nLitschi, 1989). Die Blutgef\u00e4\u00dfe sind bei der FI P stets mit einbezogen, der Nervus opticus \nkann involviert sein (Slauson und Finn, 1972).  \n \n2.6  Diagnostik der FIP \n \nDie Diagnose FIP wird heute intra vitam unt er Ber\u00fccksichtigung von Anamnese, klinischer \nSymptomatik, anhand der Laborergebnisse i nklusive Analyse des Ergu\u00dfaspirates, des \nCoronavirus-Antik\u00f6rpertiters und/oder mittels Biopsie gesichert (Barlough, 1985; Rohrer et \nal., 1993). Die Histopathologie ist die einzig e ohne Einschr\u00e4nkung anerkannte Methode zur \nDiagnosesicherung (Grahn, 1991; Sparkes et al., 1992). Die Immunfluoreszenz-Technik (Lange et al., 1987; K\u00f6lbl und Schuller, 1988) wird zum Nachweis von Antik\u00f6rpern gegen \nFCoV genutzt (Pedersen, 1976b; Osterhaus et al., 1977) und ist dem kompetitiven ELISA, \nbei dem monoklonale Antik\u00f6rper genutzt werd en (Fiscus et al., 1985), an Sensitivit\u00e4t \n\u00fcberlegen (Viefhues et al., 1990). Kai et al . (1992) beschreiben die Immunperoxidase-\nAntik\u00f6rper-Technik als m\u00f6gliche Methode der Antik\u00f6rperbestimmung bei der FIPV-\nInfektion. Schwendenwein und Koelbl (1991) berichten \u00fcber die Entwicklung eines kommerziell verf\u00fcgbaren CELISA zur Anti k\u00f6rper-Bestimmung bei der FIPV-Infektion. \nDie Ergebnisse von verschiedenen angewandten  Testsystemen f\u00fcr FIPV-Antik\u00f6rper sind \nnach Troy et al. (1996) nicht diagnostisch verwertbar. Der von \u201cIDEXX \u201centwickelte und \nlange Zeit vertriebene SNAP\u2122FIP-Test, de r einen f\u00fcr das E1 Envelope-Antigen \nspezifischen monoklonalen Antik\u00f6rper enthielt, der mit E1-spezifischen Antik\u00f6rper in der \nProbe konkurrierte, wurde aufgrund vermehrter  Kritik im letzten Quartal 1997 aus dem \nSortiment genommen (pers\u00f6nl. Mitteilung Dr. Fuchs, \u201cIDEXX\u201c). Damit entfiel einer der wenigen kommerziell erh\u00e4ltlichen Schnell-Tests f\u00fcr den praktischen Tierarzt. Die Firma \u201cA. Albrecht & Co KG\u201c, Aulendorf, hat ih ren Schnell-Test k\u00fcrzlich (1999) von FIP \nSPEED\n\u00ae in Coronavirus SPEED\u00ae umbenannt. Unbeirrt davon nennt die Firma \u201cscil animal \ncare company GmbH\u201c ihren angebotenen Schne ll-Test der Firma \u201cMegaCor Diagnostik \nGmbH\u201c (Austria) nach wie vor FASTest\u00ae FIP, obwohl der Test Corronavirus-Antik\u00f6rper \nnachweist und nicht FIP-spezifisch reagiert. Die Sensitivit\u00e4t wird von \u201cscil animal care \ncompany GmbH\u201c mit 97,4 % und die Spezifit\u00e4t mit 94,6 % angegeben. Das Diasystem\u2122 Literatur\u00fcbersicht \n 15 \nFIP-Test Kit, ein kompetitiver ELISA (CELI SA), wird von der Firma \u201cTech Amerika \nDiagnostics\u201c, Omaha, Nebraska angeboten. Man ben\u00f6tigt nur 25 \u00b5l der entsprechenden \nProbe. Nachgewiesen werden Antik\u00f6rper, di e gegen das H\u00fcllglykoprotein E1 des FIPV \ngerichtet sind. Das Testprinzip beruht  auf der kompetitiven Hemmung der Bindung \nenzymmarkierter monoklonaler Antik\u00f6rper, dur ch in der Probe vorhandene Antik\u00f6rper \ngegen das E1-Protein des auf den Teststreifen aufgebrachten FIPV. Sind in Serum oder Aszites Antik\u00f6rper vorhanden, verdr\u00e4ngen sie den monoklonalen Antik\u00f6rper von der \nspezifischen Bindungsstelle, der Farbumschlag unterbleibt. Es handelt sich also um ein \nvisuelles System (farblos = positiv und blaugr\u00fcn = negativ). Gegen\u00fcber dem IFT erwies sich der CELISA als wenig sensitiv. Erst bei hohen Antik\u00f6rper-Titern zeigte das Testkit positive Ergebnisse (Viefhues et al., 1990). \nIn der Praxis gen\u00fcgen bei der effusiven Fo rm oftmals die Ergebnisse der gr\u00fcndlichen \nUntersuchung. Die trockene Form, besonde rs wenn nur das ZNS und/oder die Augen \nbetroffen sind, stellt f\u00fcr jeden Tierarzt ei ne echte diagnostische Herausforderung dar \n(Rohrer et al., 1993). \n \n2.6.1  H\u00e4matologie und Serologie \n \nDie h\u00e4matologischen und klinisch-chemische n Befunde sind bei der effusiven und der \nnichteffusiven Form der FIP \u00e4hnlich, aber sehr variabel und nicht pathognomisch (McReynolds und Macy, 1997). Im Blut treten h\u00e4 ufig erhebliche Leukozytosen auf, die im \nallgemeinen auf eine Neutrophilie zur\u00fcckgehen, wobei ganz erhebliche Linksverschiebungen vorkommen k\u00f6nnen (Ger big und Kraft, 1979; McReynolds und \nMacy, 1997). Aber auch normale Leukozyten zahlen bis zu m\u00e4\u00dfigen Leukopenien sind \nm\u00f6glich. Gering- bis mittelgradige An\u00e4mien treten geh\u00e4uft auf. Lymphopenien (< 1,5 x \n10\n3/\u00b5l) komplettieren das ver\u00e4nderte Blutbild. Im Serum sind besonders die Glutamins\u00e4ure-\nPyruvat-Transaminase (GPT [=ALT]), die Gl utamat-Dehydrogenase (GLDH), oft auch die \nGlutamins\u00e4ure-Oxalessigs\u00e4ure-Transaminase (GOT [=AST]), die Alkalische Phosphatase \n(AP) und die Bilirubinwerte (konjugiertes Bilirubin) erh\u00f6ht (McReynolds und Macy, \n1997). Bei Nierensch\u00e4digungen lassen sich  erh\u00f6hte Blutplasmakonzentrationen von \nHarnstoff und Kreatinin nachweisen (Weiss und Scott, 1980). H\u00e4ufig findet man auch eine \nerh\u00f6hte Plasmaprotein-Konzentration  (> 80 g/l), haupts\u00e4chlich durch die Vermehrung der \nImmunglobulinfraktion (Hypergammaglobulin\u00e4mie ). Die Serumelektrophorese zeigt aber \nauch markante Erh\u00f6hungen der \u03b1- und \u03b2-Fraktionen (Gerbig und Kraft, 1979; Lutz, 1992). Literatur\u00fcbersicht \n 16 \nDie erh\u00f6hten Blutplasmakonzentrationen von Fibr inogen (> 4 g/l) sind als Ausdruck einer \nEntz\u00fcndung anzusehen. Bei der effusiven Form kann es zu einer Verbrauchskoagulopathie \n(DIC) kommen. Blutungszeit, Prothrombinzeit und partielle Thromboplastinzeit sind dabei \nverl\u00e4ngert. Bei derartigen Katzen fa nden Weiss und Scott (1980) erniedrigte \nThrombozytenzahlen und erh\u00f6hte Mengen von Fi brinabbauprodukten. Es kommt bei der \nDIC zur Abnahme der Gerinnungsfaktoren VII, VIII, IX, X und XII. \n \n2.6.1.1  Antik\u00f6rper-Bestimmung \n \n2.6.1.1.1 Indirekte Immunfluoreszenztechnik (IFT) \n \nAls Routinemethode zur Antik\u00f6rperbestimmung (i m Verlauf einer Infektion mit dem FIPV \nwerden von der Katze humorale Antik\u00f6rper [Ak]  gebildet, deren Nachweis diagnostischen \nZwecken dient [Barlough et al., 1983a]) hat si ch in verschiedenen Labors die indirekte \nImmunfluoreszenztechnik etabliert (Gie rend und Heppner, 1983; Frost und Lohrbach, \n1987; Vanden Bossche, 1990a,b). \nFrost und Lohrbach (1987) best\u00e4tigten die hohe Spezifit\u00e4t dieses Verfahrens durch \nkomplette \u00dcbereinstimmung zwischen FIP-verd\u00e4chtigem Aszitesmaterial obduzierter Katzentierk\u00f6rper und dem positiven fluoreszenzserologischen Befund. \nDie Methode ist relativ zeit- und arbeitsaufwendig. Dabei werden entweder FIPV- oder aber TGEV-infizierte Kulturen verwandt (Oster haus et al., 1977; M\u00f6stl, 1983; Lutz et al., \n1984; Lange et al., 1987), die auf Deckgl\u00e4ser oder Objekttr\u00e4ger fixiert sind. Die zu untersuchenden Serumproben werden logarithmisch verd\u00fcnnt aufgetragen, anschlie\u00dfend wird mit Konjugat markiert. Als Titer g ilt diejenige Serumverd\u00fcnnung, bei der unter dem \nMikroskop noch eine spezifische Fluor eszenz zu erkennen ist. Die enge \nAntigenverwandschaft des FIPV mit den bereits erw\u00e4hnten Coronaviren (Tabelle 1) erschwert eine eindeutige Beurteilung der er mittelten Antik\u00f6rpertiter (Reubel, 1987). Ein \nweiterer St\u00f6rfaktor sind kurz vorher erfolgte Routineimpfungen gegen andere virale Erreger. Diese aus Zellkulturen hergestellten Vakzinen enthalten in der Regel Rinderserumbestandteile, gegen die die Impfli nge Antik\u00f6rper bilden. Diese reagieren unter \nUmst\u00e4nden mit \u00e4hnlichen Bestandteilen des Testsystems. Die Folge sind dann falsch \npositive Ergebnisse (Barlough et al., 1984). Drei  bis vier Monate nach solchen Impfung \nwerden die serologischen Ergebnisse nicht mehr beeinflu\u00dft. Literatur\u00fcbersicht \n 17 \nDie CoV-Ak-Titerbestimmung kann immer nur  einen Parameter der FIP-Diagnostik \ndarstellen (Rohrer et al., 1993). Viele FCoV -Ak-Tests liefern keine signifikanten \nErgebnisse (Troy et al., 1996). Steigende CoV-Ak -Titer sind kein Indikator daf\u00fcr, da\u00df die \nKatze eine FIP entwickeln mu\u00df (Kipar et al., 1999b; Addie et al., 2000). Positive CoV-Ak-\nTiter kommen bei gesunden, d. h. klinisch  unverd\u00e4chtigen Katzen vor (Gierend und \nHeppner, 1983; Addie und Jarrett, 1992) und rech tfertigen nicht die Euthanasie eines \nTieres, zumal ein hoher Prozentsatz innerhalb eines Jahres seronegativ werden kann (Addie \nund Jarrett, 1994). Lediglich negative oder sehr hohe Ak-Titer (> 1600) k\u00f6nnen zur \nStellung der Diagnose beitragen. Niedrige oder mittlere Ak-Titer sollten nicht zur Diagnosefindung herangezogen werden. Lutz et al . (1986) stellten fest, da\u00df bei Katzen, bei \ndenen postmortal FIP diagnostiziert wurde,  die Ak-Titer > 400 lagen. Bei nachweislich \nnicht an FIP erkrankten Katzen dagegen tret en Ak-Titer > 400 nur in Ausnahmef\u00e4llen auf. \nDie Autoren betrachten deshalb Ak-Titer > 400 zusammen mit einer klaren klinischen \nSymptomatik als hilfreichen, jedoch nicht einde utigen Hinweis. Unbedingt zu beachten ist \nbei der CoV-Ak-Titerinterpretation die Haltungs form der Katzen, da die Seren aus Zuchten \nund Mehrfachkatzenhaltungen h\u00e4ufig hochtitriger sind als Seren von klinisch gesunden Katzen aus Einzelhaltung (Vanden Bossche, 1990a). Das bedeutet, da\u00df Katzen mit klinischem FIP-Verdacht aus Einzelhaltunge n mit hohen Ak-Titern wahrscheinlicher FIP \nhaben, als solche aus gr\u00f6\u00dferen Best\u00e4nden. \n \n2.6.1.2           Kompetitiver ELISA zum Nachweis von Coronavirus Immunkomplexen  \n \nIn diesem Test werden die f\u00fcr die FIP ch arakteristischen Immunkomplexe nachgewiesen \n(Pfeiffer, 1991; Schroo, 1994). Zur Untersuchung eignen sich Serum- oder Aszitesproben \n(200-300 \u00b5l sind ausreichend). Bis zum Testeinsatz sollten die Proben tiefgek\u00fchlt gelagert \nwerden. Bei einer im ELISA positiv reagie renden kranken Katze liegt mit 97%iger \nWahrscheinlichkeit eine FIP vor (Reinacher, 1994) . Die so nachgewiesene Infektion erlaubt \nbei gesunden Katzen aber keine Vorhersage, ob das Tier eine klinisch manifeste FIP \nentwickeln wird. Somit wird nur eine st attgefundene Infektion mit Virusvermehrung \nnachgewiesen, bei der zirkulierende I mmunkomplexe vorhanden sind. Ein negatives \nTestergebnis schlie\u00dft das Vorliegen einer FI P nicht aus. Bei grenzwertigen Ergebnissen \nempfiehlt sich nach sechs Wochen eine N achtestung. Nachteile des ELISA sind der enorme \nAufwand (K\u00fchlzentrifugation bei hohen Drehzahle n) und der Zeitfaktor (1\u00bd Tage). Diese \nUmst\u00e4nde beschr\u00e4nken den Routineeinsatz (Reinacher, 1994). Literatur\u00fcbersicht \n 18 \n2.6.2  Punktat \n \nObwohl FIP-Katzen die gr \u00f6\u00dfte Gruppe unter den Patienten mit K\u00f6rperh\u00f6hlenerg\u00fcssen \ndarstellen, kann die FIP keineswegs als die Hydropsursache schlechthin angesehen werden \n(Hirschberger et al., 1995). Generell werden be i der FIP wesentlich h\u00e4ufiger abdominale als \nthorakale Erg\u00fcsse beobachtet. In Zellen in den Effusionen ist Coronavirus mittels der direkten Immunfluoreszenztechnik nachweisba r (Cammarata et al., 1993). Die Aszites- und \nPleurafl\u00fcssigkeit ist klar, im fortgeschrittene n Stadium visk\u00f6s, geruchlos, fadenziehend und \nvon gelblicher oder stroh\u00e4hnlicher bis gelblichbrauner (bernstein\u00e4hnlicher) Farbe. Es handelt sich um zellarme Exsudate. An der Luft erfolgt schnell eine Gerinnung bzw. Gelierung. Fibrinflocken k\u00f6nnen enthalten sein. Das ist auch der h\u00e4ufigste Grund, wenn bei \nder abdominalen Punktion die Kan\u00fcle ve rstopft (Gerbig und Kraft, 1979). Die \nPunktionskan\u00fcle sollte deshalb mindesten s einen Durchmesser von 0,9 mm haben. Der \nErgu\u00df ist f\u00fcr gew\u00f6hnlich bakteriologisch steril (Weiss und Scott, 1980). Bei langem Verlauf ist eine pseudochyl\u00f6se Umwandlung de s Exsudates m\u00f6glich. Einige m\u00f6gliche \nLaborbefunde sind in Tabelle 3 (Weiss und Sco tt, 1980; Rohrer et al., 1993; Hirschberger \net al., 1995) zusammengefa\u00dft. \nHilfreich bei der Diagnostik bei Katzen mit K\u00f6rperh\u00f6hlenerg\u00fcssen ist im Zweifelsfall auch \nder Albuminglobulinquotient (Alb/Glob). Ein Al b/Glob < 0,6 im Serum ist spezifisch f\u00fcr \neinen entz\u00fcndlichen Proze\u00df und trennt weitgeh end FIP-kranke Patienten von anderen. Ein \nAlb/Glob \u2265 0,8 schlie\u00dft FIP fast aus (Hirschbe rger et al., 1995). Ein hohes Ma\u00df an \nSensitivit\u00e4t und Spezifit\u00e4t weist der Rivalta-Test auf (Hirschberger et al., 1995). \n \nTabelle 3: Laborbefunde bei FIP-Erg\u00fcssen (Thorax und Abdomen) \nParameter Laborwert \nLaktatdehydrogenaseaktivit\u00e4t < 300 U/l: keine FIP \nRIVALTA-Probe stets positiv \nGammaglobulin > 32%: FIP m\u00f6glich \nAlb/Glob-Quotient 0,6-0,81 \nspezifisches Gewicht 1017-1047 \nProteinkonzentration 50-80 g/l \nZellgehalt < 25 000 Leukozyten/\u00b5l Literatur\u00fcbersicht \n 19 \n2.6.3  Virusnachweis \n \nEine routinem\u00e4\u00dfige Virusisolation zur FI P-Diagnose ist nicht m\u00f6glich (Barlough und \nWeiss, 1983), da insbesondere die in Feldin fektionen dominierenden Serotyp I FCoV nur \nschlecht in der Gewebekultur wachsen (Peder sen et al., 1984a, b; Hohdatsu et al., 1992; \nVennema, 1999). In vivo wurde das FIPV elektronenmikroskopisch in Makrophagen \ninnerhalb entz\u00fcndlicher Ablagerungen nac hgewiesen (Ward, 1970; Pedersen, 1976b). Die \nImmunhistologie ist ein etabliertes Verfah ren, um postmortal mittels FCoV-Antigen-\nNachweis in Makrophagen in den Granulomen die Diagnose FIP zu best\u00e4tigen (Tammer et \nal., 1995; Tammer, 1996; Kipar et al., 1998). Intra vitam kann die histologische \nUntersuchung einer Biopsie zusammen mit dem immunhistologischen Nachweis von \nFCoV-Antigen in den Granulomen die k linische Verdachtsdiagnose FIP best\u00e4tigen \n(Reinacher, 1994; Tammer et al., 1995; Kipar et al., 1998). Mittels RT-PCR l\u00e4\u00dft sich \nFCoV-Genom in Blut, Aszites, Granulomen  und F\u00e4zes nachweisen (Li und Scott, 1994; \nHerrewegh et al., 1995b; Addie et al., 1996; Richter et al., 1996; Foley et al., 1997b; \nGamble et al., 1997; Gunn-Moore et al., 1998; Kennedy et al., 1998; Kipar et al., 1999b). \nKennedy et al. (1998) meinen, da\u00df die PCR (Asz ites oder Plasma als Proben) in der intra \nvitam-Diagnostik mit der Genauigkeit der hi stopathologischen Untersuchung vergleichbar \nist, ohne das Risiko, welches die Biopsie in sich birgt. Der Nachweis der Virusausscheidung ist mittels RT-PCR und Elek tronenmikroskopie (Negativ-Staining) zum \nNachweis von Viruspartikeln in den F\u00e4zes m\u00f6glich (Herrewegh et al., 1995b; Vieler und \nHerbst, 1995; Addie et al., 1996; Gamb le et al., 1997; Kipar et al., 1999b). \nH\u00f6k (1990, 1991) sah auch den FCoV-Antigen-N achweis in der Membrana nictitans (M3-\nTest) als spezifischen und sensitiven Test f\u00fcr die intra vitam-Diagnose einer FIP an. Sie \nkonnte bei experimentell infizierten Tieren FC oV aus der Membrana nictitans isolieren \n(H\u00f6k, 1993a, b). Allerdings ist zu bedenken, da \u00df auch Katzen, die keine FIP entwickeln, \ndurchaus lokale FCoV-Infektionen am Auge  durchmachen k\u00f6nnen. Darauf deutet der \nNachweis von Plasmazellen in situ, die FCoV -spezifische Antik\u00f6rper produzieren, in der \nKonjunktiva von Katzen ohne spezifische Augenl\u00e4sionen und ohne FIP hin (Weber, 2000). \n \n2.6.4  Zerebrospinalfl\u00fcssigkeit \n \nDie Entnahme von Liquor ist eine f\u00fcr die Katze belastende diagnostische Ma\u00dfnahme und \nsollte deshalb wohl \u00fcberlegt sein. Die Untersuchung des Liquors ist schwierig und Literatur\u00fcbersicht \n 20 \naufwendig, was die praktische Durchf\u00fchrung zus\u00e4tzlich limitiert (Rohrer et al., 1993). \nDiagnostisch verwertbar sind die stets pos itive Pandy-Reaktion (Eiwei\u00dff\u00e4llungsreaktion \nzum semiquantitativen Nachweis einer Globuli nvermehrung im Liquor cerebrospinalis mit \neiner speziellen Karbols\u00e4urel\u00f6sung) und der N achweis einer Pleozytose (Zellvermehrung \nim Liquor cerebrospinalis) (Fankhauser und Fatzer, 1977). \n \n2.6.5  Diagnoseschl\u00fcssel \n \nIm Jahre 1992 wurde aufgrund der Ergebnisse ei ner retrospektiven Studie in der Schweiz \nein Algorithmus entwickelt, der zur Diagnostik der FIP eine wertvolle Hilfe darstellt \n(Rohrer et al., 1993). Dazu wurden in den Ja hren 1982-1990 an der Veterin\u00e4rmedizinischen \nKlinik der Universit\u00e4t Z\u00fcrich 136 an FIP erkr ankte Katzen untersucht, wobei die klinische \nFIP-Diagnostik in den Mittelpunkt gestellt wurde. Schwerpunkt war die kritische Auseinandersetzung mit den serologischen Co V-Ak-Titern. Eine FIP-Diagnose, die sich \nallein auf einen positiven CoV-Ak-Titer st\u00fctzt , kommt nach Rohrer et al. (1993) einem \nKunstfehler gleich und berechtigt keinesfalls  zur Euthanasie des betroffenen Tieres. \nInteressant ist der Algorithmus haupts\u00e4chlich f\u00fcr die differentialdiagnostisch anspruchsvolle nichteffusive Form der FIP. Ein \u00e4hnliches Diagnoseschema ver\u00f6ffentlichten \n1997 McReynolds und Macy. Nur knapp 5% der an FIP erkrankten Katzen wurden in der \nStudie von Rohrer et al. (1993) nicht durch den Algorithmus erfa\u00dft. Das entspricht einer \ndiagnostischen Sensitivit\u00e4t von 95%. Die diagnostische Spezifit\u00e4t betrug 89%. \n \n2.6.6  Differentialdiagnosen der FIP \n \n2.6.6.1  Differentialdiagnosen der effusiven FIP  \n \nDie Ursachen von K\u00f6rperh\u00f6hlenerg\u00fcssen bei de r Katze k\u00f6nnen vielf\u00e4ltig sein (Kersten, \n1985). Alle Krankheitsprozesse, die zu ei ner Fl\u00fcssigkeitsansammlung in Bauch- oder \nBrusth\u00f6hle f\u00fchren k\u00f6nnen, kommen in Frage (Gerbig und Kraft, 1979). Dazu geh\u00f6ren \nSteigerung des h\u00e4mostatischen Druc kes durch Stauungen, Verminderung des \nkolloidosmotischen Druckes durch Hypalbumin\u00e4mie, entz\u00fcndliche Prozesse (Serositis purulenta), Pfortaderthrombosen, Verletzunge n des Ductus thoracicus (echter Chylus), \nEiwei\u00dfabbauprodukte bei \u00e4lteren entz\u00fcndlichen Prozessen (Pseudochylus), Verletzung der \nharnableitenden Wege, Verletzung der Galleng\u00e4nge und Gallenblase, Verletzung gr\u00f6\u00dferer Literatur\u00fcbersicht \n 21 \nGef\u00e4\u00dfe und Organe (Blutungen, H\u00e4mato me) und Tuberkulose. Als wichtigste \nDifferentialdiagnosen kommen Malignome und Herzinsuffizienz \u00e4tiologisch in Betracht \n(Hirschberger et al., 1995). Horchler-Jahn und Seidel (1993) beschrieben bei der Katze \neinen Fall von Aszites abdominalis infolge eines Luteoms. \n \n2.6.6.2  Differentialdiagnosen der nichteffusiven FIP \n \nPrinzipiell sind differentialdiagnostisch chronische entz\u00fcndliche Erkrankungen mit \nHyperglobulin\u00e4mie und andere Infektionskrankheiten (z. B. Toxoplasmose, Tuberkulose, Blastomykose, Kryptokokkose, Yersiniose, FeLV-Infektion, Kokzidiose und Tollwut) abzukl\u00e4ren (Rohrer et al., 1992, 1993; Hirschberger etal., 1995). \nZur ZNS-Form der FIP kommen besonders be i jungen Katzen differentialdiagnostisch \nKleinhirnhypoplasie oder zerebell\u00e4re Ataxie in Betracht (Fankhauser und Fatzer, 1977), \nebenso sind leukodystrophische Erkrankungen de s Gehirns (Typus Krabbe [Fatzer, 1975]), \nLipidosen und Gangliosidosen (Speicherkrankheiten) beschrieben (Hirschberger et al., 1995). \nIn Betracht ziehen sollte man bei ausschlie\u00df licher ZNS-Symptomatik bei der Katze auch \nIntoxikationen und Traumata (Fankhauser und Fatzer, 1977) \n \n2.7  Pr\u00e4vention \n \nDas Management in Katzenzuchten oder gr\u00f6\u00dfere n Best\u00e4nden spielt eine wichtige Rolle bei \nder Verh\u00fctung von Coronavirus-Infekti onen (Addie und Jarrett, 1990). Nur ein \nkonsequentes, komplexes Programm ist wir kungsvoll (Addie und Jarrett, 1995). Es wird \nangeraten, neugeborene Katzen zusammen mit ih ren Wurfgeschwistern vollst\u00e4ndig isoliert \nvon anderen Katzen zu halten. Bei einem ser opositiven Muttertier sollten die Welpen mit 5-\n6 Wochen abgesetzt und von der Mutter separiert werden, da maternale Antik\u00f6rper gegen FCoV nur bis zur 6. Woche protektiv sind. Insg esamt ist es sinnvoll, die Stre\u00dffaktoren zu \nminimieren. Dabei sollten optimale Ern\u00e4hrung, regelm\u00e4\u00dfige Impfungen und Entwurmungen sowie ein entsprechender Hygienestandard selbstverst\u00e4ndlich sein. Eine geringe Haltungsdichte wird empfohlen (B arlough und Stoddart, 1990; Weiss, 1991; Lutz \net al., 1985). CoV-Ak-positive Tiere sollten nich t in CoV-Ak-negative Best\u00e4nde verbracht \nwerden. Mit persistent FeLV-infizierten Tieren sollte nicht gez\u00fcchtet werden. Neuzug\u00e4nge in Zuchten sollten auf CoV-Ak getestet werden, eine Quarant\u00e4ne ist obligat. Sollte ein Tier Literatur\u00fcbersicht \n 22 \nan FIP erkranken, ist es sofort aus dem Best and zu eliminieren. Zuchten sollten j\u00e4hrlich bei \n10-20% der Population eine CoV-Ak-Titerbes timmung durchf\u00fchren (B\u00f6lcskei et al., 1995). \nFehr et al. (1995) nehmen an, da\u00df mit dies en Ma\u00dfnahmen, kombiniert mit der Impfung, die \nFIP-H\u00e4ufigkeit noch wirkungsvoller bek\u00e4mpft werden k\u00f6nne. Privathaushalte, die ein Tier \ndurch die FIP verloren haben, sollten sich fr \u00fchestens nach zwei Wochen sowie gr\u00fcndlicher \nReinigung und Desinfektion eine neue Katze anschaffen. Vollkommen einzeln gehaltene \nHauskatzen sind relativ ungef\u00e4hrdet, jedoch gi bt es auch hier Berichte \u00fcber Erkrankungen \n(Suter et al., 1993). \n \n2.7.1  Vakzination \n \nDas Hauptproblem bei dem Versuch der Vakzin ation ist die nicht vollst\u00e4ndig aufgekl\u00e4rte \nPathogenese der FIP sowie die antigenetisch e Kreuzreaktion zwischen den verschiedenen \nfelinen Coronavirusbiotypen. Daraus ergebe n sich viele Betrachtungsvarianten und viele \nAnsatzpunkte f\u00fcr eine eventuelle L\u00f6sung der Problematik. Viele Forscher versuchten \njahrelang, eine sichere und effektive FIP-Vakzine zu entwickeln (Scott, 1987; Olsen und Scott, 1991). Der ideale Impfstoff wurde beschrieben als eine auf dem FIPV basierende Lebendvakzine, die in die Makrophagen eindri ngt und eine zellvermittelte Immunantwort \ninduziert, ohne die Krankheit auszul\u00f6sen, vor der sie sch\u00fctzen soll (Pedersen und Black, 1983; Pedersen, 1989). Die verschiedenste n Methoden der Immunisierung wurden \nversucht, waren aber lange erfolglos (Sco tt, 1987). Eine kommerzielle FIP-Vakzine ist \nverf\u00fcgbar, aber der Einsatz ist umstritten (Wolf, 1997). \n \nTeilweisen Erfolg versprachen Versuche, Kat zen mit gering virulentem FIPV oder kleinen \nMengen virulenter Viren zu immunisieren. Dies scheiterte jedoch an der Ermittlung der \nentsprechenden Dosen. Mit derselben Dosis einer Charge wurden manche Katzen immun, andere erkrankten, wiederum andere konnten  nicht einmal dadurch infiziert werden. \nVakzinen, die totes Virus enthielten, waren eb enfalls nicht protektiv (Pedersen und Black, \n1983). Der eintretende Effekt war sogar gegente iliger Natur, es wurde eine Sensibilisierung \nder Katzen in dem Sinne bewirkt, da\u00df sie f\u00fcr eine nachfolgende FIPV-Infektion empf\u00e4nglicher wurden. Der Krankheitsverlauf war dann fulminanter und deutlich schwerer \nals bei ungeimpften Tieren. Das gleiche gesc hah mit Katzen, die mit avirulentem FIPV \n(Black-Stamm) oronasal infiziert wurden und anschlie\u00dfend einer oronasalen Belastungsinfektion mit einem virulenten  FIPV-Stamm (UCD 1 oder NWI) unterzogen Literatur\u00fcbersicht \n 23 \nwurden (Pedersen und Floyd 1985). Als Urs ache f\u00fcr das Versagen von avirulenten \nLebendimpfstoffen bei der Immunisierung ge gen das FIPV sahen Pedersen und Black \n(1983) das Ph\u00e4nomen des ADE. Au\u00dferdem stellte n sie die Hypothese auf, da\u00df avirulentes \nVirus nicht protektiv wirken k\u00f6nne, weil es nicht lange genug im K\u00f6rper persistiere. \nFehr et al. (1997) bewerteten einen modifizierten Lebendimpfstoff in einem \nDoppelblindversuch mit Placebo-Kontrolle unter Feldbedingungen als sicher bei Tieren mit \nniedrigen Antik\u00f6rpertitern gegen FCoV, wenn nur geringer Infektionsdruck besteht. \nTeilweisen Erfolg hatten Escobar et al. (1992) mit einem Immunisierungskonzept mit speziellen Antik\u00f6rpern (\u201canti-idiotypic antibodies\u201c), welches aber nicht in der Lage war, alle Tiere zu sch\u00fctzen. \nObwohl mit dem FIPV Ferkel gegen eine  TGEV-Infektion gesch\u00fctzt werden k\u00f6nnen, \nmi\u00dfgl\u00fcckten Versuche, Katzenwelpen mit dem TGEV zu immunisieren (Toma et al., 1979; \nWoods et al., 1979). Die mit TGEV vakzin ierten Katzen \u00fcberlebten eine FIPV-\nBelastungsinfektion (UCD 1) nicht (Woods  und Pedersen, 1979). Auch Versuche, bei \ndenen andere nahe verwandte Coronavi ren wie das FECV, CCV oder das HCV-229E \ngenutzt wurden, schlugen fehl (Pedersen, 1989). In dieser Ver\u00f6ffentlichung postulierte der Autor, eine auf dem FECV basierende Va kzine k\u00f6nnte eventuell deshalb nicht vor FIP \nsch\u00fctzen, weil sie zur Antik\u00f6rper-Produktion f\u00fchrt und keine zellvermittelte Immunit\u00e4t erzeugt. Immunisierungen mit verschiedenen FECV-St\u00e4mmen verst\u00e4rkten in manchen F\u00e4llen den Verlauf der Infektion mit versch iedenen FIP-St\u00e4mmen. (Evermann et al., 1991). \nCCV ergab keinen Impfschutz gegen\u00fcber einer Belastungsinfektion mit FIPV (Barlough et al., 1983b). Eine Infektion mit HCV-229E  sch\u00fctzte Katzen nicht bei einer \nBelastungsinfektion mit FIPV-Aerosol, sensibilisie rte sie aber auch nicht. Es fand nur eine \ngeringgradige oder gar keine in vivo-Vermehrung von HCV-229E in inokulierten Katzen statt (Barlough et al., 1985).  \n \nEbenfalls keinen Erfolg hatten Vennema et al. (1990) bei der Anwendung eines vacciniarekombinanten Impfstoffes. Das kodierte Gen f\u00fcr das Spike-Glykoprotein des \nFIPV wurde ins Genom des Pockenvirus eingebaut. Nach einer initialen Impfung von Katzen stellte man geringe Titer virusneutralisierender Antik\u00f6rper und einen hohen IgG-Gehalt fest. Bei der anschlie\u00dfenden Belast ungsinfektion mit dem FIPV 79-1146 starben \njedoch die mit dem rekombinanten Impfstoff vakzinierten Tiere fr\u00fcher als diejenigen, die mit einem Wildtyp-Pockenvirus immunisiert worden waren (\u201cearly death syndrome\u201c). Die Ursache daf\u00fcr sahen Vennema et al. (1990) in dem Ph\u00e4nomen des ADE. Es ist also Literatur\u00fcbersicht \n 24 \nm\u00f6glich, da\u00df eine Immunantwort gegen das vi rale Spikeprotein verheerende Folgen f\u00fcr \neine Katze haben kann, die sich zu einem sp\u00e4t eren Zeitpunkt mit dem FIPV infiziert. Die \nAutoren betonten darauf hin, da\u00df bei den Immunisierungsstrategien gegen das FIPV \nextreme Sorgfalt n\u00f6tig sei. Die Imm unisierung nach gleichem Modell mit \nvacciniarekombinantem M-Protein verk\u00fcrzte im Gegensatz zu einer Immunisierung mit \ndem N-Protein ebenfalls die \u00dcberlebenszeit n ach einer Belastungsinfektion (Vennema et \nal., 1991). \nDer Gedanke, einen Impfversuch mit einem temperatursensitiven FIPV-Stamm \ndurchzuf\u00fchren, wurde von Baldwin und Scott ( 1997) aufgegriffen. Man benutzte die FIPV-\nSt\u00e4mme UCD1 und 1146. FIPV 1146 wurde bei einer suboptimalen Temperatur von 34\u00b0C passagiert. Im Versuch wurden 14 12-Wochen alte SPF-Katzen zuerst intratracheal mit low passage-(LP) FIPV-1146 konfrontiert, am 133. Tag erfolgte eine zweite Inokulation \nintranasal mit high passage (HP)-FIPV-1146 [10\n4 bis 106 TCID 50]). Die Tiere wurden in \nzwei Gruppen geteilt. Nach 55 Tagen erfolgte die aerogene Belastungsinfektion mit virulenten FIPV-1146 oder FIPV-UCD1. Der klinische Status der Tiere, die mit der intratrachealen/intranasalen Kombination geim pft wurden, war unauff\u00e4llig, der Schutz aber \nnicht komplett, wie die histologischen Unte rsuchungen ergaben. Nach der intranasalen \nApplikation zeigten alle Tiere Serokonversi on. Im Experiment wurde mit verschiedenen \nDosierungen bei der intratrachealen Applikation gearbeitet. Serologische Reaktionen konnten bei Katzen, die mit 100 PFU (plaque  forming units) oder weniger inokuliert \nwurden, nicht gefunden werden. Auch bei 1000 PFU  reagierten nicht alle Tiere. Nur vier \nTiere (10.000, 100.000 oder 400.000 PFU) serokonvertie rten. Einige geimpfte Katzen \nerkrankten bereits bei 10 000 PFU, andere K ontrolltiere dagegen nicht, obwohl eigentlich \ndie aerosole Belastungsinfektion t\u00f6dlich h\u00e4tte sein m\u00fcssen. Die Autoren vermuten, da\u00df der \nSchutz durch das intratracheal verabreichte temperatursensitive FIPV-1146 verursacht wurde. Auch wurde in Erw\u00e4gung gezogen, da\u00df das FIPV durch die Z\u00fcchtung bei \nreduzierter Temperatur genetisch stark ver\u00e4 ndert wird, weniger virulent ist und der IgA-\nAnstieg gering ist. \n \n2.7.1.1  Primucell\u00aeFIP \n \nPrimucell\u00aeFIP erf\u00fcllt viele der n\u00f6tigen Kriterien f\u00fcr den idealen Impfstoff. Drei wichtige \nBedingungen wurden bei der Herstellung erf\u00fcllt: Literatur\u00fcbersicht \n 25 \n1. bei intranasaler Verabreichung wird in  der Nasen-Rachen-Mukosa eine starke \nImmunantwort induziert, \n2. es entsteht keine starke humorale, sondern  eine zellvermittelte Immunit\u00e4t (gemessen im \nLymphozytenstimulationstest), \n3. eine systemische Ausbreitung des Virus unterbleibt. \nDas Impfvirus (vom Serotyp II abgeleitet) unterscheidet sich durch \nTemperaturempfindlichkeit, RNA-Synthese, E1-P rotein (jetzt als M-Protein bezeichnet), \nThermolablit\u00e4t und das ausschlie\u00dfliche Wachst um in oropharyngealen Geweben bei einer \nTemperatur von 31\u00b0C (Christianson et al., 1989;  Gerber et al., 1989) von dem virulenten \nFIPV-Elternstamm. Die Proteine der temperat ursensitiven (ts)-Mutante, die in den Zellen \ndes oberen Respirationstraktes exprimiert werden, stimulieren die Bildung von lokalem IgA, so da\u00df die Prim\u00e4rinfektion nach E xposition unterbleibt (Gerber et al., 1991). Bei \ngeimpften Katzen wurde das ts-Virus aus dem Pharynx, den Tonsillen, der Trachea und den \nEndoturbinalia am ersten, zweiten und vierten Tag nach der Vakzination isoliert. Eine \nsystemische Ausbreitung wurde nicht gefunden (Christianson et al., 1989). \nBeeintr\u00e4chtigungen durch andere oder von anderen Impfstoffen konnten nicht \nnachgewiesen werden (Gerber, 1995). \nDie Vakzine Primucell\u00aeFIP ist prinzipiell auch geeignet, eine FECV-Infektion zu \nverhindern. In Versuchen mit seronegativen  SPF-Katzen konnten die Impftiere vor einer \nFECV-Infektion bzw. vor einer FECV-induzierten  Enteritis gesch\u00fctzt werden (Hoskins et \nal., 1995a). \nVorab get\u00e4tigte Studien zeigten die Sicherhe it der Vakzine (Gerber et al., 1989). Hawkins \n(1991) wandte allerdings ein, da\u00df die dauernde  Stabilit\u00e4t der ts-Virusmutanten noch nicht \nbewiesen sei. Auch m\u00fcsse gekl\u00e4rt werde n, ob eine Rekombination des Impfvirusstammes \nmit Feldviren vorkommen k\u00f6nnte, was f\u00fcr vakz inierte Katzen eine verheerende Wirkung \nhaben k\u00f6nnte. Der Impfschutz der Vakzine lag nach  einer ersten oralen Infektion mit einem \nvirulenten (homologen) FIPV-DF 2 bei 85%, nach  einer zweiten bei 80 %. Keines der Tiere \nzeigte eine ADE. Die geimpften Katzen wies en h\u00f6here IgA-Spiegel im Speichel auf \n(Gerber et al., 1990, 1991). \nScott et al. (1992, 1995a) stellten fest, da\u00df der Schutz vor experimentellen Infektionen vom \nVirusstamm und insbesondere von der Virusdosis  abh\u00e4ngig ist. Sie beobachteten die ADE \nbei Infektion mit hohen Dosen des homologen Vi russtammes sowie bei Infektion durch den \nheterologen Virusstamm 79- 1146. Eine Exposition mit > 105 TCID 50 (Tissue culture \ninfectious dose 50%) f\u00fchrte bei einigen Tieren  zu einem schnelleren Krankheitsverlauf. Sie Literatur\u00fcbersicht \n 26 \nkonnten damit die fr\u00fcheren Ergebnisse von Gerb er et al. (1990) nicht best\u00e4tigen. Die \nexperimentelle Belastungsinfektion bezeic hneten sie als kritischen Faktor f\u00fcr die \nWirksamkeit der Vakzine. \nAuch gegen eine Infektion mit dem britis chen Feld-FIPV-Stamm CVR 1036 konnte die ts-\nFIPV-Vakzine nicht sch\u00fctzen. Orale Infektionsdosen von 103 bis 105 TCID 50 verursachten \nzu 75% und dar\u00fcber FIP (McArdle et al., 1995). \nHoskins et al. (1995b) berichteten \u00fcber eine  Studie, bei der 20 Tiere in der 16. und 19. \nLebenswoche intranasal mit einer kommerziellen Charge des ts-FIPV vakziniert wurden, \n20 andere Tiere dienten als Kontrollgruppe. Vier  Wochen nach der Boosterung erfolgte f\u00fcr \nalle Tiere die Belastungsinfektion mit 103 TCID 50 des FIPV-DF2. In der Impfgruppe \nerkrankten 5%, in der Kontrollgruppe 25% klin isch an FIP. In der endg\u00fcltigen Auswertung \nnach Sektion und Immunhistologi e betrug die gesch\u00fctzte Fraktion (preventable fraction) \n50%. \nFanton (1991) wies in Langzeitstudien nach, da\u00df die Vakzine Katzen nicht f\u00fcr eine FIP \nsensibilisiert. Die Anwendung k\u00f6nne au\u00dferdem  ohne Ber\u00fccksichtigung des FeLV- oder \nFIV-Status erfolgen. \nIn einer anderen Feldlangzeitstudie (Posto rino Reeves et al., 1992) wurden 582 Katzen \nverschiedenen Alters mit je 2 Dosen vakzin iert. 453 Tiere waren 541 Tage f\u00fcr diese Studie \nverf\u00fcgbar. Davon starb nur ein Ti er an FIP (Inzidenz: 0,2 %). Weiterhin zeigte diese Studie \ndie Unbedenklichkeit einer gleichzeitigen vera breichten anderen Routineimpfung, was bei \n68 % der Katzen praktiziert wurde. Negativ e Effekte durch die Kombinationsimpfungen \nkonnten nicht beobachtet werden. \nBerichte \u00fcber den Einsatz der Primucell\u00aeFIP-Vakzine mehrten sich in den letzten Jahren, \nviele sind aber kritisch zu betrachten, weil of tmals eine Kontrollgruppe fehlte. Im Juli 1989 \nkam es in einer Mehrfachkatzenhaltung (Rasse : Cornish Rex) mit 39 Tieren aufgrund einer \ndazugesetzten Katze zum Einschleppen des FIPV. Das hinzugekomme ne Tier starb, die \nObduktion ergab den Befund \u201cnichteffusive FI P\u201c. In den n\u00e4chsten 6 Monaten starben 17 \nKatzen. Davon wurde die Diagnose effusive FIP bei 7 Katzen durch die Sektion best\u00e4tigt, \nbei den restlichen wurde aufgrund der deutlichen Symptomatik auf eine Sektion verzichtet. Im Februar 1990 entschied man sich dann, alle  verbliebenen 19 Tiere (3 Tiere wurden \nverkauft) intranasal mit Primucell\n\u00aeFIP zu immunisieren. Geboos tert wurde nach 21 Tagen. \nDie im Anschlu\u00df geworfenen insgesamt 39 We lpen wurden im Alter von 8 und 11 Wochen, \nsp\u00e4tere W\u00fcrfe sogar in der 3., 6. und 9. Lebens woche immunisiert. Damit waren die Tiere \ndeutlich unter dem vom Hersteller empfohlenen  Impfalter. Die Population wurde dann 18 Literatur\u00fcbersicht \n 27 \nMonate lang ab der initialen Impfung beobachtet. Es starben weitere 9 adulte Tiere, jedoch \nnur 1 Welpe an FIP. Aufgrund der Ergebnisse wurde postuliert, da\u00df die Impfung eine sichere Ma\u00dfnahme und Hilfe sei, um die Kr ankheit unter Kontrolle zu halten (Panzero, \n1992). \nHoskins et al. (1994) f\u00fchrten an 40 16-Wochen alten SPF-Katzen eine Studie zur Wirksamkeit von Primucell\n\u00aeFIP durch. Alle Tiere wurden Routineimpfungen unterzogen, \nnachfolgend in zwei Gruppen von je 20 Tieren randomisiert und separat gehalten. Eine Gruppe wurde mit einer kommerziellen Charge der Vakzine Primucell\n\u00aeFIP in der 16. und \n19. Lebenswoche intranasal geimpft. Die zweite Gruppe blieb unbehandelt. Placebos wurden nicht verwandt. Im Alter von 23 Wochen, vier Wochen nach der Boosterung der Gruppe 1 mit Primucell\n\u00aeFIP, wurden alle Tiere unter Infektionsdruck gebracht. Dazu \nerfolgte die orale Applikation von 103 TCID des FIPV-Stammes DF 2 in jedes Tier. Die \nBeobachtungsperiode betrug 8 Wochen und liefe rte klare Ergebnisse. Es erkrankten nur \neine vakzinierte Katze, aber f\u00fcnf Kontro lltiere. Am Ende des Versuchs durchgef\u00fchrte \nhistopathologische Untersuchungen an den eu thanasierten Tieren ergaben f\u00fcr FIP \ncharakteristische Ver\u00e4nderungen bei sechs Ti eren der Impfgruppe und bei 12 Tieren der \nKontrollgruppe. Daraus resultierte ein 50%iger Schutz durch die eingesetzte Vakzine. Die Gewichtszunahmen im Versuchzeitraum ware n in der Impfgruppe deutlich \u00fcber denen der \nKontrollgruppe. Die Erh\u00f6hung der K\u00f6rpertemperat ur war bei allen vakzinierten Tieren \ngeringer als in der Kontrollgruppe. Serokonversion zeigten alle Katzen, die Impftiere bereits nach der Boosterung und Inokulation. Die Kontrollkatzen wiesen nach der Infektion \ndeutlich ansteigende FCoV-Ak-Titer auf, die \u00fcber denen der Impftiere lagen. \nVon Januar 1993 bis November 1994 wurde in der Schweiz ein Doppelblindversuch mit \nPrimucell\u00aeFIP bez\u00fcglich der Sicherheit und Wirksamkeit der Vakzine durchgef\u00fchrt (Fehr \net al., 1995). Es wurden also ein Placebo und der echte Impfstoff verwandt, ohne da\u00df der \nTester im Versuchszeitraum aufgekl\u00e4rt war, welche Charge Placebo und welche Vakzine war, lediglich die Etiketten waren farblich verschieden. Getestet wurde in Zuchten, in denen in der Vergangenheit FIP-F\u00e4lle aufg etreten waren, und an Jungtieren. Es wurde \nrandomisiert. Die Nebenwirkungen der Impfung wa ren minimal. FIP-F\u00e4lle traten in der \nKontroll- und der Impfgruppe gleicherma\u00dfen auf, erst nach 150 Tagen gab es einen \nsignifikanten Unterschied zugunsten der vakz inierten Gruppe. Der Impfstoff wurde als \nsicher und mit dem Potential, sch\u00fctzen zu k\u00f6nnen, eingestuft. Bei bereits infizierten Tieren, \nvermochte der Impstoff nicht mehr zu sch\u00fctzen. Im nachhinein erwiesen sich \u00fcber 50% der \ngeimpften Katzen zum Zeitpunkt der ersten Vakzination als serologisch CoV-Ak-positiv.  Literatur\u00fcbersicht \n 28 \nPostorino Reeves (1995) untersuchte  die Wirkung der Vakzine Primucell\u00aeFIP \u00fcber 16 \nMonate in einem Tierheim. Die FIP-Pr\u00e4valen z lag dort in der Vergangenheit bei \u00fcber vier \nProzent. Alle in den Bestand kommenden gesunden Tiere (FeLV-Ag/FIV-Ak-negativ) \nwurden intranasal geimpft, entweder mit Primucell\u00aeFIP (254 Tiere) oder einem Placebo \n(246 Tiere). Die Gesamtverluste waren in beiden Gruppen \u00e4hnlich, ungew\u00f6hnliche \nKrankheiten traten nicht auf. Die FIP-Inzidenz war in der Impfgruppe signifikant niedriger. \n \nDie Akzeptanz f\u00fcr eine FIP-Impfung ist bei den Katzenz\u00fcchtern in Ungarn nach den Angaben von B\u00f6lcskei et al. (1995) gering. Die Ursache daf\u00fcr sehen die Autoren in \nfolgenden offenen Fragen: \n1. l\u00e4\u00dft sich eine Katze unter Feldbedingungen wirksam sch\u00fctzen, \n2. lassen sich seropositive Katzen durch die Vakzination sch\u00fctzen, \n3. mu\u00df man unter Feldbedingungen mit der ADE rechnen; wenn ja, wie h\u00e4ufig? \nKleinere und mittlere Katzenz\u00fcchter (< 3 bzw. 3-5 Zuchkatzen) sowie Katzenliebhaber lassen nach dieser Untersuchung h\u00e4ufig gege n FIP impfen, gr\u00f6\u00dfere Katzenz\u00fcchter (mehr \nals 5 Katzen) verzichten dagegen meis t darauf. Aufgrund der Ergebnisse ihrer \nretrospektiven FIP-Studie wurde aber von den Autoren die Vakzinierung empfohlen. \nKatzen, die neben den Routineimpfungen auch gegen FIP vakziniert wurden, erkrankten \nweniger. Eine Absicherung der Diagnose FIP zur Ermittlung der wahren Inzidenz gab es \njedoch nicht. \n \n2.8.  Therapie \n \nEine symptomatische Therapie ist immer a ngezeigt, nicht zuletzt, um Schmerzen und \nLeiden des Tieres zu lindern. Sinnvoll ist sie aber nur im Anfangsstadium der FIP (Bilkei, \n1988; B\u00f6lcskei und Bilkei, 1995a, b), wenn die allgemeine k\u00f6rperliche Verfassung noch \nnicht durch Inappetenz, An\u00e4mie oder ZNS-Sy mptome beeintr\u00e4chtigt ist (Hoskins, 1991). \nBei reiner Augensymptomatik kann eine Therapie versucht werden (Slauson und Finn, 1972). Eine dauerhaft wirksame Therapie is t derzeit nicht bekannt. Lutz (1992) lehnt \nTherapieversuche in der Praxis grunds\u00e4t zlich ab und vertritt die Auffassung, da\u00df bei \nfeststehender Diagnose eine Indikation zur Euth anasie besteht, vorrangig um andere Tiere \nnicht der Gef\u00e4hrdung einer Ansteckung ausz usetzen und weil die M\u00f6glichkeit einer \nwirklichen Heilung kaum besteht. Bei Therap ieversuchen mit verschiedenen Wirkstoffen \nund Placebo an \u00fcber 100 Katzen mit FIP-Symptomen wurde die Untersuchung Literatur\u00fcbersicht \n 29 \nabgebrochen, als klar wurde, da\u00df die Ti ere der Placebo-Gruppe (0,9%ige NaCl) eine \nl\u00e4ngere \u00dcberlebendauer aufwiesen als Katzen  der Versuchsgruppen mit den verschiedenen \nWirkstoffen (Lutz, 1992). \nDer Einsatz von Immunmodulatoren wie z.B.  Diethylcarbamazine (Kitchen, 1988) oder \nInterferonen, Promudolin, Propionibacterium acnes und antiviralen Medikamenten wie z.B. \nRibavirin (Weiss und Oostrom-Ram, 1989;  Weiss et al., 1993), zus\u00e4tzlich zu \nCyclosporinen, Glucokortikoiden und a nderen Entz\u00fcndungshemmern ist vielen \nTherapieans\u00e4tzen gemein (Barlough und Shacklett, 1994; B\u00f6lcskei und Bilkei, 1995a, b), aber nur differenziert sinnvoll (Weiss, 1995) . Beim Einsatz von Zytostatika ist eine \nregelm\u00e4\u00dfige Blutbildkontrolle n\u00f6tig. Diese Ther apie ist geeignet, das Leben des Patienten \nzu verl\u00e4ngern. Nachfolgend seien in Tabelle 4 einige Modelle vorgestellt, die zumindestens vor\u00fcbergehend (meist einige Wochen bis Monate) Therapieerfolge (Besserung des \nklinischen Zustandes) verzeichnen konnten. \n \nTabelle 4: a) Therapieprotokoll Z\u00fcrich (Lutz et al., 1985): 50%iger zeitweiser     Therapieerfolg \nMedikament Verabreichung und Dosierung \nVoren\u00ae (Dexamethason-21-isonicotinat) 2 mg (Tag 1 und Tag 5) i.m. \nAmpicillin 20 mg/kg 3 x tgl. \u00fcber 10 Tage peroral \noder \nPrednisolon (Tabletten) 10 mg 2 x tgl. \u00fcber 7 Tage peroral \n5 mg 2 x tgl. \u00fcber die n\u00e4chsten 7 Tage peroral \n2,5 mg 2 x tgl. \u00fcber die n\u00e4chsten 3 Tage \n1,25 mg 1 x tgl. \u00fcber die n\u00e4chsten 3 Tage \nAmpicillin 20 mg/kg 3 x tgl. \u00fcber 25 Tage peroral \nb) Therapiemodell von B\u00f6lcskei und Bilkei (1995b) \n Medikation zeitweiser Therapieerfolg \n1. Prednisolon, Ampicillin und Cyclophosphamid 37,5% der FIP-F\u00e4lle in drei Jahren \n2. Interferon \u03b1 2 A Human in Intervallen 60% der FIP-F\u00e4lle in drei Jahren \n3. Baypamun\u00ae 1 x w\u00f6chentlich \u00fcber 6 Wochen 29% der FIP-F\u00e4lle in drei Jahren \n \nAls begleitende Ma\u00dfnahme bei der effusive n Form empfehlen Barlough und Weiss (1983), \nzweimal t\u00e4glich den Ergu\u00df abzuziehen und anschlie\u00dfend fibrinolytische Enzyme \neinzubringen. Daneben wird eine parenteral e Elektrolyt- und Fl\u00fcssigkeitsgabe angeraten.Literatur\u00fcbersicht \n 30 \n2.9  Prognose \n \nDie Prognose der FIP gilt als infaust (Oster haus, 1979; Maess, 1985; Suter et al., 1993), \nauch wenn \u00fcber zeitliche Remissionen nach immunsuppressiver Intensivtherapie berichtet \nwurde. Ob es die M\u00f6glichkeit gibt, da\u00df die FIP spontan wieder abheilt, ist ungewi\u00df, aber \neher unwahrscheinlich (Hawkins, 1991). Es gi bt einzelne Berichte, da\u00df Katzen mit \nklinischer FIP-Symptomatik die Infektion \u00fcberstanden h\u00e4tten (B\u00f6lcskei et al., 1995). Dabei stellt sich aber immer die Frage, ob es \u00fcbe rhaupt eine sichere Diagnose der FIP unter \nPraxisbedingungen geben kann. Die meisten Tiere \u00fcberleben de facto die FIP nicht (Suter \net al., 1993). Material und Methoden 31 \n3.  Material und Methoden \n \n3.1  Versuchsaufbau \n \nDie W irksam keit einer Vakzine gegen die Feline Inf ekti\u00f6se Peritonitis bei nat\u00fcrlicher \nInfektion unter Tierheim bedingungen l\u00e4\u00dft sich di rekt in einem  Tierheim  aus verschiedenen \nGr\u00fcnden nicht testen. Praktischer Haupthinde rungsgrund sind die Tierschutzvereine, fast \nimmer Mitbetreiber der Tierheim e, deren Satzungen die Beteiligungen an Tierversuchen \nstrikt ausschlie\u00dfen. Daher schien es sinnvoll, die Haltungsbedingungen eines Tierheim es in \ngeeigneten R\u00e4um lichkeiten nachzustellen. Dies erfolgte auf dem  Gel\u00e4nde der Lehr- und \nVersuchsstation Liebertwolkwitz der Universit\u00e4t Leipzig. \nGrundlage f\u00fcr Versuchsaufbau und Versuc hsdurchf\u00fchrung waren das Protokoll 2184D-10-\n95-155 der Firm a \u201cPfizer\u201c und die GCPV-Richtlinie (Good Clinical Practice for the \nConduct of Clinical Trials for Veterinary Medicinal Products). \u00dcber einen effektiven \nVersuchszeitraum  von 42 W ochen wurden 50 Kat zen als Population in einem  tierartgerecht \nhergerichteten Stall zusam men gehalten. 40 Ti ere waren spezifisch-pathogenfreie (SPF) \nKatzen (20 weiblich / 20 m \u00e4nnlich) im  empf\u00e4nglichen Alter f\u00fcr die FIP (21 W ochen zum  \nZeitpunkt des Challenge), von denen die ei ne H\u00e4lfte m it der Vakzine Prim ucell\u00aeFIP vor \nKontakt m it einer Infektionsquelle im munisier t wurde. Die andere H\u00e4lf te diente als \nKontrollgruppe. Ein Placebo f\u00fcr die Kontrollgruppe wurde nicht verwandt. \nDie Einteilung der SPF-Tiere in  die Gruppen T1 und T2 erfolgte nach einer vorgegebenen \nRandom isierungsliste des Versuchsprotokolls  (Tabelle 6), die dem  Durchf\u00fchrenden \nbekannt war. Die daraus resultierende Geschl echtsverteilung ist in der Abb. 1 ersichtlich. \nAlle SPF-Tiere waren den \u00fcblichen Routineim pfungen (siehe Tabelle 10) unterzogen \nworden. \nZehn Tiere stam mten aus verschiedenen Tierheim en und dienten als nat\u00fcrlicher \nInfektionsquelle. Zum  Zeitpunkt der \u00dcbernahm e aus den Tierheim en waren diese Tiere \nnicht klinisch krank, reagierten aber im  kom petitiven ELISA zum  Nachweis der f\u00fcr die FIP \ntypischen Im munkom plexe (Pfeiffer, 1991; Reinacher, 1994; Schroo, 1994) positiv. Diese \nTiere waren Virustr\u00e4ger, welche praktisch in  jedem  Tierheim  zu finden sind, dort aber in \nder Regel nicht als solche erkannt werden. Die Haltung der SPF-Tiere m it den Virustr\u00e4gern \nerm\u00f6glichte einen Feldversuch, in dem  ein Feldvirus und nat\u00fcrliche \u00dcbertragungswege \ngenutzt wurden. \n  Material und Methoden 32 \nW\u00e4hrend des Versuchs wurde allen Tieren zur serologischen Statusbestim mung (siehe \nTabelle 7) regelm \u00e4\u00dfig Blut entnom men. Die Bl utentnahm en erf olgten jeweils aus der Vena \njugularis bzw. aus der Vena cephalica ante brachii. Es wurden Kan\u00fclen m it 0,6 bis 0,9 m m \nDurchm esser der Firm a B. BRAUN (B. Bra un Petzhold Gm bH, Melsungen) benutzt. Als \nProbenauffanggef\u00e4\u00dfe dienten Kabevette\u00ae (KABE Labortechnik Gm bH, N\u00fcm brecht-\nElsenroth) Monovette\u00ae oder Multivette\u00ae  (SARSTEDT AG & Co., N\u00fcm brecht) in der \nSerum ausf\u00fchrung bzw. m it EDTA versetzt . Gestorbene und aufgrund der Erkrankung \neuthanasierte Tiere sowie bis zum  Versuchse nde gesunde und euthanasierte Tiere wurden \nseziert. Es erfolgte eine pathologisch-anat omische, histologische und im munhistologische \nUntersuchung zur Kl\u00e4rung, ob die Tiere an FIP erkrankt waren oder nicht. Gestorbene, \nverendete oder aufgrund des fortgeschrittene n FIP-Krankheitsverlaufs euthanasierte \nTierheim tiere wurden zwecks Diagnosebest\u00e4tigung ebenfalls obduziert. Jedes Tier erhielt \neine Sektionsnum mer. Unter dieser Num mer wurden Probenm aterial sowie histologische \nSchnitte am  Institut f\u00fcr Veterin\u00e4r-Pathologie archiviert. Die histologischen Untersuchungen \nwurden von einer Fachtier\u00e4rztin f\u00fcr Pa thologie ohne Kenntnis der Tiernum mern \ndurchgef\u00fchrt. Gleicherm a\u00dfen wurde be i den im munhistologischen Untersuchungen \nverfahren. Nach Vorliegen der Sekti onsbefunde, sowie der histologischen und \nimmunhistologischen Ergebnisse wurde die Diagnos e f\u00fcr das betreffende Tier gestellt. Die \nserologischen Ergebnisse wurden dazu nich t herangezogen. Im  Versuch erkrankte Tiere \nwurden therapiert (siehe Tabelle 5), leidende  oder nicht therapief\u00e4hige Patienten wurden \neuthanasiert (Ketam in\u00ae-Xylazin\u00ae-Narkose m it nachfolgender Narcoren\u00ae-Injektion i.v.). \nTherapieversuche im  Sinne der Heilung der FIP wurden nicht durchgef\u00fchrt. Im  \nAnfangsstadium  der FIP erf olgte eine sym ptomatische Therapie. Kortikoide, Zytostatika, \nImmunmodulatoren und dergleichen wurden nich t eingesetzt. \u00dcberlebende Tierheim tiere \nwurden am  Versuchsende laut Auflage de r Tierversuchsgenehm igung verm ittelt, weitere \nUntersuchungen an ihnen wurden nicht dur chgef\u00fchrt. \u00dcber f\u00fcnf der verm ittelten \nTierheim katzen liegen nach Versuchsende Inform ationen bez\u00fcglich des \nGesundheitzustandes vor. \n  Material und Methoden 33 \nTabelle 5: im  Versuch eingesetzte Therapeutika \n\u2022 Therapeutika (Firm a) \u2022 Wirksubstanzen \nSynulox\u00ae (Pfizer) Amoxicillin, Clavulans\u00e4ure \nClam oxyl\u00ae  (Pfizer) Amoxicillin \nSuanatem\u00ae1 (Merial) Spiram ycin, Metronidazol \nTerram ycin\u00ae Augensalbe (Pfizer) Oxytetracyclin, Polym ycin B \nVetoscon\u00ae Augensalbe (Pf izer) Cloxacillin \nFicortril\u00ae Augensalbe 2,5% (Pfizer) Hydrocortisonacetat \nBerlicetin\u00ae Augentropfen 1% (Chauvin ankerpharm ) Azidam fenicol \nAtropin 1% Dispersa Augens albe (CIBA Vision) Atropin \nChibro-Am uno\u00ae 3 Augentropfen (Chibret) Indom etacin \nOrisel\u00ae  (Selectavet) Neom ycinsulfat, Nystatin, \nHexachlorcyclohexan, \nTriam cinolon \nBefedo\u00ae Crem e (Pfizer) Propylenglycol, Apfels\u00e4ure, \nBenzos\u00e4ure, Salicyls\u00e4ure \nParenteral Elektrolytl\u00f6sung (Pfizer) Elektrolyte \nGuanistrep\u00ae-Paste (Merial) Sulfaguanidin, \nDihydrostreptom ycinsulfat \nNutri-Cal\u00ae (Albrecht) Mineralstoffe, Vitam ine, \nSpurenelem ente, Proteine \nVMP-Pfizer\u00ae-Katzenpaste (Pfizer) Mineralstoffe, Vitam ine, \nSpurenelem ente, Proteine \na/d-Futter (Hill`s) Vitam ine, Mineralstof fe, \nSpurenelem ente, Proteine \n(umsetzbare Energie: 4,1 MJ/kg \nKatze) \nMegalac\u00ae-Alm asilat (Krewel Meuselbach) Alum inium magnesium silicathydrat \nSerocat\u00ae (Hoechst-Roussel [seit Mai 2001 au\u00dfer \nHandel ]) serum neutralisierende Ak gegen \nPanleukopenie, Rhinotracheitis, \nCalicivirusinf ektion \n \n3.2  Versuchsdurchf\u00fchrung \n \n3.2.1  Randomisierung \n \nDie Random isierung (Tabelle 6) wurde en tsprechend dem  Protokoll 2184D-10-95-155 der \nFirm a \u201cPfizer\u201c laut Liste durchgef\u00fchrt. \n  Material und Methoden 34 \nTabelle 6: Random isierungsprotokoll \nNumme r Tier-Identifikation Gruppe Behandlung \n1 H6 1395 T2 Prim ucell\u00aeFIP \n2 H6 1404 T2 Prim ucell\u00aeFIP \n3 H6 1408 T2 Prim ucell\u00aeFIP \n4 H6 1410 T2 Prim ucell\u00aeFIP \n5 H6 1455 T1 Kontrolle \n6 H6 1451 T2 Prim ucell\u00aeFIP \n7 H6 1452 T1 Kontrolle \n8 H6 1443 T2 Prim ucell\u00aeFIP \n9 H6 1401 T1 Kontrolle \n10 H6 1400 T2 Prim ucell\u00aeFIP \n11 H6 1453 T2 Prim ucell\u00aeFIP \n12 H6 1456 T1 Kontrolle \n13 H6 1399 T1 Kontrolle \n14 H6 1435 T1 Kontrolle \n15 H6 1437 T1 Kontrolle \n16 H6 1449 T2 Prim ucell\u00aeFIP \n17 H6 1409 T1 Kontrolle \n18 H6 1433 T2 Prim ucell\u00aeFIP \n19 H6 1405 T1 Kontrolle \n20 H6 1402 T1 Kontrolle \n21 H6 1427 T2 Prim ucell\u00aeFIP \n22 H6 1450 T2 Prim ucell\u00aeFIP \n23 H6 1442 T1 Kontrolle \n24 H6 1431 T1 Kontrolle \n25 H6 1441 T1 Kontrolle \n26 H6 1430 T1 Kontrolle \n27 H6 1397 T1 Kontrolle \n28 H6 1448 T1 Kontrolle \n29 H6 1411 T2 Prim ucell\u00aeFIP \n30 H6 1464 T2 Prim ucell\u00aeFIP \n31 H6 1434 T2 Prim ucell\u00aeFIP \n32 H6 1444 T2 Prim ucell\u00aeFIP \n33 H6 1436 T2 Prim ucell\u00aeFIP \n34 H6 1391 T1 Kontrolle \n35 H6 1466 T2 Prim ucell\u00aeFIP \n36 H6 1446 T2 Prim ucell\u00aeFIP \n37 H6 1425 T1 Kontrolle \n38 H6 1424 T1 Kontrolle \n39 H6 1432 T1 Kontrolle \n40 H6 1440 T2 Prim ucell\u00aeFIP \n  Material und Methoden 35 \nAbb.1:  Geschlechtsverteilung der SPF-Tiere nach random isierter    \n  Einteilung in T1 und T2 \n \n 12 SPF-Tiere\n(60,0%)\n8 SPF-Tiere\n(40,0%)8 SPF-Tiere\n(40,0%)\n12 SPF-Tiere\n(60,0%)m\u00e4nnlic h m\u00e4nnlic h\n20 S PF-Kontrolltiere 20 S PF-Primucell\u00ae-Tiereweiblich weiblic h\nT1 T2\n \n \n  Material und Methoden 36 \n3.2.2  Zeitliches Management und Impfregime \n \nDas zeitliche Managem ent und das Im pfregim e f\u00fcr alle Tiere gehen aus Tabelle 7 hervor. \nTabelle 7: chronologischer Ablauf der Studie \nDatum  Versuchs-\nwoche Tier-\ngruppe Alter der SPF-\nTiere in \nWochen \n(\u00b1 0,5 W ochen) Aktivit\u00e4t \n(Probenentnahm en, Vakzinationen, \nWiegen,) \n01.11.1996 0 T1/T2 9 Blutentnahm en f\u00fcr A \n01.11.1996 0 T1/T2 9 Vakzination m it Felocell \uf8eaCVR gegen \nKatzenschnupfen, Panleukopenie und \nLeukocell \uf8ea2 gegen Leukose \n22.11.1996 3 T1/T2 12 Vakzination m it Felocell \uf8eaCVR-T \ngegen Katzenschnupfen, \nPanleukopenie (Boosterung) und \nTollwut und Leukocell \uf8ea2 gegen \nLeukose (Boosterung) \n20.12.1996 7 T1/T2 16 Trennen von T1 und T2 \n20.12.1996 7 T2 16 Vakzination m it Prim ucell\u00aeFIP \n10.01.1997 10 T2 19 Vakzination m it Prim ucell\u00aeFIP \n(Boosterung) \n17.01.1997 11 T3  Num mernt\u00e4towierung der Ohren \n24.01.1997 12 T1/T2/T3 21 Blutentnahm en f\u00fcr A und B, \nZusam mensetzen von T1 und T2 sowie \nEinbringen der Tierheim katzen (T3) in \ndie Gruppe \n04.04.1997 22 T1/T2/T3 31 Blutentnahm en f\u00fcr A und B \n16.06.1997 32 T1/T2/T3 41 Blutentnahm en f\u00fcr A, B und C \n25.08.1997 42 T1/T2/T3 51 Blutentnahm en f\u00fcr A, B und C \n26.08.1997 43 T1/T2 52 Euthanasie der SPF-Tiere und \nObduktion \ndanach 43-53 T3 - Verm ittlung an Privatpersonen \n \nLegende der Tabelle 7 \nT1 = SPF-Tiere, Kontrollgruppe (n=20) \nT2 = SPF-Tiere, m it Prim ucell\u00aeFIP vakziniert (n=20) \nT3 = FIP-Im munkom plex-positive Tierheim katzen (nat\u00fcrliche Infektionsquelle (n=10)) \nA = FIPV-Ak-Titerbestim mung \nB = ELISA \nC = PCR \n  Material und Methoden 37 \n3.2.3  Haltung der Tiere \n \nBei der Haltung von Katzen in gr\u00f6\u00dfere n Gruppen ohne Ausgang werden die \nVerhaltensbed\u00fcrfnisse der Katzen h\u00e4ufig nur  teilweise ber\u00fccksichtigt (Sch\u00e4rr, 1991, 1997). \nAuch in Tierheim en und Zuchten stehen fi nanzielle, hygienische und arbeitstechnische \nAspekte einer vollst\u00e4ndigen Ber\u00fccksichtigung oft entgegen (pers\u00f6nliche Mitteilungen von \nDr. Schreier [Tierheim  Bitterfeld], Hr. J acob und Fr. T\u00c4 Mayer [Tierheim  Dresden]). \nKatzen sind nicht, wie oft angenom men wir d, generell Einzelg\u00e4nger, sondern sie k\u00f6nnen \ndurchaus sehr gesellig und sozial sein, wenn bestim mte Voraussetzungen erf\u00fcllt sind \n(Morris, 1994). Im  Hinblick auf Langeweile und Isolationsstre\u00df ist sogar die Einzelhaltung \nder Tiere ein gr\u00f6\u00dferes Problem  (Sch\u00e4r, 1991). Katzen sind nicht, wie vielerorts noch \ngedacht wird, weil sie sehr viel schlafen (b is 18 h t\u00e4glich), pflegeleichte Haustiere. Sie \nhaben enorm e Anspr\u00fcche an Raum strukturierung, Besch\u00e4ftigungsm \u00f6glichkeiten und \nGruppenzusam mensetzung sowie Betreuung (F utterportionen, -tem peratur, -turnus, \nKontakt zum  Menschen, etc. [Sch\u00e4r, 1989; Me rtens und Sch\u00e4r, 1988]). Entscheidend ist vor \nallem  die Gr\u00f6\u00dfe der Grundfl\u00e4che, die unbedingt \u2265 2 m2/Tier betragen sollte (Goldhorn, \n1987; Schm itz, 1990; Sch\u00e4r, 1997). Jeder Kat ze m u\u00df bei Bedarf ein Versteck zur \nVerf\u00fcgung stehen, in das sie sich vor Artge nossen, dem  Betreuer oder frem den Personen \nzur\u00fcckziehen kann. Das ist ein Grundbed\u00fcrfnis  einer jeden Katze (Mertens, 1994). Im  \neigenen Versuch wurden stabile Materialie n wie Holz oder Kunststoff zur Schaffung von \nUnterschlupfm \u00f6glichkeiten verwandt, aber auch ein auf den Kopf gestellter Pappkarton m it \nseitlichen \u00d6ffnungen erf\u00fcllte diesen Zw eck. Desweiteren m \u00fcssen ausreichend \nAussichtspl\u00e4tze, \u201cSpielzeug\u201c, Kratzb\u00e4u me und Platz f\u00fcr Verfolgungsjagden sowie \nspontanes Rennen zur Verf\u00fcgung stehen (Merte ns und Sch\u00e4r, 1988; Sch\u00e4r, 1997). Frisches \nWasser und Trockenfutter standen ad libitum  bereit. Feuchtfutter (\u201cW hiskas\u201c Rind, \nGefl\u00fcgel, Ente oder Kabeljau, Effem  Gm bH, Verden [Aller ]) wurde zweim al t\u00e4glich \nangeboten. Die t\u00e4gliche Menge richtete si ch nach dem  Bedarf der Tiere, ca. 200-300 \nGram m pro Tier. Eine junge Katze hat einen Energiebedarf von ca. 250 kcal/kg \nK\u00f6rperm asse (Kolb, 1982). Das Tier-Fre\u00dfplatz-Ve rh\u00e4ltnis betrug im mer mindestens 2:1 f\u00fcr \ndas Feuchtfutter. Kr\u00e4nkliche oder schlecht fr essende Tiere erhielten separat a/d-Futter \n(Hill`s [Heiland ], Ham burg). Die Katzentoiletten wurden je von m ehreren Tieren genutzt, \nentscheidend war eine ausreichende r\u00e4um liche  Gr\u00f6\u00dfe und die Tiefe der Einstreu. Der Rand \nder Katzentoiletten war so hoch, da\u00df Sichtschut z bestand. Schwere Streu war vorteilhafter. \nAls Katzentoiletten dienten 90-Liter-Plastbeh\u00e4lter, gef\u00fcllt m it einer Tonklum pstreu \n  Material und Methoden 38 \n(\u201cNatusan\u201c, Effem  GmbH, Verden [Aller ])  mit einer Mindesteinf\u00fcllh\u00f6he von 10-12 cm . \nF\u00fcr je 5 Jung- bzw. 2 bis 4 Alttiere stand eine Katzentoilette zur Verf\u00fcgung. Aufgrund der \nVersuchsvorgaben konnte bei der Gr uppenzusam mensetzung auf Alter, \nGeschlechtsverteilung und innerartliche Sozia lisierung keine R\u00fccksicht genom men werden. \nDa es sich bei den SPF-Katzen jedoch um  Tier e handelte, die in innerartlich sozialisierten \nGruppen herangewachsen waren, entstanden kaum  Problem e. Das rechtzeitige Kastrieren \nder Kater in der Versuchswoche 18 (ca. 27 W ochen Lebensalter) verhinderte grobe \nRangeleien, die nicht selten zu erheblichen Verletzungen f\u00fchren k\u00f6nnen. Au\u00dferdem  wurde \ndadurch verhindert, da\u00df W eibchen, die zu de fensiven Verhaltensm ustern neigen, von den \nJungkatern in ein Paria-Dasein gedr\u00e4ngt wurden (Sch\u00e4r, 1996). \n \n3.2.3.1  Beschreibung der Versuchstierst\u00e4lle \n \nDie Tiere wurden in speziell hergerichtet en Versuchstierst\u00e4llen auf dem  Gel\u00e4nde der \nUniversit\u00e4t Leipzig gehalten. In den W interm onaten diente der Stahl-Glas-Tierstall vom  \nTyp TG 10, in den Som mermonaten (a b 13.05.1997, d.h. ab Versuchswoche 27) der \nTierstall vom  Typ GSP (Glas, Stahl, Plas t) 17 der Unterbringung der Versuchstiere. Das \nGSP 17 war in einen offenen (Masche ndraht) und einen geschlossenen Teil \n(Einfachverglasung) von ann\u00e4hernd gleicher Gr\u00f6\u00dfe, abgetrennt durch feststellbare, \nschlie\u00dfbare Fl\u00fcgelt\u00fcren (Stahl und Plast) m it Durchschlupf geteilt. W \u00e4hrend der Trennung \nder Versuchstiere (ab dem  20.12.1996 bis zum  24.01.1997, Versuchswochen 7 bis 12) in \ndie Gruppen T1 und T2 zum  Zeitpunkt der Im pfung wurde zus\u00e4tzlich ein dem  TG 10 \nvergleichbarer weiterer Tierstall (TG 10 a) ge nutzt. Die einzelnen Daten der Tierst\u00e4lle \nhierzu sind der Tabelle 8 zu entnehm en. Allen St\u00e4llen war eine Schleuse vorgeschaltet. Die \nWinterbeheizung wurde durch eine \u00f6lbetriebene Pum penwarm wasserheizung m it \nvollautom atischer Steuer- und Regeltechnik gew\u00e4 hrleistet. Die Raum temperatur war exakt \n(\u00b1 1\u00b0C) einstellbar. Das TG 10 wies ein sowohl vollautom atisch als auch von Hand \nsteuerbares Sonnenstoffdach zur Minderung des di rekten Lichteinfalls (Lux-Steuerung) auf. \nDie Seitenwandverglasung war im  Som mer mit blauer lichtabsorbierender Farbe abget\u00f6nt, \nwom it dem  Treibhausklim a des Stalles entgeg engewirkt wurde. Das Bodenm aterial war \nEstrichbeton. Die L\u00fcftung erfolgte autom atisch \u00fcber \u00be der gesam ten Hausl\u00e4nge m ittels in \nStufen ausstellbaren Dachsegm enten. Die L\u00fcftungsklappen konnten auch m anuell bet\u00e4tigt \nwerden. Durch ein in 3 m  H\u00f6he \u00fcber die ge samte Grundfl\u00e4che gespanntes feinm aschiges \nNetz wurden eventuelle Ausbruchsversuche verhindert. In allen H\u00e4usern wurden m ehrere \n  Material und Methoden 39 \nAufenthaltsebenen geschaffen, vorzugsweis e aus dem  nat\u00fcrlichen Material Holz. \nKratzb\u00e4um e (Birnbaum ), z.T. m it Handlauf seilen um mantelt, wurden jeweils in m ehreren \nVarianten bis zu einer H\u00f6he von 2,5 m  insta lliert. Um gest\u00fclpte Holzkisten (m it Decken \nausgelegt oder m it Heu versehen), Europaletten\uf6da, Pappkartons, Plastrohre, Laufbretter, \nSitzb\u00f6cke, an Seilen h\u00e4ngende Gum miringe und vieles m ehr strukturierten den Raum . \nKatzengras wurde regelm \u00e4\u00dfig neu angeboten. Zu s\u00e4tzliche Infrarotstrahler boten den Tieren \nnachts die M\u00f6glichkeit, sich an warm en Pl\u00e4tzen aufzuhalten. Hervorragend als Spielzeug \nhaben sich Tischtennisb\u00e4lle, Papiert\u00fcten, Ra sseln etc. bew\u00e4hrt. Der Futterplatz war \nabgeteilt. Es wurde im mer an diesem  Platz gef \u00fcttert. \n \nTabelle 8: Daten zu den Versuchtierst\u00e4llen, in denen die SPF-Tiere untergebracht waren \n TG 10 \n(Gruppen T1 und T2) GSP 17 \n(Gruppen T1 und T2) TG 10 a \n(Gruppe T1) \nFl\u00e4che in m2 101,48 127,68 83,20 \nH\u00f6he (First) in m  4,98 3,50 3,00 \nBreite in m  8,60 5,70 5,20 \nL\u00e4nge in m  11,80 22,40 16,00 \nVerglasung Thermoscheiben Einfachverglasung Therm oscheiben \nRaum temperaturen \u2205 20\u00b0C \u2205 24\u00b0C \u2205 19\u00b0C \nLuftfeuchtigkeit \u2205 58% \u2205 55% \u2205 58% \n \n3.2.4  Erforderliche Genehmigungen \n \n  Das Versuchsvorhaben TVV-Nr.: 2/96-\u201cPr\u00fcf ung der W irksam keit einer Vakzine gegen \nFeline Infekti\u00f6se Peritonitis bei Katzen unter Tierheim bedingungen\u201c war nach dem  \nTierschutzgesetz in der Fassung der Bekanntm achung vom  17.02.1993 (BGBl. S. 254) \ngenehm igungspflichtig. Die Genehm igung wurd e auf Antrag und nach Pr\u00fcfung durch das \nRegierungspr\u00e4sidium  Leipzig per Bescheid am  12.07.1996 erteilt. Ein wesentlicher \nAuflagepunkt war die Verm ittlung der Tierhe imkatzen im  Anschlu\u00df an den Versuch. \nS\u00e4mtliche w\u00e4hrend des Versuchs n\u00f6tigen \u00c4nderungen waren genehm igungspflichtig. Die \nentsprechenden Genehm igungen wurden erte ilt. Die SPF-Tiere aus den USA unterlagen \neiner Einfuhrgenehm igung (Binnenm arkt-Tierseuchenschutz-Verordnung in der Fassung \nvom 31. M\u00e4rz 1995 [BGBl. \u0399 S. 431], ge\u00e4ndert durch die Verordnung vom  21. M\u00e4rz 1996 \n[BGBl . \u0399 S. 528]). Diese wurde durch das S\u00e4chsische Staatsm inisterium  f\u00fcr Soziales, Material und Methoden 40 \nGesundheit und Fam ilie auf Antrag hin am  08.10.1996 erteilt. Die Grenzkontrollstellen \nwurden, entsprechend der VO, 24 h vor Einfuhr  der Tiere inform iert, die Genehm igungen \nlagen diesen in Fotokopie vor. Die Einfuhr der Tiere wurde beim  zust\u00e4ndigen Veterin\u00e4r- \nund Lebensm ittelaufsichtsam t einen W erktag vor der Einfuhr angezeigt. Alle Tiere \nunterlagen der Verordnung \u00fcber Aufzei chnung \u00fcber Versuchstiere und deren \nKennzeichnung vom  20. Mai 1988 (BGBl. \u0399 S. 639).  \n \n3.2.4.1  Beh\u00f6rdliche Kontrollen \n \nDie eingef\u00fchrten SPF-Tiere unter lagen einer 14-t\u00e4gigen Quarant\u00e4ne. Diese wurde durch die \n\u00dcberwachungsbeh\u00f6rde Landratsam t Leip ziger Land, Lebensm ittel\u00fcberwachungs- und \nVeterin\u00e4ram t am 12.11.1996 \u00fcberpr\u00fcft. Die Kont rollen des Regierungspr\u00e4sidium s Leipzig \nbez\u00fcglich der erteilten Auflagen aus der Tierversuchsgenehm igung erfolgten in \nunregelm \u00e4\u00dfigen Abst\u00e4nden m it und ohne Vorank\u00fcndigung. \n \n3.3  Versuchstiere \n \n3.3.1  Spez ifisch pathogenfreie (SPF)-Tiere \n \nDie 40 spezifisch pathogenfreien Katzen (SPF-Tiere), je 20 weiblich und 20 m \u00e4nnlich, \nwurden von der Firm a \u201cHarlan-W inkelm ann Gm bH\u201c (Borchen) geliefert. Zulieferer war \n\u201cHarlan Sprague Dawley, Inc.\u201c aus Indianapo lis, Indiana (USA). Die Tiere wurden am  \n22.09.1996 bestellt und am  30.10.1996 (nach Deut schland \u00fcber Am sterdam ) aus \nIndianapolis geliefert. Der Transport erfo lgte in 20 Spezialbeh\u00e4ltern. Bei der Ankunft \nwaren die Tiere 9 W ochen alt, gesund und ungeim pft. Zur eindeutigen Identifikation waren \ndie Katzen vor der Einfuhr jeweils in beid en Ohren m it gr\u00fcner Farbe t\u00e4towiert. Die \nT\u00e4towierungen eines jeden Tieres bestanden aus dem  Harlan-Firm enzeichen (rechtes Ohr) \nund H6 sowie nachgestellt einer vierstelligen  Num mer (linkes Ohr). Die Begleitpapiere \nbelegten Art (Felis silvestris felis catus) und Rasse (Dom estic Shorthair), die Abstam mung \nund den Status der Tiere. \n  Material und Methoden 41 \nGarantiert wurde das Freisein von bestim mten felinen Antik\u00f6rpern (\u201cAntibody Profile \nDefined\u2122\u201c der Firm a Harlan [APD\u2122]), die gerichtet sind gegen: \n\u2022 Caliciviren (FCV) \n\u2022 Chlam ydien \n\u2022 Coronaviren (FECV/FIPV) \n\u2022 Herpesviren (FVR/FHV-1) \n\u2022 Immundefizienzvirus (FIV/FTLV) \n\u2022 Leuk\u00e4m ievirus (FeLV) \n\u2022 Parvovirus (FPV) \n\u2022 Synzytialvirus (FeSFV) \n\u2022 Toxoplasm en \nDie m \u00e4nnlichen SPF-Tiere wurden in der Vers uchswoche 18 (ca. 27 W ochen Lebensalter) \nkastriert. \n \n3.3.2  Tierheimkatz en \n \nZur Auswahl geeigneter Tierheim katzen, die al s nat\u00fcrliche Infektionsquelle im  Versuch \ngenutzt wurden, kam  ein kom petitiver ELISA  zum  Nachweis FIP-Virus-spezif ischer \nImmunkom plexe zur Anwendung. Bis zum  Versuc hsbeginn wurden die Tiere in Gruppen \nzu je 5 bis 6 Tieren in Tierst\u00e4llen des Instituts f \u00fcr Veterin\u00e4r-Pathologie der Universit\u00e4t \nLeipzig gehalten. Dem  Versuchsvorhaben st anden 15 Tiere zur Verf\u00fcgung. Vier der 15 \nTiere starben vor Versuchsbeginn an FIP. Die verbleibenden 11 Katzen bildeten im  \nVersuch die Gruppe T3, wobei im  Versuch m aximal 10 Tiere eingesetzt wurden. Nachdem  \ndas erste Tier der Gruppe T3 am  24.02.1997 verstarb, wurde die Gruppe durch das \nverbleibende Tier wieder auf 10 Tiere erg\u00e4nzt. \n  Material und Methoden 42 \nTabelle 9: \u00dcbersicht \u00fcber die Gruppe T3 (Tierheim katzen) \nTier-\nIdentif ikation \n(T\u00e4towierung \nrechtes Ohr) Geburtsterm in \nz.T. gesch\u00e4tzt Geschlecht Gewicht bei \n\u00dcbernahm e in \nkg bisherige \nHaltungart \n41 Juli 1996 m\u00e4nnlich-kastr.* 2,46 unbekannt \n42 Ende 1994 m\u00e4nnlich-kastr. 2,80 Wohnungstier \n43 Juli 1996 m\u00e4nnlich-kastr.* 2,26 unbekannt \n44 25.05.1995 m\u00e4nnlich-kastr. 3,47 Freig\u00e4nger \n45 Mitte 1995 weiblich 2,43 unbekannt \n47 Anfang 1995 weiblich 2,85 Wildfang \n48 Ende 1993 weiblich-kastr. 2,64 Wohnungstier \n49 Mitte 1995 m\u00e4nnlich-kastr. 3,08 unbekannt \n50 April 1996 weiblich 1,86 Wildfang \n51 April 1996 weiblich 2,14 Wildfang \n52 April 1996 weiblich 1,52 Wildfang \n*= erst nach Erhalt aus dem  Tierheim  kastriert \n \n3.4  Impfstoffe \n \n3.4.1  Die Vakz ine Primucell\u00aeFIP \n \nDer Im pfstoff Prim ucell\u00aeFIP gegen die FIP wurde von \u201cSm ithKline Beecham \u201c, \nmittlerweile von \u201cPfizer\u201c \u00fcbernom men, Ende der 80iger Jahre von Norden Laboratories, \nLincoln, NE, USA, entwickelt. Es handelt sich  um einen lyophilisierten Lebendim pfstoff. \nSeit M\u00e4rz 1991 ist er in Deutschland ko mmerziell erh\u00e4ltlich. \u201cPfizer\u201c ist im mer noch \nweltweit der einzige Anbieter eines Im pfstoffes gegen die FIP. Der Im pfvirusstam m \nNorden DF 2 wild-type FIP-Virus (wt-FIPV) wurde von einer klinisch an FIP erkrankten \nKatze post m ortem aus der Leber isoliert (Christianson et. al., 1989). Nach m ehreren \nPassagen in Gewebehom ogenaten von SPF-Katzen wurde das Virus auf Katzennierenzellen \n(NL-FK-1 cell line) angez\u00fcchtet. Die Atte nuierung erfolgte durch 99 Passagen, wobei bei \nden letzten 39 Passagierungen die Tem peratur von 39\u00b0C auf 31\u00b0C gesenkt wurde. Im  \nAnschlu\u00df an die letzte Passage erfolgte ei ne UV-Bestrahlung (Dauer 5 m in, Distanz 5 cm , \nWestinghouse 782-30 Lam pe, 118 V, 0,5 A, 60 Zyklen), danach die Reinigung und \n  Material und Methoden 43 \nLyophilisierung des Antigens. Das entstandene av irulente Im pfvirus kann sich optim al bei \n31\u00b0C , aber nicht bei Tem peraturen von 39\u00b0C (der norm alen K\u00f6rpertem peratur der Katze) \nverm ehren. Bei Tem peraturen ab 54\u00b0C wird es  zerst\u00f6rt. Dadurch unterscheidet sich das \ntemperaturtsensitive (ts)-FIPV von dem  urspr \u00fcnglichen DF 2-wt-FIPV (Christianson et al., \n1989). Das attenuierte, ts-FIPV wird unter  Zusatz von Gentam icinsulfat (m ax. 100 \n\u00b5g/Im pfdosis) als Prim ucell\u00aeFIP angeboten. Die Applikation erfolgt intranasal. Die \nPackungsbeilage em pfiehlt Grundim munisierung ab einem  Lebensalter von 16 W ochen und \neine Boosterung nach 3 W ochen sowie j\u00e4hrliche W iederholungsim pfungen. \nIm Versuch wurde ein Im pfstoff m it 5,5 log 10CCID 50/Dosis verwendet (Vorschlag von Jay \nGerber, Pfizer-Study-Protokoll 2184D-10-95-155). Als Ausgangstiter im  Wirksam keitstest \nder Vakzine (Charge 29057L) wurden 7,2 log 10CCID 50/Dosis erm ittelt. Daraus ergab sich \nein Verd\u00fcnnungskoeffizient von 50 (von 107,2 zu 105,5). Die Zubereitung des einsatzf\u00e4higen \nImpfstoffes (20 Dosen a` 0,5 m l) erfolgte  vor Ort. Vier tiefgefrorene (-79\u00b0C) \nPrim ucell\u00aeFIP-Pellets (Chargen-Nr.: FD 29057L) wurden jeweils m it 1 m l 0,9%iger \nsteriler Kochsalzl\u00f6sung aseptisch rehydriert. Nach Aufl\u00f6sen der Pellets wurden jeweils \n0,25 m l der L\u00f6sung aseptisch in ein steriles 30 m l-Gef\u00e4\u00df gegeben, anschlie\u00dfend wurde m it \n24 m l steriler Kochsalzl\u00f6sung aufgef\u00fcllt. Dem entsprechend standen 50 Im pfdosen m it \neinem  Titer von 5,5 log 10CCID 50/Dosis zur Verf\u00fcgung. 20 Im pfdos en von je 0,5 m l wurden \nim Versuch bei der Gruppe T2 (siehe Tabelle  7) beidseitig intranasal appliziert. Die \nverbleibende Menge wurde zu je 2 m l porti oniert, z\u00fcgig gefroren und anschlie\u00dfend in \nTrockeneis gelagert. Unm ittelbar danach erf olgte der Transport ins European Clinical \nDevelopm ent Laboratory der Firm a Pfi zer (B-1348 Louvain-la-Neuve), wo die \nR\u00fccktitration und Pr\u00fcfung erfolgte. Der W irksam keitstest der frischen Vakzine (Pr\u00fcfung \ndes Antigengehalts) ergab im  geom etrischen Mittel 107,2 CCID 50/Dosis, nach 7 Tagen \nAufbewahrung der Vakzine bei einer Raum temperatur von 37\u00b0C wurde ein Antigengehalt \nvon 105,5 CCID 50/Dosis erm ittelt. Die Pr\u00fcfung der Probe auf Tem peratursensitivit\u00e4t ergab \nbei 31\u00b0C einen Titer von 107,2 CCID 50/Dosis und bei 39\u00b0C einen Titer von 103,8 \nCCID 50/Dosis, woraus sich schlie\u00dfen l\u00e4\u00dft, da \u00df sich das Im pfvirus bei 31\u00b0C 2000- bis 3000-\nfach st\u00e4rker verm ehrte als bei 39\u00b0C. Die Suche nach Frem dviren verlief negativ. Der \nSterilit\u00e4tstest verlief positiv. Der Gehalt an Gentam icinsulfat betrug < 100 \u00b5g/Dosis. F\u00fcr \nden am  20.12.1996 eingesetzten Im pfstoff ergab sich abschlie\u00dfend ein Titer von 105,4 \nCCID 50/ml und f\u00fcr die Charge, die zur Boos terung am  10.01.1997 verwendet wurde, ein \nTiter von 105,5 CCID 50/ml. \n \n  Material und Methoden 44 \n3.4.2  Andere eingesetz te Impfstoffe \n \nTabelle 10: \u00dcbersicht \u00fcber die anderen eingesetzten Im pfstoffe \nVakzine Chargennum mer und Hersteller Applikation, \nForm ulation \nFelocell \uf8eaCVR \n(lebendes attenuiertes \nRhinotracheitisvirus, \nCalicivirus und \nPanleukopenievirus) 30 471 L (\u201cSm ithKline Beecham \u201c) und \n32 414 L (\u201cPfizer\u201c) lt. Hersteller \n1 ml s.c./ Tier \nFelocell \uf8ea-T \n(inaktiviertes Tollwutvirus) 202609 (\u201cSm ithKline Beecham \u201c) lt. Hersteller \n1 ml s.c./ Tier \nLeukocell \uf8ea2 \n(Leukoseantigen gp 70, \n FOCMA\u00ae\u00ae) 32 293 L (\u201cPfizer\u201c) lt. Hersteller \n1 ml s.c./ Tier \nEine Pr\u00fcfung der Im pfstoffe m ittels R\u00fccktitration wurde nicht durchgef\u00fchrt. \n \n3.5 Angew andte Tests und Labormethoden \n \n3.5.1 Kompetitiver ELISA (Enz yme-linked immunosorbent assay) z um Nachw eis \n l\u00f6slicher Immunkomplexe in Seren und Exsudaten FIP-verd\u00e4chtiger Katz en \n \nBei einer FIPV-Infektion zirkulieren a bh\u00e4ngig vom  Erkrankungsstadium  Immunkom plexe \nim Serum  bzw. sind in eventuell vorha ndenen Brust- und/oder Bauchh\u00f6hlenerg\u00fcssen \nnachweisbar (Jacobse-Geels et al., 1982; Horzinek  et al., 1986). Auf dieser Tatsache basiert \ndas Testprinzip des vorliegenden ELISA, der ur spr\u00fcnglich von Nancy Pfeiffer, \u201cSm ithKline \nBeecham  Anim al Health\u201c, Lincoln, Nebras ka, entwickelt (Pfeiffer, 1991) und von Schroo \n(1994) unter praktischen Bedingungen ausg etestet sowie optim iert wurde. Die \nDurchf\u00fchrung des Tests erfolgte am  Institut f\u00fcr Veterin\u00e4r-Pathologie der Universit\u00e4t \nLeipzig. \n \n3.5.1.1  Antigen-Beschichtung der Mikrotiterplatten \n   (Nunc\uf8e8, 96-Loch-Mikrotiterplatte)  \n \nDas Antigen (FIP-Virus von einem  Feldisolat , [von W . Herbst, Institut f\u00fcr Hygiene und \nInfektionskrankheiten der Tiere, Justus-Lie big-Universit\u00e4t Gie\u00dfen, gereinigt und zur \n  Material und Methoden 45 \nVerf\u00fcgung gestellt]) wurde im  CoatingBu ffer (siehe 9.3.1) 1:300 verd\u00fcnnt und je 100 \u00b5l \ndieser L\u00f6sung in jede Kavit\u00e4t einer 96-Loch-Mikrotiterplatte (Nunc Gm bH, W iesbaden) \npipettiert. Anschlie\u00dfend wurde die Platte m it einem  Deckel und Parafilm\u00ae verschlossen und \n12 bis 16 h bei 4\u00b0C inkubiert. Nach vollst\u00e4 ndiger Entleerung der Mikrotiterplatte durch \nAusschlagen auf m ehreren Lagen Zellsto ff, wurden die Vertiefungen m it je 300 \u00b5l \nBlockierungsl\u00f6sung (siehe 9.3.1) zur Blockier ung freier Bindungstellen gef\u00fcllt. Daraufhin \nwurde die Platte erneut fest verschlossen und 1 h bei 37\u00b0C inkubiert, anschlie\u00dfend entleert \nund zweim al mit Aqua bidest. gesp\u00fclt. \nDanach erfolgte die Trocknung bei 37\u00b0C \u00fcber 4 h. \n \n3.5.1.2  Aufbereitung der Serum- und Exsudatproben \n \nUm feste Bestandteile aus den Serum - und Ex sudatproben zu entfernen, wurden diese 3 \nmin in einer Tischzentrifuge zentrifugiert und der \u00dcberstand zum  sp\u00e4teren Testeinsatz \nvorsichtig abgesaugt. Bis zum  Testeinsatz wu rden die Proben bei einer Tem peratur von -\n79\u00b0C aufbewahrt. Die Proben wurden zu 200 \u00b5l portioniert, um  mehrmaliges Auftauen und \nwiederholtes Einfrieren zu verm eiden. \n \n3.5.1.3  Probenvorbereitung \n \nZur F\u00e4llung der l\u00f6slichen Im munkom plexe wurd en 10 m l Pr\u00e4zipitationsreagenz (siehe \n9.3.1) und 200 \u00b5l der zu testenden Serum - bzw. Exsudatprobe sowie der Positiv- und \nNegativkontrolle (siehe 9.3.1) in ein konisches Ze ntrifugenr\u00f6hrchen aus Glas pipettiert. Die \nR\u00f6hrchen wurden m it Deckel oder Parafilm\u00ae verschlossen, sorgf\u00e4ltig gesch\u00fcttelt und wie \nfolgt weiter behandelt: \n1) Inkubation f\u00fcr 12-16 h bei 4\u00b0C \n2) Zentrifugation bei 1500 x g f\u00fcr 20 m in bei 4\u00b0C \n3) Vorsichtiges Absaugen des \u00dcberstande s mit einer Einm alpipette, Hinzuf\u00fcgen von \n 500 \u00b5l Pr\u00e4zipitationsreagenz; Resuspendieren \n4) Zentrifugation bei 1500 x g f\u00fcr 20 m in bei 4\u00b0C \n5) Absaugen des \u00dcberstandes \n6) Zugabe von 200 \u00b5l PBS, sch\u00fctteln, anschlie\u00dfend verschlie\u00dfen der R\u00f6hrchen \n7) Inkubation f\u00fcr 25 m in bei 37\u00b0C \n  Material und Methoden 46 \n8) Kr\u00e4ftiges Sch\u00fctteln der R\u00f6hrchen, um  das Pr\u00e4zipitat vollst\u00e4ndig in L\u00f6sung zu \n bringen \n \n3.5.1.4  Durchf\u00fchrung des Tests \n \n1) Herstellen einer 1:1-Verd\u00fcnnung von jeder pr \u00e4zipierten Serum - bzw. Exsudatprobe \n(120 \u00b5l Probe + 120 \u00b5l Verd\u00fcnnungsl\u00f6sung [siehe 9.3.1]) \n2) Belegen der Antigen-beschichteten (s. 3.5.1.1.) Mikrotiterplatte m it 50 \u00b5l/Vertiefung \nder hergestellten Proben-Verd\u00fcnnung. Die Vertiefung A 1 stellt den Leerwert dar, die \nVertiefung B 1 bleibt bis zu Schritt 10 ungef\u00fcllt. Von jeder Probe wird ein \nDoppelansatz hergestellt, A 2-A5 wird m it Verd\u00fcnnungsl\u00f6sung belegt. \nSchem atische Darstellung der Belegung der Mikrotiterplatte: \n 1 2 3 4 5 6 7 8 9 10 11 12 \nA L V V V V 16* 20* 24* 28* 32* 36* 40* \nB  + + Pfd. Pfd. 16* 20* 24* 28* 32* 36* 40* \nC 1* 4* 7* 10* 13* 17* 21* 25* 29* 33* 37* 41* \nD 1* 4* 7* 10* 13* 17* 21* 25* 29* 33* 37* 41* \nE 2* 5* 8* 11* 14* 18* 22* 26* 30* 34* 38* 42* \nF 2* 5* 8* 11* 14* 18* 22* 26* 30* 34* 38* 42* \nG 3* 6* 9* 12* 15* 19* 23* 27* 31* 35* 39* 43* \nH 3* 6* 9* 12* 15* 19* 23* 27* 31* 35* 39* 43* \nL = leer    Pfd = Negativkontrolle (gepooltes Pferdeserum ) \n* = Probennum mer   + = Positivkontrolle (bekannt positives Katzenserum ) \nV = Verd\u00fcnnungsl\u00f6sung \n3) Inkubation der Platte unter Luftabschlu\u00df f\u00fcr 30 m in bei 37\u00b0C \n4) Auftragen des m Ak (siehe 9.3.1), 50 \u00b5l/Vertiefung, in einer Verd\u00fcnnung von \n 1:10 000 \n5) Inkubation der Platte unter Luftabschlu\u00df f\u00fcr 30 m in bei 37\u00b0C \n6) Entleeren des Platteninhaltes, dreim aliges W aschen m it je 300 \u00b5l Waschl\u00f6sung \n (siehe 9.3.1) pro Kavit\u00e4t, zweim aliges Aussp\u00fclen m it Aqua bidest., vollst\u00e4ndiges \n Ausleeren durch Ausschlagen auf einer Lage Zellstoff \n7) Auftragen der Enzym konjugatl\u00f6sung (siehe 9.3.1), 100 \u00b5l/Vertiefung, in einer \n Verd\u00fcnnung von 1:25 000 \n  Material und Methoden 47 \n8) Inkubation der Platte unter Luftabschlu\u00df f\u00fcr 60 m in bei 37\u00b0C \n9) Entleeren des Platteninhaltes, dreim aliges W aschen m it je 300 \u00b5l Waschl\u00f6sung pro \n Kavit\u00e4t, Aussp\u00fclen m it Aqua bidest., vollst\u00e4ndiges Ausleeren durch Ausschlagen \nauf einer Lage Zellstoff \n10) Auftragen der ABTS-L\u00f6sung (siehe 9.3.1), 100 \u00b5l/Vertiefung, und Inkubation f\u00fcr \n30 m in bei Raum temperatur unter Lichtausschlu\u00df \n11) Messen der Extinktion in einem  ELISA -Photom eter bei einer W ellenl\u00e4nge von 405 \n nm und einer Referenzwellenl\u00e4nge von 490 nm  \n12) Hinzuf\u00fcgen der Stopl\u00f6sung (siehe 9.3.1), 100 \u00b5l/Vertiefung, und erneute Messung \n der Extinktion \n \n3.5.1.5  Ausw ertung der Me\u00dfergebnisse \n \nVon jeder getesteten Probe wurde aus beiden  Extinktionswerten des Doppelansatzes der \nDurchschnittswert berechnet. Ebenso erm ittelte m an den Durchschnittswert der \nExtinktionswerte des Vierfachansatzes der Verd\u00fcnnungsl\u00f6sung, welcher als 100%-W ert \ndiente. Die prozentuale Hem mung der Extinktion der getesteten Proben berechnet sich nach \nfolgender Form el: \n Prozent Hem mung = 1  Durchschnitt Ex tinktion de r  Probe\nDurchschnitt Ex tinktion V erd\u00fcnnung sl\u00f6sung \nDer \u201cCut-off\u201c-W ert wurde von Schroo (1994) er mittelt und liegt bei 25%, das entspricht \neiner Extinktion von 75%. Proben m it Extinktionswerten zwischen 75% und 80% wurden \nals grenzwertig eingestuft und erneut getestet. \n \n3.5.2  Indirekter Immunfluoresz enztest (IFT) \n \nDer indirekte Im munfluoreszenztest (Lange et al., 1987; K\u00f6lbl u. Schuller, 1988) wurde \nzum Nachweis von Antik\u00f6rpern gegen das Virus der Felinen Infekti\u00f6sen Peritonitis genutzt \n(Pedersen, 1976b; Osterhaus et al., 1977). Die Serum - und Aszitesproben wurden im  \nInstitut f\u00fcr klinische Pr\u00fcfung Ludwigsbur g Gm bH, Veterin\u00e4rm edizinisches Labor, \nuntersucht. Die f\u00fcr die Testdurchf\u00fchrung ben\u00f6tigten, m it TGEV-infizierten (Stam m \nPurdue) Monolayer (PD 5) m it je 10 Felder n wurden von Prof. Dr. Lutz, Universit\u00e4t \nZ\u00fcrich, bereitgestellt. Die m it Aceton fixier ten Monolayer wurden bis zur Verwendung bei \n-20\u00b0C gelagert. \n  Material und Methoden 48 \n3.5.2.1  Testdurchf\u00fchrung \n \n1) Die Objekttr\u00e4ger werden auf Raum temperatur gebracht \n2) Von den Patientenseren werden je 25 \u00b5l in den Ver d\u00fcnnungen 1:25, 1:50, 1:100 und \n 1:400 auf die Testfelder pipettiert  \n3) Inkubation f\u00fcr 30 m in bei 37\u00b0C in einer feuchten Kam mer  \n4) 15 m in Waschen in phosphatgepufferter Salzl\u00f6sung (PBS ) \n5) 30 m in Inkubation m it 25 \u00b5l Konjuga t (Fluoreszein-Isothyocyanat [FITC]-\nmarkiertes Anti-Katzen-IgG [Binding-s ite, Heidelberg], Verd\u00fcnnung im  Test \n1:1000 [5 m l PBS, 5 \u00b5l Anti-Katze-IgG-K onjugat, 10 \u00b5l Evans Blue]) in einer \nfeuchten Kam mer \n6) Sorgf \u00e4ltiges Sp\u00fclen m it PBS 15 m in \n7) Abtrocknen der Objekttr\u00e4ger \n8) Eindecken in Glycerin-PBS (pH-W ert 7,2) \n9) Beurteilung m it dem  Fluoreszenzm ikroskop (UV-Licht m it 340 nm ) \nBei Antik\u00f6rper-positiven Proben f \u00e4rbt sich da s Zytoplasm a der inf izierten Zellen hom ogen \ngr\u00fcn. Die infizierten Zellen wa ren als gr\u00fcn aufleuchtende Zellinseln erkennbar. Es wurde \nmit einem  Schwellenwert von 1:100 gearbeitet. Als Antik\u00f6rper-Titer wurde diejenige \nSerum verd\u00fcnnung bestim mt, bei der ein Unterschied zwischen den virusspezifisch \nfluoreszierenden Zellinseln einerseits und dem  nichtinfizierten Zellhintergrund andererseits \ngerade noch deutlich zu erkennen war. Dabei war es bei positiven Proben m it einem  Titer > \n1:400 n\u00f6tig, die Monolayer m it entsprech end h\u00f6herer Serum verd\u00fcnnung (1:800 bis 1:3200) \nneu zu beschicken. Der Test wurde dann mit der neuen Probenverd\u00fcnnung wiederholt, um  \nden endg\u00fcltigen Titer bestim men zu k\u00f6nnen. \n \n3.5.3  Reverse Transkriptase-Polymerase-Ketten-Reaktion \n  (reverse transcriptase-polym erase chain reaction, RT -PCR) \n \nDie RT-PCR (Herrewegh et al., 1995b; Addie et  al., 1996; Gunn-Moore et al., 1998) wurde \nam Departm ent of Clinical Veterinary Science, Division of Molecular and Cellular \nBiology, University of Bristol, UK, von Dr. Danielle Gunn-Moore, PhD, durchgef\u00fchrt. \nDazu wurden die frisch entnom menen, m it dem  Antikoagulans EDTA versetzten Blut-\nproben (ca. 2-3 m l/Tier, in Kabevette\u00ae [KABE Labortechnik Gm bH, N\u00fcm brecht-Elsen-\nroth], Monovette\u00ae oder Multivette\u00ae [SARSTEDT AG & Co., N\u00fcm brecht]) gek\u00fchlt (4\u00b0C) \n  Material und Methoden 49 \nper Kurier verschickt. Alle Konzentrationsangaben beziehen sich auf das Endvolum en der \njeweiligen L\u00f6sung. \n \n3.5.3.1  Isolierung und Kultivierung der Monozyten  \n \n1) Zentrifugieren des Blutes bei 2000 x g f\u00fcr 10 m in; Aufnahm e der Buffy Coat -Zellen \n(Schicht aus Leukozyten und Throm bozyte n, die sich im  zentrifugierten Blut \noberhalb der verdichteten Erythroz yten absetzt) und Verd\u00fcnnung m it RPMI-\nZellkultur-Medium  mit 5% (v/v) fetalem  K\u00e4lberserum  (Sigm a, Deisenhofen), 0,1 \n\u00b5g/m l L-Glutam in (Sigm a, Deisenhofen), 50 \u00b5g/m l Gentam ycin, 10 \u00b5g/m l \nConcanavalin A (Sigm a, Deisenhofen) und 10 \u00b5g/m l Lipopolysaccharid vom  E. coli  \nSerotyp 0127:B8 (Sigm a, Deisenhofen) auf ein Endvolum en von 10 m l \n2) Kultivierung f\u00fcr etwa 16-18 h bei 37\u00b0C und 5% CO 2 in 25 cm2 -\nGewebekulturflaschen (Corning, UK); Entfer nen der nichtadh\u00e4renten Zellen durch \nmehrmaliges W aschen m it warm em, sterilem  PBS-Puffer \n3) Zugabe von 5 m l einer Suspension von whole feline embryo  (WFE) -Zellen (~ 5 x \n104 Zellen/m l) in Eagle`s Minim um Essen tial Medium  (MEM, Sigm a, Deisenhofen) \nmit 10% (v/v) fetalem  K\u00e4lberserum , 0,23% (w/v) Natrium bikarbonat, 0,1 \u00b5g/m l L-\nGlutam in, 1% (v/v) nicht-essentiellen Am inos\u00e4uren (Gibco-BRL, Burlington, ON, \nCanada), 0,05% (v/v) Laktalbum in-Hydr olysat (Gibco-BRL, Burlington, ON, \nCanada) und 50 \u00b5g/m l Gentam ycin \n4) Kultivierung bei 37\u00b0C und 5% CO 2; nach 4 Tagen \u00dcberf\u00fchren der durch Inkubation \nmit Trypsin abgel\u00f6sten Zellen in 75 cm2-Gewebekulturflasche (Corning); nach 7 \nTagen Entnahm e von  2/3 der zur Subkultivierung hergestellten Zellsuspension nach \nTrypsin-Behandlung, zentrifugieren bei 2000 x g f\u00fcr 5 m in, waschen in sterilem  \nPBS-Puffer, lysieren in 1 m l RNA-Extraktionsl\u00f6sung (TRI Reagenz\u00ae; Sigm a, \nDeisenhofen) und einfrieren bei \u201370\u00b0C;  Subkultivierung des verbleibenden 1/3 der \nZellsuspension (Gesam tdauer der Kultivierung: 4 W ochen) \n \n3.5.3.2  RNA-Extraktion  \n \n1) Pipettieren der Zellen in TRI-Reagenz\u00ae (Sigm a, Deisenhofen), bis das Lysat eine \nfl\u00fcssige Konsistenz erreicht (ca. 20 \u2013m aliges Dr\u00fccken des Lysates durch  auf 5 m l-\nSpritze aufgesetzte Kan\u00fcle [21 G]) \n  Material und Methoden 50 \n2) Mischen auf dem  Vortexer f\u00fcr 30 sec; Zugabe von 200 \u00b5l \nHochdruckfl\u00fcssigkeitschrom atographie (H PLC)-f\u00e4higes Chloroform  (Sigm a, \nDeisenhofen) \n3) Mischen auf dem  Vortexer f\u00fcr 30 sec;  zentrifugieren bei 13000 x g f\u00fcr 15 m in bei \n4\u00b0C (Hettich Zentrif uge EBA 12R; Hettich Zentrif ugen, Tuttlingen) \n4) Verbringen der oberen, w\u00e4\u00dfrigen Schicht in 1,5 m l Mikrozentrifugen-\nReaktionsgef\u00e4\u00df ; Zugabe der gleichen Menge (ca. 0,5 m l) auf 4\u00b0C gek\u00fchltes \nIsopropanol (Sigm a, Deisenhofen). \n5) Mischen auf dem  Vortexer; einfrieren der Proben f\u00fcr m indestens 30 m in bei -20\u00b0C; \nauftauen, zentrifugieren bei 13000 x g f\u00fcr 15 m in bei 4\u00b0C \n6) Verwerfen des \u00dcberstands, waschen des Pellets durch Zugabe von 1 m l 75% \nEthanol ( molecular grade ; Haym an) \n7) Mischen auf dem  Vortexer; zentrifugieren bei 8000 x g f\u00fcr 10 m in bei 4\u00b0C \n8) Verwerfen des \u00dcberstands, lufttr ocknen; resuspendieren in 20 \u00b5l \nDiethylpyrokarbonat (DEPC)-behandeltem  Wasser \n9) Bestim mung der RNA-Menge in eine m Spektrophotom eter (Ultrospec 2, LKB \nBiochrom ; Cam bridge, UK) (Gunn-Moore, 1997b) \nZum  Ausschlu\u00df einer m \u00f6glichen Degradierung der RNA w\u00e4hrend der Extraktion wurden \neinzelne Proben auf 2%igem  Agarosegel  elektrophoretisch aufgetrennt und m it \nEthidium brom id (200 ng/m l Agarose) gef\u00e4rbt. \n \n3.5.3.3  DNase-Behandlung zur Entfernung kontaminierender genomischer DNA  \n \n1) Erhitzen der RNA-Extrakte auf 94\u00b0C f\u00fcr 5 m in; anschlie\u00dfendes K\u00fchlen auf Eis \n2) Ansatz der Reagenzm ischung (0,1 \u00b5g/\u00b5 l RNA; 20 m M Tris-HCl (pH 8,3); 50 m M \nKCl; 2,5 m M MgCl 2, 0,1 U/\u00b5l DNAse 1 (m olecular bioloy grade, Gibco-BRL, \nBurlington, ON, Canada); DEPC-W asser ad 50 \u00b5l); Inkubation f\u00fcr 15 m in bei \nRaum temperatur \n3) Stoppen der Reaktion durch Zugabe von 2,5 m M EDTA; anschlie\u00dfende Inkubation \nf\u00fcr 15 m in bei 65\u00b0C \n  Material und Methoden 51 \n3.5.3.4. Synthese der cDNA (RT-Reaktion)  \n \nEs wurde ein kom merziell erh\u00e4ltlicher Kit (SuperScript Pream plification System  for First \nstrand cDNA synthesis; SuperScript \u2122, Gibc o-BRL, Burlington, ON, Canada) verwandt. \n1) Zugabe von 0,5 \u00b5g Oligodesoxythym idintriphosphat (dT) 12-18 Prim er zu den \nDNAse-behandelten RNA-Extrakten (ca. 2- 5 \u00b5g RNA); Inkubation f\u00fcr 10 m in bei \n70\u00b0C \n2) K\u00fchlen f\u00fcr m indestens 1 m in auf Eis \n3) Volum eneinstellung auf 20 \u00b5l durch Zusatz von: \n4) 20 m M Tris-HCl (pH 8,4), 50 m M KCl, 2,5 m M MgCl 2, 0,5 m M \nDesoxynucleosidtriphosphat (dNTP)-Mix , 10 m M DTT und 10 U/\u00b5l SuperScript 2 \nRT reverse transcriptase (Gibco-BRL, Burlington, ON, Canada); Inkubation f\u00fcr 45 \nmin bei 45\u00b0C; Inaktivierung f\u00fcr 15 m in bei 70\u00b0C; K\u00fchlung auf Eis. \n5) Zugabe von 0,1 U/\u00b5l E. coli -RNase H; Inkubation f\u00fcr 20 m in bei 37\u00b0C; Lagerung \nder cDNA bei -20\u00b0C \n \n3.5.3.5  Oligonukleotid-Primer  \n \nEs wurden Prim er f\u00fcr den C-Term inus de s S-Gens (Prim er A-F, A-R, B-F und B-R; \nbasierend auf der Sequenz des FIPV 79-1146- Stam mes; de Groot et al., 1987) und das \nhochkonservierte N-Gen (Prim er NF, NR1 und NR2; Vennem a et al., 1991) von FCoV \nsowie Prim er f\u00fcr das Glycerinaldehyd-3-P hosphat-Dehydrogenase\u2013Gen als \u201chousekeeping \ngene\u201c eingesetzt (Gunn-Moore, 1997b; Gunn-M oore et al., 1998). F\u00fcr FCoV wurden die \nPrim er als \u201cnested\u201c oder \u201csem i-nested\u201c-Paar e konstruiert. Die Prim er-Sequenzen sind in \nAbbildung 2 dargestellt.  \n  Material und Methoden 52 \nAbbildung 2: FCoV und Glycerinaldehyd-3- Phosphat-Dehydrogenase (GAPDH) Prim er \nPrimer       Amplifikat  \n Gr\u00f6\u00dfe  Bindungs-  Gr\u00f6\u00dfe Sequenz  5\u00b4\u21923\u00b4 \n  ( nt) stelle   ( nt)       \nFCoV (S)   \nA-F  24 2537 \u21922560   TCA CAC ATT CTG ACG GAG ACG TGC \nA-R  24 3375 \u21903352   CGC TTT AGC AAC AGT GGC AAG ACC \nA-F + A-R     839 \nB-F  23 2750 \u21922772   CAA TGG GTG CCA GACTTG AAA AC \nB-R  25 3104 \u21903080   GCT ACA CCT GGT AGAACC ATG ATG C \nB-F + B-R     355 \nFCoV (N)   \nNF  28 436\u2192463   CCA CCA CAA TTC CAG CTT GAA GTG AAC C \nNR1  49 1021 \u2190995   GCG CGC GCG CGC GCG CGC GCC GGG ATT \n TTC TTT GCC TCT GAT CCT TAG C \nNR2  45 809\u2190785   GCG CGC GCG CGC GCG CGC GCA GCA TTT \nGGCAGC GTT ACC ATT GGC \nNF + NR1     587 \nNF + NR2     373 \nG3PDH-F 22 167\u2192189   CCT TCA TTG ACC TCA ACT ACA T \nG3PDH-R 21 546\u2190566   CCA AAG TTG TAC TGG ATC ACC \nG3PDH-F + G3PDH-R   399 \nF = forward prim er (vorw\u00e4rtslaufender Prim er) \nR = reverse prim er (r\u00fcckw\u00e4rtslaufender Prim er) \nnt = Nukleotide  \n \n3.5.3.6  Polymerase-Ketten-Reaktion (PCR)  \n \n- Master-Mix f\u00fcr die 1. PCR: \n20 m M Tris-HCl (pH 8,4); 50 m M KCl; 2,0 nM MgCl 2; 200 \u00b5M dNTP-Mix; 0,1 U/\u00b5l \nAmpliTaq Gold \uf8ea DNA-Polym erase (Perkin Elm er); 2 \u00b5l (5% (v/v)) cDNA-Verd\u00fcnnung; je \n3 \u00b5M FCoV-Prim er; Auff\u00fcllen m it DEPC-W asser auf ein Endvolum en von 50 \u00b5l \n- eingesetzte Prim er: \nf\u00fcr das S-Gen A-F und A-R und f\u00fcr das N-Gen NF und NR1 \n  Material und Methoden 53 \n- PCR-Protokoll (Therm ocycler: Touchdown-Hybaid, T\u00fcbingen) \n10 m in bei 94\u00b0C \n35 Zyklen: 1 min bei 94\u00b0C \n1 min bei 55\u00b0C \n2 min bei 72\u00b0C \n10 m in bei 72\u00b0C \n \n- 2. PCR: \nFalls das PCR-Produkt der 1. PCR im  Agarosegel (s. 3.5.3.7) keine positive Bande \nerbrachte, wurde eine zweite PCR durchgef\u00fchr t, indem  2 \u00b5l des Produkts aus der 1. PCR in \ndie 2. PCR eingesetzt wurden \n- Masterm ix: siehe oben \n \n- eingesetzte Prim er \nf\u00fcr das S-Gen B-F und B-R und f\u00fcr das N-Gen NF und NR2 \nDas PCR-Protokoll ist identisch m it der ersten PCR. \n \n- Kontrollen: \nPositiv- und Negativkontrollen liefen in jedem  Abschnitt der PCR-Reaktion m it. Die \nPositivkontrollen enthielten am plifizierte cDNA,  die aus der Kontroll-RNA des Kits (s. \n3.5.3.4) unter Benutzung des PCR-Prim ers (0,1 \u00b5M) des Kits hergestellt wurden, sowie \nexperim entell hergestellte FCoV-cDNA-Proben, die als stark positiv bekannt waren (Gunn-\nMoore, 1997b; Gunn-Moore et al., 1998). Nega tivkontrollen enthielten keine RT, keine \nPrim er oder keine cDNA-Kontrollen. \n- housekeeping gene GAPDH: \nDas PCR-Protokoll ist identisch m it dem  f\u00fcr die PCR f\u00fcr die Coronavirus-Sequenzen. \n \n3.5.3.7  Nachweis der PCR-Produkte mittels Agarosegel-Elektrophorese und   \n   Ethidiumbromid-F\u00e4rbung \n \nDie DNA wurde m ittels Elektrophorese in ei nem 2%igen Agarose/Tris-Acetat-EDTA \n(TAE, s. Anhang L\u00f6sungen und Puffer)-Gel mit 200 ng/m l Ethidium brom id-Agarose \naufgetrennt (10 \u00b5l PCR-Produkt m it 2 \u00b5l 6 x Gel Loading Solution (Sigm a, Deisenhofen) je \nin eine Kavit\u00e4t). Die DNA-Bruchst\u00fccke wurden  mit einem  UV-Transillum inator (UVP Inc.; \n  Material und Methoden 54 \nCam bridge, UK) sichtbar gem acht und fotogr afiert (Polaroid Schwarz-W ei\u00df-Film  667; \nSigm a, Deisenhofen). \n \n3.5.3.8  Quantifizierung der PCR-Produkte  \n \nDie Quantifizierung der PCR-Produkte erfolgte anhand der Intensit\u00e4t der Banden im  \nEthidium brom id-gef\u00e4rbten Agarosegel im  Vergleich zur Intensit\u00e4t der Banden in den \nPositivkontrollen und der G3PDH-Bande der glei chen Probe. Dem entsprechend wurden die \nuntersuchten Proben f olgenderm a\u00dfen beurteilt: \n- negativ (d.h. keine Monozyten-assoziierte FCoV-Vir\u00e4m ie \nnachweisbar) \n(+) schwach positiv \n+ m\u00e4\u00dfig positiv \n++ stark positiv \n+++ sehr stark positiv \n \n3.5.3.9  Best\u00e4tigung der Spezifit\u00e4t der Banden  \n \nDie Spezif it\u00e4t der Banden im  Ethidium brom id-gef \u00e4rbten Gel wurde m ittels Southern \nBlotting und der Elektrochem olumineszen z (ECL\u2122, Am ersham  Life Science; \nBuckingham shire, UK) zum  Nachweis der spezifisch gebundenen Sonden best\u00e4tigt (Gunn-\nMoore, 1997b; Gunn-Moore et al., 1998). \n \n3.5.4  Fixierung der Gew ebe \n \nGewebeproben der gro\u00dfen Parenchym e (Geh irn, Lunge, Leber, Niere, D\u00fcnn- und \nDickdarm , Mesenteriallym phknoten, Knoche nmark, Milz sowie alle m akroskopisch \nver\u00e4nderten Gewebe wurden routinem \u00e4\u00dfig f\u00fcr 12-18 h in 10% neutralisiertem , \nungepuffertem  Form alin fixiert. Die Ge webeproben wurden im  Einbettautom aten \nHypercenter XP (Shandon, Frankfurt) in Vogel-Histo-Com p.\u00ae (VO-5-1002; Vogel, Gie\u00dfen) \nbei 60\u00b0 C eingebettet. \n  Material und Methoden 55 \n3.5.5   Histopathologische Pr\u00e4paration \n \nVon den eingebetteten Geweben wurden Schnitte hergestellt, auf  Eiwei\u00df-Glyzerin-\nbeschichtete Objekttr\u00e4ger aufgezogen und m it H\u00e4m atoxylin-Eosin (HE) gef\u00e4rbt. \nF\u00fcr die im munhistologischen Untersuchungen wurden Schnitte auf SuperFrost*/Plus-\nObjekttr\u00e4ger (041300; Menzel Gl\u00e4ser, Bra unschweig) aufgezogen, ca. 1 h vor einem  \nVentilator luftgetrocknet und anschlie\u00dfend direkt weiterverarbeitet. \n \n3.5.6  Nachw eis des Coronavirus-Antigens \n \nZum  Nachweis des Coronavirus-Antigens wu rde ein m onoklonaler Antik\u00f6rper (FCV3-70) \n(Custom s Monoclonals International, Sacram ento, USA) unter Anwendung der PAP-\nMethode (Tam mer et al., 1995; Kipar et al ., 1998) eingesetzt. S\u00e4m tliche Inkubationen \nwurden, sofern nicht anders verm erkt, bei Raum temperatur durchgef\u00fchrt. \n1) Entparaf finieren der Schnitte in Roti-Histol\u00ae f\u00fcr 10 m in, danach 2 x \nIsopropylalkohol und 1 x 96% Alkohol f\u00fcr je 3 m in \n2) Inaktivierung der endogenen Peroxidase in Methanol m it frisch zugesetztem  0,5% \n H 2O2 f\u00fcr 30 m in \n3) TUF(Target Unm asking Fluid)-Behandl ung: W aschen der Schnitte in Aqua dest. \n Erhitzen der verd\u00fcnnten TUF-L\u00f6sung (1 Teil TUF + 2 Teile Aqua dest. [Dianova \n GmbH, Ham burg]) in Plastikk\u00fcvetten im  Wasserbad auf 94\u00b0 C. Inkubation der \n Schnitte f\u00fcr 10 m in bei 94\u00b0 C in einer K\u00fcvette; anschlie\u00dfendes Abk\u00fchlen der \nSchnitte in den K\u00fcvetten bei Raum temperatur au\u00dferhalb des W asserbades f \u00fcr 15 \nmin. W aschen der Schnitte f\u00fcr 1 m in in Aqua bidest. und anschlie\u00dfend in TBS \n4) Aufbringen der Objektr\u00e4ger auf CoverplatesTM (Life Science International, \n Frankfurt/Main) und Einf\u00fchren der CoverplatesTM (Life Science International, \n Frankfurt/Main) in die Halterung \n5) Inkubation m it 10% Rattenserum  in TBS f\u00fcr 10 m in \n6) Auftragen des m onoklonalen Prim \u00e4rantik\u00f6r pers (FCV3-70) (Custom s Monoclonals \n International, Sacram ento, USA) (1 : 100 in TBS). \n Inkubation der Schnitte f\u00fcr 12 bis 18 h bei 4\u00b0C \n7) Sp\u00fclen der Schnitte durch Einbringen von 2 m l TBS in das Coverplate \uf8ea (Life \nScience International, Frankfurt/Main) \n \n  Material und Methoden 56 \n8) Auftragen des 1:100 in TBS verd\u00fcnnten Se kund\u00e4rantik\u00f6rpers (Ratte anti-Maus IgG) \n (DIANOVA Gm bH, Ham burg) \n9) Sp\u00fclen der Schnitte durch Einbringen von 2 m l TBS in das Coverplate \uf8ea (Life \nScience International, Frankfurt/Main) \n10) Auftragen des 1:500 in TBS verd\u00fcnnt en Maus-PAP (DIANOVA Gm bH, Ham burg). \n Inkubation der Schnitte f\u00fcr 30 m in \n11) Sp\u00fclen der Schnitte durch Einbringen von 2 m l TBS in das Coverplate \uf8ea (Life \nScience International, Frankfurt/Main) \n12) Inkubation der Schnitte unter st\u00e4ndigem  R\u00fchren (Magnetr\u00fchrer) in frisch \n hergestelltem  0,05% 3,3`-Diam inobenzidintetrahydrochlorid m it 0,01% H 202 in  \n 0,1 M Im idazolpuffer (pH 7,1) f\u00fcr 10 m in \n13) Waschen der Schnitte 3 x f\u00fcr je 5 m in in TBS und 1 x 5 m in in Aqua dest. \n14) Gegenf\u00e4rben m it Papanicolaous H\u00e4m atoxylin f\u00fcr ca. 20 sec und Bl\u00e4uen der Schnitte \nin Leitungswasser f\u00fcr 5 m in \n15) Waschen f\u00fcr 1 m in in Aqua dest. \n16) Entw\u00e4ssern der Schnitte in der aufsteigenden Alkoholreihe und zweim aliges Kl\u00e4ren \nin Roti-Histol\uf6da \n17) Eindecken in Eukitt\uf6da \n  Ergebnisse 57 \n4.  Ergebnisse  \n \nMit Hilfe des kompetitiven ELISA zum Nach weis von FIPV-spezifischen l\u00f6slichen \nImmunkomplexen in Seren und Exsudaten wurden  nat\u00fcrlich FIPV-infizierte Katzen aus \nverschiedenen Tierheimen selektiert und als nat\u00fcrliche Infektionsquelle (unbekannte \nFeldviren) im Versuch eingesetzt. In den ein zelnen Tierheimen reagierten 5 % bis 16 % der \ngetesteten Tiere im ELISA positiv. Insgesamt wurden 265 Katzen serologisch getestet. 18 \nTiere (7%) davon reagierten im ELISA positiv. 15 Tiere konnten f\u00fcr den Versuch \n\u00fcbernommen werden. Vier dieser Tiere (Gruppe  T3) verstarben bereits vor Versuchsbeginn \nan der effusiven Form der FIP, so da\u00df noch 11 Tiere in den Versuch gelangten. Der \nklinische Status der meisten in den Versuc h gelangten Tierheimkatzen blieb unver\u00e4ndert. \nEin Tier der Gruppe T3 entwickelte eine klinisch manifeste Coronavirus-Enteritis, an der es in der Versuchswoche 16 verstarb. Eine weitere  Tierheimkatze starb in der Versuchswoche \n35 an der effusiven Form der FIP. \nIn der Versuchswoche 12 wurden alle Gruppen zusammengesetzt (Versuchsbeginn im engeren Sinne = Challenge). Trotz des gro\u00dfz \u00fcgigen Platzangebotes kam es vermehrt zu \nRangk\u00e4mpfen, bei welchen die \u00e4lteren und schwer eren Tierheimkatzen klar dominierten. \nAber auch zwischen den SPF-Katzen gab es  erhebliche Auseinandersetzungen, was zu \nverschiedenen Verletzungen f\u00fchrte, die z. T. veterin\u00e4rmedizinisch behandelt werden \nmu\u00dften (diverse Hautri\u00dfwunden haupts\u00e4chlic h im Kopfbereich, Augenverletzungen). Bei \nden SPF-Katzen fiel der Zahnwechsel und bei de n m\u00e4nnlichen SPF-Tieren die Kastration in \ndiese Zeit. \nBereits vor dem Auftreten der Felinen Infekti\u00f6sen Peritonitis trat ca. eine Woche nach dem Zusammensetzen aller Tiere, d.h. in der Versuchswoche 13, in allen drei Gruppen eine \u201cKatzenschnupfensymptomatik\u201c auf. Vorrangige Symptome waren Augen- und Nasenausflu\u00df (anfangs ser\u00f6s, sp\u00e4ter sero-muk\u00f6s), Lidschwellungen, Niesen sowie eine Verschlechterung des Allgemeinbefindens (Inappetenz, Mattigkeit). \n \n4.1  Gewichtsentwicklung der SPF-Tiere \n \nDie Gewichtsentwicklung der SPF-Tiere war unabh\u00e4ngig vom Impfstatus und insgesamt \nausgeglichen (Abb. 3). Die leichteste und die schwerste Katze der Jungtier-SPF-Population \nstarben am Anfang des Versuches (nicht an FIP, sondern an respiratorischen Erkrankungen). Das Durchschnittsgewicht der am Versuchsende 12 Monate alten Tiere lag bei 2,82 kg (3,17 kg bei den m\u00e4nnlichen und 2,63 kg bei weiblichen Tieren). Laut Harlan Ergebnisse 58 \nSprague Dawley, Inc., Indianapolis, Indiana (USA), betr\u00e4gt das Durchschnittsgewicht der \nSPF-Katzen schon nach 45 W ochen ca. 3,52 kg (4,25 kg bei den m \u00e4nnlichen und 2,8 kg bei \nweiblichen Tieren). \nAbb. 3  \n05001000150020002500300035004000\n22.11.1996 19.12.1996 04.04.1997 16.06.1997 25.08.1997\nGewichtsentwicklung al ler SPF-Katzen im VersuchszeitraumGewicht in Gramm\n \n \n4.2  Serologische und andere Testergebnisse \n \nAlle Tiere zeigten im  Laufe des Versuchs Serokonversion. Die Vakzine Prim ucell\u00aeFIP \ninduzierte CoV-Antik\u00f6rper-Titer von 1:50 bis 1:800. Nach einsetzendem  Infektionsdruck \nstiegen die CoV-Antik\u00f6rper-Titer bei einzelnen Im pf- und auch Kontrolltieren bis auf > \n3200. Nicht alle Tiere, die hohe CoV-Antik\u00f6rper-T iter aufwiesen, erkrankten auch an FIP. \nEbenso gab es im  ELISA zeitweise positiv reagierende Tiere, die nicht an FIP erkrankten \nund bei denen am  Versuchsende auch keine FIP festgestellt werden konnte. Auf der \nanderen Seite erkrankten und starben Tiere an FI P, die im  ELISA negativ reagierten. Einige \nTiere, die an FIP erkrankten, waren niedrig titrig und im  ELISA negativ, andere wiederum  \nhochtitrig und positiv im  ELISA. Eine Gesetzm \u00e4\u00dfigkeit oder Signifikanz konnte nicht \ngefunden werden. Auff\u00e4llig sind aber die \u00e4hn lichen Verl\u00e4ufe der CoV-Antik\u00f6rper-Titer und \nder ELISA-Ergebnisse (Vorhandensein l\u00f6slicher Im munkom plexe in Seren) in der \ngraphischen Auswertung (siehe 9.2 [Antik\u00f6rper-Titer- und ELISA-Verl\u00e4ufe ]) bei einigen \nTieren, eine Gesetzm \u00e4\u00dfigkeit konnte aber auch hier nicht gefunden werden. Die Serologie \ngab bei den SPF-Tieren keinen Hinweis f\u00fcr die Diagnose FIP oder f\u00fcr die Prognose, eine \nFIP zu entwickeln. Ergebnisse 59 \nDer Nachweis der FCoV-Infektion erfolgte am lebenden Tier auch direkt mittels RT-PCT \nzum Nachweis von FCoV-Genom in Monozyten nach deren Ko-Kultivierung mit felinen Embryonalzellen (Gunn-Moore, 1997b; Gunn-Moore et al., 1998). Der Nachweis der Monozyten-assoziierten Vir\u00e4mie erfolgte ab Vorliegen des Infektionsdrucks f\u00fcr ca. 5 Monate zweimal im Abstand von ca. 10 Wochen bei allen Tieren, die den Versuch bis dahin \u00fcberlebt hatten. S\u00e4mtliche Tierheimkatzen waren mindestens bei einem der Tests positiv, von den 17 SPF-Katzen, die mindestens einmal untersucht wurden, waren 16 positiv. Am Versuchsende waren 20 von 23 \u00fcberlebenden Tieren (SPF-Tiere und \nTierheimkatzen) in der RT-PCR positiv. \n \n4.3  Klinisch unauff\u00e4llige SPF-Tiere  \n \nSieben SPF-Tiere (H6 1455, H6 1443, H6 1433, H6 1427, H6 1436, H6 1425 und H6 1432) waren w\u00e4hrend des gesamten Versuchszeitraumes klinisch unauff\u00e4llig und zeigten keinerlei Symptome irgendeiner Erkrankung. Das sind 17,5 % aller SPF-Tiere. Davon waren 3 Tiere (2 weiblich / 1 m\u00e4nnlich) aus der Gruppe T1 (Kontrollgruppe) und 4 Tiere (3 weiblich / 1 m\u00e4nnlich) aus der Gruppe T2 (Primucell\n\u00ae-Gruppe). Bei keinem dieser Tiere konnte am \nVersuchsende in der Obduktion FIP diagnos tiziert werden. Zwei Tiere wiesen CoV-\nAntik\u00f6rper-Titer > 3200 in der Versuchswoche 22 (erste Blutentnahme nach Challenge) auf. Am Versuchsende beliefen sich die CoV-Antik\u00f6rper-Titer auf maximal 1 : 400, im kompetitiven ELISA reagierten alle negativ und in der RT-PCR zeigten 5 von den 7 Tieren eine positive Reaktion. \n \n4.4  Andere Todesursachen als FIP \n \nIn der Tabelle 11 findet sich eine \u00dcbersicht \u00fcber die anderen Todesursachen als FIP. Ergebnisse 60 \nTabelle 11: Andere Todesursachen im  Versuchszeitraum  \n Anzahl der im  \nVersuch gestorbenen \nTiere Befund Geschlecht \nT1 (SPF-Kontrolltiere) 1 \n1 K\u00fcm merer \nPleuritis (Nokardiose) weiblich \nm\u00e4nnlich \nT2 (Prim ucell\u00ae-\nGruppe) 1 \n \n1 katarrhalisch-eitrige \nPneum onie \nNarkosezwischenfall bei \nAugenoperation m\u00e4nnlich \n \nm\u00e4nnlich \nT3 (Tierheim katzen) 1 Coronavirus-Enteritis m\u00e4nnlich \n \n4.5  Chronologische \u00dcbersicht der Todesf\u00e4lle \n \nAbb. 4: \nChronologische \u00dcbersicht der Todesf\u00e4lle (aller Ursachen) im  Versuchszeitraum : \n36 9 12 15 18 21 24 27 30 33 36 39 42\nVersuchszeitraum in Wochen012345\nF\u00e4lle\npro\nWoc he\nGruppe T1 (20 SPF-Kontrolltiere -  12 Tiere gestorben )\nGruppe T2 (20 SPF-\" Primucell\u00ae \"-Impftiere - 14 Tier e gestorben )\nGruppe T3 (11 FIP- positive Tierheim katzen - 2 Tiere gestorben )zusammengesetz t \u21d1\n \nDie Versuchswoche 12 stellt den Versuchsbeginn im  engeren Sinne dar (Zusam mensetzen \naller Tiere, Beginn des nat\u00fcrlichen Infektionsdrucks f\u00fcr die SPF-Prim ucell\u00ae-Tiere und die \nSPF-Kontrolltiere, Challenge). Ergebnisse 61 \n4.6  FIP-F\u00e4lle \n \nDer erste FIP-Fall wurde ca. sechs Wochen n ach Einbringen der Tierheimkatzen (T3) in \nder Versuchswoche 18 (6 Wochen nach der Exposition) klinisch manifest. Es folgten \nwenige Tage sp\u00e4ter eine Vielzahl von FI P-Erkrankungen bei den SPF-Tieren (Abb. 13 und \n14, Anhang 9.1). Es handelte sich \u00fcberwiegend um die effusive Form der FIP (Abb. 10-15, \nAnhang 9.1). Ein SPF-Tier \u00fcberlebte  eine FIPV-Infektion mit klinischer Manifestation. Es \nwar nach abgeklungener Symptomatik (A bb. 16-18, Anhang 9.1) vollkommen genesen und \nklinisch unauff\u00e4llig. Am Versuchsende war es  in der Obduktion FIP-negativ. Im Verlauf \ndes Versuches starben bzw. wurden im Fina lstadium der FIP oder anderer Erkrankungen 28 \nTiere (Tabelle 12) euthanasiert. Zw\u00f6lf Tier e stammten aus der Kontrollgruppe und vierzehn \naus der Primucell\u00ae-Impfgruppe. Zus\u00e4tzlich starben 2 de r Tierheimkatzen. Die Diagnose \neiner FIP wurde post mortem durch den Se ktionsbefund, den histopathologischen Befund \nund den immunhistologischen Nachweis von FI PV-Ag in den L\u00e4sionen best\u00e4tigt. Die \nverbleibenden SPF-Katzen wurden am Versuchsende zwecks Abkl\u00e4rung einer FIP \neuthanasiert. Es handelte sich um sechs SPF-Primucell\u00ae-Impftiere und acht SPF-\nKontrolltiere. Bei keinem dieser Tiere fanden sich Ver\u00e4nderungen im Sinne einer FIP. \nAuff\u00e4llig waren bei fast allen dieser SPF-Ti ere Ver\u00e4nderungen der lymphatischen Gewebe \n(follikul\u00e4re Hyperplasie und vergleichsweise verbreiterte T-Zell-Zonen in den Mesenterial-lymphknoten und der Milz, sowie eine Thymushyperplasie). \nAufgrund der Tierversuchsauflagen (Vermittlung der T3-Tiere) konnten die Tierheimkatzen am Versuchsende nicht untersucht werden. Alle vermittelten Katzen waren bei Abgabe jedoch klinisch unauff\u00e4llig. Zu f\u00fcnf der vermittelten Katzen existieren noch Informationen nach Ablauf des Versuches: si e sind alle gesund bzw. klinisch unauff\u00e4llig. \nKeines der Tiere erkrankte klinisch manifest an FIP oder einer anderern Erkrankung oder verstarb an FIP oder einer anderen Erkrankung (Stand 1.7.2001). \nTabelle 12 und Abbildung 5 geben einen \u00dcb erblick \u00fcber die FIP-Erkrankungen des \nVersuchs. Es gab keinen signifikanten Unterschied (p = 0,53) zwischen der SPF-Primucell\n\u00ae-Impfgruppe und der SPF-Kontrollgruppe bez \u00fcglich der Anzahl der Tiere, die an \nFIP erkrankt waren. Zur Anwendung kam der Mantel-Haenzsel Chi-Quadrat-Test. Weiterhin ergab sich kein signifikanter Unterschied in der Geschlechtsverteilung der an FIP erkrankten Tiere (Abb. 6). Ergebnisse 62 \nAbb. 5:  chronologische \u00dcbersicht \u00fcber das Auftreten der einzelnen Form en der FIP \nbei    den SPF-Katzen \n0 3 6 9 12 15 18 21 24 27012345\nKatze mit der trockenen Form der FIP - nur ZNS\nKatzen mit der effusiven Form der FIP\nKatzen mit der trockenen Form der FIP \n \nTabelle 12 \nGruppe Anzahl im  \nVersuch \ngestorbener* Tiere davon Befund FIP \n(Inzidenz in %) FIP \nweiblich FIP \nm\u00e4nnlich \nT1 (SPF-Kontrolltiere) 12 10 (50% von T1) 7 3 \nT2 (Prim ucell\u00ae-\nGruppe) 14 12 (60% von T2) 3 9 \nT3 (Tierheim katzen) 2 1 (9%) 1 0 \nalle Gruppen zusam men 28 23 (45%) 11 12 \n*bzw. im  Finalstadium  der FIP oder anderer Erkrankungen euthanasiert \n \nAbb. 6: Geschlechtsverteilung de r an FIP erkrankten SPF-Tiere \n10\n12weibl iche SPF -Tiere\nm\u00e4nn liche SPF -Tiere45 %\n55 %\n Ergebnisse 63 \n4.7  Preventable fraction  \n \nAus Tabelle 12 ergibt sich eine gesch\u00fctzte Fraktion (preventable fraction) von -20 %, \nerrechnet nach der Form el: \n Preventable fraction = Inzidenz de r Gruppe T1 - Inzidenz de r Gruppe T2\nInzidenz de r Gruppe T1x 100 \n \n4.8  Formen der FIP \n \nDie FIP trat bei den SPF-Tieren sowohl in der feuchten als auch in der trockenen Form  auf \n(Abb. 13, 14 und 16). \nDie effusive Form  lag in den m eisten F\u00e4llen in typischer Auspr\u00e4gung vor (Abb. 10-15, \nAnhang 9.1). Die Aszitesm enge betrug im  Durchs chnitt 350 m l. Im Vergleich zu Tieren m it \nder trockenen Form  der FIP zeigten Tier e mit der effusiven Form  der FIP einen \nfulm inanteren und k\u00fcrzeren Krankheitsverlauf,  die Krankheitsdauer lag im  Durchschnitt \nbei 14 Tagen (anf\u00e4nglich 7 Tage, sp\u00e4ter bi s 33 Tage). Eine Au\u00dfnahm e bildeten eine \nTierheim katze (Nr. 45) und wenige SPF-Kat zen (H6 1431, H6 1444), bei denen sich die \nKrankheitsdauer bei der effusiven Form  der FI P \u00fcber m ehrere W ochen erstreckte. Tabelle \n13 zeigt die Krankheitsform en und -verl\u00e4ufe der an FIP erkrankten SPF-Katzen in \nchronologischer Reihenfolge m it Angabe de r Aszitesm engen. Erstes wahrnehm bares \nSymptom war stets die progressive Aszite sbildung. Das Allgem einbefinden der Tiere war \nh\u00e4ufig lange Zeit ungest\u00f6rt (Abb. 10-15, Anha ng 9.1), der Appetit erhalten. Fieber bzw. \nK\u00f6rpertem peraturerh\u00f6hung konnten durch stichpr obenartiges Messen nicht festgestellt \nwerden. Erst m it massiver Aszitesbildung ka m es zur Beeintr\u00e4chtigungen der Atm ung und \nder Bewegungsfreiheit des jeweiligen Tieres. Die Verdauung war nur in seltenen F\u00e4llen \ngest\u00f6rt. Durch abdom inale Punktion zu diagnos tischen Zwecken lie\u00dfen sich bis zu 250 m l \nAszites problem los gewinnen. Das Punktat war in allen F\u00e4llen charakteristisch f\u00fcr die FIP. \nDie Punktion hatte lediglich einen kurzfristigen therapeutischen Effekt. Ergebnisse 64 \nAbb. 7:  Verteilung der FIP-Form en bei den 23 aufgetretenen F\u00e4llen (alle   \n   Gruppen) im  Versuchszeitraum  \n16\n70%\n7\n30%1 x nur ZNSx effusive Form\nx trockene F orm\n \nTiere m it der trockenen Form  der FIP zei gten \u00fcberwiegend unspezifische Sym ptome. \nDaraus resultierte das Problem , da\u00df der Zeitpunkt  der klinischen Manifestation nur schwer \noder gar nicht zu bestim men war. Die durch schnittliche Krankheitsdauer lag bei 17 Tagen \n(anf\u00e4nglich 4 Tage, sp\u00e4ter 42 Tage). Tiere m it der trockenen Form  der FIP waren \u00fcber den \ngesam ten Versuchszeitraum  anzutreffen. Vorrangige klinische Sym ptome waren der \nGewichtsverlust bzw. die verm inderte Gewichtszunahm e, der wechselnde Appetit, Habitus- \n(Abb. 16, Anhang 9.1) und W esensver\u00e4nderungen, Kontaktscheue zum  Pflegepersonal und \nzu anderen Tieren, Augenver\u00e4nderunge n (Abb. 18, 19 und 21-26, Anhang 9.1 und Tabelle \n14) und ZNS-St\u00f6rungen (Ataxien, Trem or, Nystag mus etc.). Ein Tier entwickelte eine \nausschlie\u00dflich zentralnerv\u00f6se klinische Sy mptomatik (Tier-Nr.: H6 1451, Sektions-Nr.: \n433/97). \nDurch sym ptomatische Therapie war eine Beeinflussung der Krankheitsdauer und des \nKrankheitsverlaufes nicht feststellbar. Es wurden keine Kortikoide, Im munmodulatoren, \nParam unit\u00e4tsinducer, Zytostatika oder antivir ale Medikam ente eingesetzt, weil dies m it \ndem Versuchsaufbau und der GCPV-Richtlinie nicht in Einklang zu bringen gewesen w\u00e4re. Ergebnisse 65 \nTabelle 13: Krankheitsformen und -verl\u00e4ufe, chronologisch, bei der effusiven Form der \n                       FIP mit Angabe der Aszitesmengen \nTier-Nr. Sex Gruppe Todestag \ndes Tieres FIP-Formen \n(A: Aszites [ml], \nT: Trocken) Krankheits-\ndauer in \nTagen Tage seit \nInfektions-\nbeginn \nH6 1451 F \"Primucell\" 05.03.1997 T, nur ZNS 8 43 \nH6 1410 M \"Primucell\" 08.03.1997 A (200 ml) 4 46 \nH6 1411 F \"Primucell\" 10.03.1997 T mit Diarrhoe 4 48 \nH6 1400 M \"Primucell\" 10.03.1997 A (300 ml) 7 48 \nH6 1402 M Kontrolle 12.03.1997 A (400 ml) 6 50 \nH6 1452 M Kontrolle 12.03.1997 A (400 ml) 8 50 \nH6 1446 M \"Primucell\" 16.03.1997 A (300 ml) 10 54 \nH6 1401 F Kontrolle 18.03.1997 A (400 ml) 10 56 \nH6 1464 M \"Primucell\" 26.03.1997 A (50 ml), ZNS 12 64 \nH6 1434 M \"Primucell\" 26.03.1997 A (400 ml) 7 64 \nH6 1397 F Kontrolle 29.03.1997 T 13 67 \nH6 1391 F Kontrolle 29.03.1997 A (500 ml) 23 67 \nH6 1395 F \"Primucell\" 03.04.1997 A (400 ml) 16 72 \nH6 1437 F Kontrolle 03.04.1997 A (400 ml) 27 72 \nH6 1399 F Kontrolle 07.04.1997 T 6 76 \nH6 1404 M \"Primucell\" 08.04.1997 A (400 ml) 14 77 \nH6 1409 F Kontrolle 01.05.1997 T incl. Augen 20 103 \nH6 1431 F Kontrolle 05.05.1997 A (300 ml) 33 107 \nH6 1424 M Kontrolle 05.05.1997 T 33 107 \nH6 1450 M \"Primucell\" 30.06.1997 T incl. ZNS 12 132 \nH6 1466 M \"Primucell\" 02.07.1997 T incl.  Augen 42 134 \nH6 1444 M \"Primucell\" 18.07.1997 A (400 ml) 11 150 \n \n4.8.1.  Augenver\u00e4nderungen \n \nBei f\u00fcnf (12,5 %) der 40 SPF-Tiere (mit und ohne FIP) traten Augenver\u00e4nderungen im Versuchszeitraum auf, bei denen die Ursache durch die FIPV-Infektion vermutet wurde (Tab. 14). Ergebnisse 66 \nTabelle 14: Augenver\u00e4nderungen \nTier Gruppe klinischer ophthalmologischer Befund FIP-Form \nH6 1466 Primucell\u00ae Irisverf\u00e4rbungen beidseits von leuchtend gelb (Abb. \n20, Anhang 9.1) nach orange, rechts: Uveitis anterior, \nstreuende Gef\u00e4\u00dfinjektionen (Abb. 21 und 22, Anhang 9.1) und endotheliale Pr\u00e4zipitate, Fundus: scharf umrissene lokale Retinaatrophie trocken \nH6 1453 Primucell\u00ae tempor\u00e4rer bilateraler Nickhautvorfall (Abb. 16 und \n17, Anhang 9.1), Kammerwassertr\u00fcbung, Uveitis anterior, Fibrinpr\u00e4zipitate frei schwebend in der vorderen Augenkammer (Abb. 18, Anhang 9.1) - nach 3 Wochen wieder vollkommen aufgeklart, Iris\u00f6dem, Fundus: chorio-retinitische Narben, Irishinterfl\u00e4chenpigmentstrang (Abb. 19, Anhang 9.1) kein Ergu\u00df* \nH6 1451 Primucell\u00ae Nystagmus trocken \nH6 1450 Primucell\u00ae Irisverf\u00e4rbungen, Drohreflex \u00b1, Miosis, Augen \nvollkommen starr (unbeweglich, folgen nicht der Finger-bewegung oder sich bewegenden Objekten) trocken \nH6 1448 Kontrolle Anisokorie (Abb. 23, Anhang 9.1), rechts: \nEnophthalmus, Bulbusverkleinerung, Rubiosis iridis (Abb. 24, Anhang 9.1), Iris\u00f6dem, Neovaskularisationen (Abb. 25, Anhang 9.1), chronische Uveitis, Uveitis posterior, Miosis, Pupillen\u00f6dem, Chorioretinitis, Fundus: Hyporeflexien, Infiltrate subretinal (Abb. 26, Anhang 9.1) kein Ergu\u00df* \n \n        * trotz deutlicher klinischer FIP-Symptomatik (vorrangig ZNS-Symptome [und Titer >             3200 bzw. positive Reaktion im ELISA]) w\u00e4hrend des Versuchszeitraumes am  Versuchsende kein FIP-Befund in den Sektionen Ergebnisse 67 \n4.9  FIP und andere Erkrankungen in der Population  \n \nAbb. 8: H\u00e4ufigkeiten von Katzenschnupfen be i den 22 an FIP erkrankten SPF-Katzen \n18\n82%\n418%FIP-Katzen, die\nzeitgleich oder\nvorher an\nKatzenschnupfen\nerkrankten\nFIP-Katzen ohne\nandere\nErkrankungen\n \n \nAbb. 9: H\u00e4ufigkeiten von Katzenschnupfen bei den 18 nicht an FIP erkrankten Katzen  \n10\n8Tiere ohne Katz enschnupfen\nTiere mit Katz enschnupfen56 %\n44 %\n \n \n4.10 Rohdaten in Tabellenform \n \nDie Tabellen geben einen \u00dcberblick \u00fcber die Ergebnisse der angewandten diagnostischen \nTests f\u00fcr jedes Tier und \u00fcber die Diagnose FIP am  Versuchsende. \nTabelle 15 \u00dcbersicht \u00fcber die Gruppe T1 (Kontroll-Gruppe)  S. 68 \nTabelle 16 \u00dcbersicht \u00fcber die Gruppe T2 (Prim ucell\u00ae-Gruppe) S. 69 \nTabelle 17 \u00dcbersicht \u00fcber die Gruppe T3 (Tierheim katzen)  S. 70 Tabelle 15: \u00dcbersicht \u00fcber die  SPF-Kontrolltiere (T 1), chronologisch geordnet\nTier-Nr. Tier- AK-Titer AK-Titer AK-Titer AK-Titer AK-Titer PCR PCR ELISA ELISA ELISA ELISA Sex Todestag Sektions- Sektionsbefund (Diagnose)\n(T\u00e4t.-Nr.) Nr. vom vom vom vom vom (Bristol) (Bristol) vom vom vom vom des Tieres Nr.\nlt.Pfizer 01.11.1996 24.01.1997 04.04.1997 16.06.1997 25.08.1997 16.06.1997 25.08.1997 24.01.1997 04.04.1997 16.06.1997 25.08.1997 F/M Vet.pathologie\nH6 1435 14 negativ * ***** negativ * * * F 29.12.1996 2562/96 \"K\u00fcmmerer\"\nH6 1402 20 negativ  1:50 ***** negativ * * * M 12.03.1997 498/97 FIP\nH6 1452 7  1:25 negativ ***** negativ * * * M 12.03.1997 499/97 FIP\nH6 1401 9  1:25 negativ ***** negativ * * * F 18.03.1997 536/97 FIP\nH6 1397 27 negativ  1:50 ***** negativ * * * F 29.03.1997 607/97 FIP (in der Vir\u00e4mie), Pneumonie\nH6 1391 34 negativ negativ ***** negativ * * * F 29.03.1997 608/97 FIP\nH6 1437 15 negativ  1:50 ***** negativ * * * F 03.04.1997 644/97 FIP\nH6 1430 26 negativ negativ 400 **** negativ positiv * * M 07.04.1997 669/97 Pleuritis (Nocardiose)\nH6 1399 13 negativ negativ >3200 **** negativ positiv * * F 07.04.1997 688/97 FIP\nH6 1409 17 negativ negativ 100 **** negativ negativ * * F 01.05.1997 881/97 FIP\nH6 1431 24 negativ  1:25 400 **** negativ negativ * * F 05.05.1997 900/97 FIP\nH6 1424 38 negativ  1:25 >3200 **** negativ grenzwertig * * M 05.05.1997 901/97 FIP\nH6 1405 19  1:25  1:25 800 200 50 negativ + negativ negativ grenzwertig negativ F 26.08.1997 1760/97 obB.H6 1441 25 negativ negativ 25 200 25 negativ (+) negativ positiv positiv negativ F 26.08.1997 1765/97 obB.H6 1448 28 negativ  1:25 100 800 400 + ++ negativ negativ positiv negativ M 26.08.1997 1769/97 obB., trotz vor\u00fcbergehender Symptome (ZNS, Auge)\nH6 1456 12 negativ negativ 100 100 50 negativ +++ negativ negativ positiv negativ M 27.08.1997 1778/97 obB.H6 1432 39 negativ  1.25 400 400 400 + negativ negativ negativ positiv negativ M 27.08.1997 1781/97 obB.H6 1425 37 negativ negativ >3200 25 50 + ++ negativ negativ negativ negativ F 27.08.1997 1782/97 obB.H6 1442 23 negativ negativ >3200 400 400 negativ negativ negativ positiv positiv negativ M 28.08.1997 1788/97 obB.H6 1455 5 negativ  negativ 25 100 negativ negativ (+) negativ grenzwertig positiv negativ F 28.08.1997 1789/97 obB./i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0/i0\n/i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\nErgebnisse: 10 x FIP = 50 % (davon 3 m\u00e4nnlich, 7 weiblich), * = Exitus letalis  Ergebnisse, Seite 68Tabelle 16: \u00dcbersicht \u00fcber die SPF-(Primucell\u00ae-) Impftiere (T2), chronologisch geordnet\nTier-Nr. Tier.- AK-Titer AK-Titer AK-Titer AK-Titer AK-Titer PCR PCR ELISA ELISA ELISA ELISA Sex Todestag Sektions- Sektionsbefund (Diagnose)\n(T\u00e4t.-Nr.) Nr. vom vom vom vom vom (Bristol) (Bristol) vom vom vom vom des Tieres Nr.\nlt.Pfizer 01.11.1997 24.01.1997 04.04.1997 16.06.1997 25.08.1997 16.06.1997 25.08.1997 24.01.1997 04.04.1997 16.06.1997 25.08.1997 F/M Vet.pathologie\nH6 1408 3 negativ  1:200 ***** negativ * * * M 08.02.1996 251/97 Pneumonie (\"Katzenschnupfen\")\nH6 1451 6  1:25  1:200 ***** negativ * * * F 05.03.1997 433/97 FIP (ausschlie\u00dflich ZNS-Form)\nH6 1410 4  1:25  1:50 ***** negativ * * * M 08.03.1997 457/97 FIP\nH6 1411 29 negativ  1:100 ***** negativ * * * F 10.03.1997 472/97 FIP (in der Vir\u00e4mie)\nH6 1400 10 negativ  1:400 ***** negativ * * * M 10.03.1997 473/97 FIP\nH6 1446 36 negativ  1:100 ***** negativ * * * M 16.03.1997 524/97 FIP\nH6 1464 30 negativ  1:400 ***** negativ * * * M 26.03.1997 587/97 FIP\nH6 1434 31 negativ  1:200 ***** negativ * * * M 26.03.1997 588/97 FIP\nH6 1395 1 negativ  1:400 ***** negativ * * * F 03.04.1997 639/97 FIP\nH6 1404 2 negativ  1:400 100 **** negativ negativ * * M 08.04.1997 699/97 FIP\nH6 1440 40 negativ  1:800 200 **** negativ positiv * * M 10.06.1997 1172/97 Narkosezwischenfall\nH6 1450 22 negativ  1:100 50 25 * + * negativ positiv negativ * M 30.06.1997 1342/97 FIP (inklusive ZNS, Auge)\nH6 1466 35 negativ  1:100 800 25 * + * negativ positiv positiv * M 02.07.1997 1353/97 FIP (inklusive Auge)\nH6 1444 32 negativ  1:100 800 >3200 * ++ * negativ negativ grenzwertig * M 18.07.1997 1508/97 FIPH6 1443 8 negativ  1:100 25 negativ 100 negativ + negativ negativ positiv negativ F 25.08.1997 1755/97 obB.H6 1436 33 negativ  1:100 200 100 50 + (+) negativ negativ negativ negativ M 26.08.1997 1759/97 obB.H6 1449 16 negativ  1:100 50 100 200 + + negativ negativ negativ negativ F 26.08.1997 1768/97 obB.H6 1427 21 negativ  1:200 200 1600 200 negativ (+) negativ positiv negativ negativ F 27.08.1997 1779/97 obB.H6 1433 18 negativ  1:50 >3200 100 400 + negativ negativ negativ negativ negativ F 27.08.1997 1780/97 obB.H6 1453 11 negativ  1:400 >3200 800 100 negativ ++ negativ negativ negativ negativ F 28.08.1997 1787/97 obB., trotz vor\u00fcbergehender Symptome (Z NS, Augen)/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0/i0\n/i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\nErgebnisse: 12 x FIP = 60 % (davon 9 m\u00e4nnlich, 3 weiblich), * = Exitus letalis Ergebnisse, Seite 69Tabelle 17: \u00dcbersicht \u00fcber die Tierheimkatzen (T3) = Infektionsgruppe\nTier-Nr. AK-Titer AK-Titer AK-Titer AK-Titer AK-Titer PCR PCR ELISA bei ELISA ELISA ELISA ELISA Sex Todestag Sektions- Sektionsbefund (Diagnose)\n(T\u00e4t.-Nr.) vom vom vom vom vom (Bristol) (Bristol) \u00dcbernahme aus vom vom vom vom des Tieres Nr.\n01.11.1996 24.01.1997 04.04.1997 16.06.1997 25.08.1997 16.06.1997 25.08.1997 dem Tierheim 24.01.1997 04.04.1997 16.06.1997 25.08.1997 F/M Vet.pathologie\n41  1:400  1:800 400 25 25 + (+) positiv negativ grenzwertig positiv grenzwertig M nach Versuch vermittelt\n42  1:200  1:100 400 100 400 + ++ positiv positiv positiv positiv positiv M nach Versuch vermittelt\n43  1:200  1:200 800 25 100 + + positiv negativ positiv positiv negativ M nach Versuch vermittelt\n44  1:200  1:100 **** * positiv negativ * * * M 24.02.1997 378/97 Coronavirus-Enteritis\n45  1:100  1:800 >3200 100 * + * positiv negativ negativ negativ * F 09.07.1997 1425/97 FIP46  1:6400 * **** * positiv * * * * F 20.01.1997 152/97 FIP (kurz vor Versuchsbeginn verendet)\n47  1:400  1:400 400 800 100 negativ +++ positiv positiv positiv positiv negativ F nach Versuch vermittelt\n48  1:400  1:800 100 neg. 400 negativ +++ positiv negativ negativ positiv positiv F nach Versuch vermittelt\n49  1:200  1:200 100 25 100 negativ + positiv positiv positiv positiv negativ M nach Versuch vermittelt\n50  1:200  1:800 200 800 400 ++ ++ positiv positiv negativ positiv negativ F nach Versuch vermittelt\n51  1:50  1:800 >3200 400 100 negativ + positiv positiv negativ grenzwertig negativ F nach Versuch vermittelt\n52  1:200  1:400 100 400 100 + + positiv negativ negativ positiv negativ F nach Versuch vermittelt/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0/i0\n/i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0 /i0/i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0/i0\n/i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0 /i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0 /i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0/i0\n* = Exitus letalis  Ergebnisse, Seite 70Diskussion 71 \n5. Diskussion \n \n5.1 Versuchsbedingungen \n \nZiel dieser Arbeit war es, die Wirksam keit des Im pfstoffes Prim ucell\u00aeFIP im  Tierversuch unter \nTierheim bedingungen zu untersuchen. Die Haltung unter Tierheim bedingungen erfolgte auf \ndem Gel\u00e4nde der Lehr- und Versuchsstation Liebertwolkwitz der Universit\u00e4t Leipzig \nentsprechend den Anforderungen einer artgerechten Haltung von Katzen (Goldhorn, 1987; \nMertens und Sch\u00e4r, 1988; Schm itz, 1990; Mertens, 1994; Sch\u00e4r, 1997). Die Tiere wurden als \neine Gruppe in einem  gro\u00dfen Geb\u00e4ude, einem  ehem aligen Gew\u00e4chshaus, gehalten. Die Tiere \nkonnten Fre\u00dfn\u00e4pfe, Katzentoiletten und Spiel- oder Liegepl\u00e4tze frei w\u00e4hlen, so dass ein \nungehinderter Kontakt der Tiere untereinander sowie Kontakt m it den Ausscheidungen (F\u00e4zes, \nUrin, Speichel) anderer Tiere m \u00f6glich war, wie es auch in gr\u00f6\u00dferen Gruppenhaltungen in \nTierheim en erfolgt. Jeder Katze stand auch ein Versteck zur Verf\u00fcgung, in das sie sich vor \nArtgenossen, dem  Betreuer oder frem den Personen zur\u00fcckziehen konnte. Da es sich bei den \nSPF-Katzen um  Tiere handelte, die in innerartlich sozialisierten Gruppen herangewachsen \nwaren, entstanden zun\u00e4chst kaum  Problem e. Nach dem  Zusam mensetzen von SPF-Tieren (zu \ndem Zeitpunkt 21 Wochen alt) und Tierheim katzen kam  es verm ehrt zu Rangk\u00e4m pfen m it \nDom inanz der \u00e4lteren und schwereren Tierheim katzen. Dies f\u00fchrte zum Auftreten teils \nbehandlungsbed\u00fcrftiger Haut- und Augenverletzungen. Au\u00dferdem  erfolgte in dieser Zeit der \nZahnwechsel bei den SPF-Katzen. Die Kater wurden kastriert. Die SPF-Tiere waren vor dem  \nZusam mensetzen der Tiere einer zus\u00e4tzlichen Belastung ausgesetzt (Prozedur der Im pfung m it \nPrim ucell\u00aeFIP), von der die Kontrolltiere verschont blieben. S\u00e4m tliche Tiere m achten nach \ndem Zusam mensetzen eine Phase erh\u00f6hten sozialen und psy chischen Stresses durch (Sch\u00e4r, \n1998a, b). \nDie Rahm enbedingungen des Versuchs waren durch das Protokoll 2184D-10-95-155 der Firm a \nPfizer, die GCPV-Richtlinie und die Tierversuchsgenehm igung definiert. Die GCPV-Richtlinie \nund das Protokoll 2184D-10-95-155 der Firm a Pfizer m achten den Einsatz von SPF-Tieren \nunerl\u00e4\u00dflich, was eine m \u00f6glichst weitgehende Standardisierung der Versuchsbedingungen und \neine wissenschaftliche Erfa\u00dfbarkeit und Verwertbarkeit erm \u00f6glichte. Die Anzahl der in den \nVersuch eingebrachten SPF-Katzen entpricht de r Populationsgr\u00f6\u00dfe anderer Vakzinations- und \nInfektionsversuche sowie anderer unter SPF-Bedingungen gehaltenen Tiergruppen, in denen \nUntersuchungen zur FIPV-Verm ehrung erfolgten (Hoskins et al., 1994; Poland et al., 1996; \nFoley  et al., 1997b; Herrewegh et al., 1997). \n  Diskussion 72 \nDie aus Tierheim en stam menden Katzen wurden im  Anschlu\u00df an den Versuch verm ittelt und \nstanden dementsprechend nicht m ehr f\u00fcr eine abschlie\u00dfenden Untersuchung in Form  einer \nSektion zur Verf\u00fcgung. S\u00e4m tliche SPF-Katzen wurden am  Versuchsende euthanasiert, seziert \nund pathologisch-histologisch untersucht. \n \n5.2. Infektionsstatus der SPF-Katz en und der Tierheimkatz en vor Beginn des \n Versuchs  \n \nBei den Tierheim katzen wurde lediglich der FeLV-, FIV- und FCoV-Infektionsstatus \nbestim mt. Der Nachweis von FeLV-p27\u2013Antigen und von FIV-Antik\u00f6rpern mittels \nkommerziellem  Schnelltest (Snap \uf8ea, IDEXX, W\u00f6rrstadt) verlief durchweg mit negativem  \nErgebnis. Der bei s\u00e4m tlichen sezierten Katzen des Versuchs routinem \u00e4\u00dfig erfolgte \nimmunhistologische Nachweis von FeLV-Antigen an form alin-fixierten und paraffin-\neingebetteten Geweben (Milz, Mesenterially mphknoten, Knochenm ark und Jejunum  \n[Kovacevic et al., 1997 ]) zeigte ebenfalls durchweg ein negatives Ergebnis, so dass sich kein \nHinweis auf FeLV-Infektionen bei den Tierhe im- und SPF-Katzen ergibt. Desweiteren waren \ns\u00e4mtliche SPF-Katzen zus\u00e4tzlich gegen FeLV geim pft (Leukocell \uf8ea2, Pfizer, Karlsruhe). \nVier der insgesam t 15 m ittels des kom petitiven ELISA zum Nachweis FIPV-spezifischer \nImmunkom plexe (Pfeiffer, 1991; Schroo, 1994) selektierten Katzen starben bereits vor dem \neigentlich Versuchsbeginn, d.h. w\u00e4hrend die Tiere in Gruppen zu 5-6 Tieren gehalten wurden, \nan FIP. Im  Laufe des Versuchs entwickelte ein Teil der SPF-Katzen eine FIP, ein anderer Teil \nwurden lediglich FCoV-infiziert und schied Virus aus. Som it erwies sich der kom petitive \nELISA als geeignet f\u00fcr ein Screening von Katzen, um  m\u00f6gliche FCoV-Infektionsquellen als \nTr\u00e4ger des FIPV-Bioty ps von FCoV ohne Virusisolierung zu identifizieren. \nDie SPF-Tiere waren spezifisch pathogenfrei. Di es beinhaltete das garantierte Freisein von \nAntik\u00f6rpern gegen felines Calicivirus, Chlam ydien, FCoV, felines Herpesvirus (FVR/FHV-1), \nFIV/FTLV, FeLV, felines Parvovirus, felines Sy nzytialvirus und Toxoplasm en. Vor dem \neigentlichen Versuchsbeginn waren die Katzen entsprechend den Herstellerangaben gegen \nfelines Herpesvirus, felines Calicivirus und felines Parvovirus geim pft worden \n(Felocell\u2122CVR; Pfizer, Karlsruhe). Es traten ab ca. 1 Woche nach dem eigentlichen \nVersuchsbeginn, d.h. dem Zusam mensetzen von Tierheim - und SPF-Katzen, in allen \nTiergruppen eine \u201cKatzenschnupfensy mptomatik\u201c m it Augen- und Nasenausflu\u00df, \nLidschwellungen, Niesen und gest\u00f6rtem  Allgem einbefinden auf. Eines der Tiere starb 3 \nWochen nach Versuchsbeginn und wies eine katarrhalisch-eitrige Pneum onie auf. Knapp 82% \nder Tiere, die an FIP starben, wiesen zeitgleich oder vorher Sy mptome des Katzenschnupfens \n  Diskussion 73 \nauf. M\u00f6gliche Ursachen f\u00fcr die Erkrankungen trotz Im pfung k\u00f6nnten eine Immunsuppression \ndurch den Stre\u00df des Zusam mensetzens der Tiere, ein erh\u00f6hter Infektionsdruck f\u00fcr \nentsprechende virale Erreger (Calici- und Herpesvirus) sowie bakterielle Erreger und \nClam ydien durch die Tierheim katzen, und eine m \u00f6gliche Im munsuppression durch den \ngleichzeitigen FCoV-Infektionsdruck darstellen (Haagm ans et al., 1996). Auch eine geringe \nSchutzwirkung der jeweiligen Im pfstoffkom pomente gegen die vorhandenen Virusst\u00e4m me ist \nm\u00f6glich. \n \n5.3 Impfung \n \nDas FIP-Im pfvirus (Prim ucell\uf8e8-FIP; Pfizer, Karlsruhe), das lebendes, sich bei der norm alen \nK\u00f6rpertem peratur der Katze von ca. 39\u00b0C nicht verm ehrendes, avirulentes FIPV (DF2) enth\u00e4lt \n(Christiansen et al., 1989), wurde in Im pfdosen m it einem  Titer von 5,5 log 10CCID 50/Dosis \nbeidseitig intranasal appliziert. Die Tiere wurden zweim al gem \u00e4\u00df Herstellerangaben im \nAbstand von 3 Wochen geim pft (Erstim pfung und Boosterung). Zus\u00e4tzlich erfolgten jeweils \nR\u00fccktitration und Pr\u00fcfung der frischen Vakzine-Chargen. Der Antigengehalt/Titer lag im \nMittel bei 105,4 CCID 50/ml bzw. 105,5 CCID 50/ml. Das Im pfvirus verm ehrte sich bei 31\u00b0C 2000 \nbis 3000-fach st\u00e4rker als bei 39\u00b0C. Die Suche nach Frem dviren verlief negativ, der \nSterilit\u00e4tstest positiv. Der Im pfstoff entsprach som it den erforderlichen Bedingungen. In der \nLiteratur wird die Unbedenklichkeit des Im pfvirusstam mes beschrieben, Angaben \u00fcber FIP-\nInduktion durch die Im pfung oder anderweitige Gef\u00e4hrdungen oder Nebenwirkungen sind \nnicht bekannt (Gerber, 1995). \nDie Vakzinierung induzierte eine Serokonversion m it CoV-Antik\u00f6rper-Titern von 1:50 bis \n1:800, nachgewiesen am  13. Tag nach der Boosterung, so dass sie prinzipiell als erfolgreich \nanzusehen ist (Gerber et al., 1991; Gerber, 1994). Die erfolgreiche R\u00fccktitrierung und Pr\u00fcfung \nder Vakzine best\u00e4tigte, dass es sich beim  Virus in den Im pfchargen um  verm ehrungsf\u00e4higes \nVirus handelte.  \n \n5.4 FCoV/FIPV-Infektionsdruck \n \nEs ist davon auszugehen, dass der FCoV-Infektionsdruck auf die SPF-Katzen, der m it dem  \nHinzusetzen der Tierheim katzen einsetzte, sehr hoch gewesen ist, da 20% der \nKatzenpopulation (d.h. die 10 Tierheim katzen unter den insgesam t 50 Katzen) aufgrund des \npositiven Ergebnisses im  kom petitiven ELISA zum  Nachweis von zirkulierenden FCoV-\nspezifischen Im munkom plexen als potentielle Virusausscheider angesehen werden m\u00fcssen. \n  Diskussion 74 \nDer Anteil an Tieren, die als Infektionsquellen einzusch\u00e4tzen sind, lag in diesem  Versuch \ndemnach etwas h\u00f6her als durchschnittlich in den Tierheim en, aus denen die selektierten Katzen \nstam mten, in denen der Anteil an Tieren, die im  kom petitiven ELISA zum  Nachweis FCoV-\nspezifischer Im munkom plexe ein positives Ergebnis hatten, bei m aximal 16 % und im  \nDurchschnitt bei 7 % lagen.  \nMit den ungeim pften SPF-Katzen wurde eine FCoV-naive Tierpopulation der Infektion \nausgesetzt. Es ist bekannt, dass em pf\u00e4ngliche Katzen nahezu unm ittelbar infiziert werden und \ninnerhalb von 7-14 Tagen eine Serokonversion durchm achen (Pedersen et al., 1981a). Sechs \nWochen nach dem  Zusam mensetzen waren bereits 14 SPF-Katzen an FIP erkrankt und \ngestorben oder euthanasiert und seziert worden. Untersuchungen in Katzenzuchten ergaben, \ndass eine positive Korrelation besteht zwischen der Anzahl an empf\u00e4nglichen nichtinfizierten \nTieren, die neu in einen Bestand m it FCoV-Ausscheidern kom men, und der \u201cSchwere der \nInfektion\u201c (Kass und Dent, 1995). \nEin Teil der Tiere dieses Versuchs wurde im  Rahm en zus\u00e4tzlicher Untersuchungen auf eine \nVirusausscheidung m ittels Elektronenm ikroskopie (Negativ-Staining-Technik) und RT-PCR \nzum Nachweis von Virusgenom  in den F\u00e4zes untersucht (Kipar et al., 1999b). Hier zeigte sich, \ndass ein Teil der Tiere, die sp\u00e4ter an FIP starben, sowie ein Teil der SPF-Katzen, die bis zum \nEnde des Versuchs \u00fcberlebten, CoV ausschieden (Kipar et al., 1999b), was sowohl deren \nEmpf\u00e4nglichkeit f\u00fcr die Infektion als auch deren m \u00f6gliche Rolle als sekund\u00e4re \nInfektionsquelle unterstreicht. Auch in anderen Untersuchungen m ittels RT-PCR zum  \nNachweis von FCoV-Genom  in den F\u00e4zes wurde bei nat\u00fcrlich infizierten Katzen eine \nallerdings interm ittierende Ausscheidung \u00fcber einen l\u00e4ngeren Zeitraum  (untersucht wurden \nKatzen \u00fcber einen Zeitraum  von bis zu 13 Monaten) festgestellt (Addie et al., 1996; Foley  et \nal., 1997b; Herrewegh et al., 1997; Harpold et al ., 1999). Harpold et al. (1999) konnten zeigen, \ndass in einer FCoV-durchseuchten Katzenpopulation \u00bc der Tiere \u00fcber 75% der Zeit eines \nJahres FCoV ausschieden. \nCoV haben generell eine sehr hohe Mutationsrate. Man kann davon ausgehen, dass m it jeder  \nRNA-Replikation m ehrere Punktm utationen in der genom ischen RNA akkum ulieren, so dass \nsogar ein aus einem  Plaque gewonnenes CoV -Isolat eine Population aus verwandten \nQuasispezies repr\u00e4sentiert (Holm es und Lai, 1996). Dies best\u00e4tigen Ergebnisse von Gunn-\nMoore et al. (1999), die m ittels denaturierender Gradientengelektrophorese im  Blut FCoV-\ninfizierter Katzen m it und ohne FIP nachweisen konnten, dass im  hochvariablen S-Gen von \nFCoV eine deutliche Variation zwischen verschiedenen Tieren, aber auch im Einzeltier zu \nverschiedenen Zeitpunkten besteht. Dies zeigt, dass FCoV im  Einzeltier als kom plexe \nViruspopulationen vorkom men (Quasispezies).  \n  Diskussion 75 \nBer\u00fccksichtigt m an, dass die als Infektionsquellen fungierenden Katzen aus verschiedenen \nBest\u00e4nden stam mten, ist davon auszugehen, da ss hier eine gute Voraussetzung f\u00fcr das \nAuftreten eines sehr breiten Quasispezies-Spektrum s in den infizierten Katzen gegeben ist. \nDies konnten Gunn-Moore et al. (1999) bei Welpen aus Best\u00e4nden m it unterschiedlichen \nZulieferern belegen, die ebenfalls die gr\u00f6\u00dfte Variabilit\u00e4t an FCoV aufwiesen, was die Autoren \nauf eine Ko-Infektion der Tiere m it mehreren FCoVs zur\u00fcckf\u00fchren. \nUntersuchungen zum  FIP-Vorkom men in einer geschlossenen Katzenpopulation deuten auch \ndarauf hin, dass die entscheidende Infektionsquelle f\u00fcr em pf\u00e4ngliche Katzen chronisch \ninfizierte asy mptom atische Tiere sind (Herrewegh et al., 1997). \n \n5.5 Nachw eis der FCoV-Infektion \n \nDer Nachweis der FCoV-Infektion erfolgte am lebenden Tier indirekt \u00fcber Serologie (FCoV-\nAntik\u00f6rpertiter-Bestim mung, kompetitiver ELISA zum  Nachweis zirkulierener FIPV-\nspezifischer Im munkom plexe) und direkt m ittels RT-PCT zum  Nachweis von FCoV-Genom  in \nMonozy ten nach deren Ko-Kultivierung m it felinen Em bryonalzellen (Gunn-Moore, 1997a,b; \nGunn-Moore et al., 1998). Der Nachweis der Monozy ten-assoziierten Vir\u00e4m ie erfolgte ab \nVorliegen des Infektionsdrucks f\u00fcr ca. 5 Monate zweim al im Abstand von ca. 10 Wochen bei \nallen Tieren, die den Versuch bis dahin \u00fcberlebt hatten. S\u00e4m tliche Tierheim katzen waren \nmindestens bei einem  der Tests positiv, von den 17 SPF-Katzen, die m indestens einm al \nuntersucht wurden, waren 16 positiv. Gunn-Moore et al. (1998) wiesen in Katzenbest\u00e4nden mit \nendem ischer FCoV-Infektion bei 80-90% der Tiere eine FCoV-Vir\u00e4m ie nach, die auch \u00fcber \neinen Zeitraum  von 12 Monaten bestehen blieb. Diese Ergebnisse best\u00e4tigen, dass auch der \nNachweis einer FCoV-Vir\u00e4m ie keine Aussage dar\u00fcber zul\u00e4\u00dft, ob ein Tier f\u00fcr die Entwicklung \neiner FIP pr\u00e4disponiert ist (Gunn-Moore et al., 1998). Allerdings findet sich eine Korrelation \nzwischen dem  Nachweis einer Monozy ten-assoziierten Vir\u00e4m ie und FCoV-Antik\u00f6rpertitern \n(Gunn-Moore et al., 1998).  \n \n5.6 FIP-F\u00e4lle \n \nDie aufgetretenen FIP-F\u00e4lle entsprachen klinisch und pathologisch weitgehend dem  \nklassischen Bild der FIP bei der effusiven und der trockenen Form  (Kriegleder und Geyer, \n1984; Rohrer et al., 1993; Hirschberger et al., 1995). Es trat vorrangig die effusive Form  der \nFIP auf, was die Ergebnisse von Hirschberger et al. (1995) best\u00e4tigt, die die exsudative \nVerlaufsform  als ausgesprochene Jungtiererkrankung identifizierten. Die Krankheitsdauer war \n  Diskussion 76 \nzu Beginn des Versuchs k\u00fcrzer, der klinische Verlauf fulm inanter. Sp\u00e4tere FIP-Erkrankungen \nim Versuch zeigten einen subakuten Verlauf. ZNS-Sy mptome und Augenver\u00e4nderungen \nfanden sich nur bei einem  geringeren Teil (12,5%) der SPF-Tiere. Die charakteristischen \nAugenver\u00e4nderungen wie Iritis, Uveitis, Tr\u00fcbungen des Augenkam merwassers (Krebiel et al., \n1974; Kellner u. Litschi, 1989, Shell, 1997) berechtigen aber die Augenuntersuchungen zur \nFIP-Diagnostik, da sie ein wichtiges Leitsy mptom  sein kann (Rohrer et al., 1993; Weber, \n2000). Es ergab sich keine Geschlechtsdispos ition; die zum Zeitpunkt des Versuchsbeginns \nerfolgte Kastration der Kater schien keine di rekte Disposition f\u00fcr die Erkrankung darzustellen.  \nDas Auftreten mehrerer FIP-F\u00e4lle praktisch gleichzeitig bereits kurze Zeit (6 Wochen) nach \nBeginn des Infektionsdrucks spricht daf\u00fcr, da ss ein hochvirulentes FIPV in die SPF-Population \neingebracht und \u00fcbertragen wurde, da sonst eine praktisch gleichartige und gleichgerichtete \nMutation zum gleichen Zeitpunkt in verschiedenen Tieren angenom men werden m \u00fc\u00dfte. \nAnderseits spricht das Auftreten von Peaks an Krankheitsf\u00e4llen (Abb. 4, 5) daf\u00fcr, dass \nhochvirulente Varianten neu entstanden sind. In jedem  Fall deutet die H\u00e4ufung von F\u00e4llen \ninnerhalb kurzer Zeitspannen darauf hin, dass eine Virus\u00fcbertragung von Tier zu Tier \nzumindest in diesen F\u00e4llen eher wahrscheinlich ist als die Entstehung und Verm ehrung der \nhochvirulenten FIPV-Mutante jeweils neu im  infizierten Einzeltier, wie sie in anderen \ndurchseuchten Populationen beobachtet wurde (Hickm an et al., 1995; Herrewegh et al., 1997; \nVennem a et al., 1998). Hier k\u00f6nnte der Unterschied zwischen einer naiven, wenn auch zur \nH\u00e4lfte geim pften SPF-Katzenpopulation und ei ner durchseuchten Hauskatzenpopulation \npathogenetisch und epizootiologisch eine wesentliche Rolle spielen. F\u00fcr das Einbringen eines \nhochvirulenten FIPV-Stam mes in die Population spricht auch der insgesam t sehr hohe \nProzentsatz an FIP-F\u00e4llen (45%) in dieser Studie im  Vergleich zu anderen Untersuchungen \n(Postorino Reeves et al., 1992; Hoskins et al., 1994, 1995b). \n \n5.7 Beurteilung anderer pathogenetischer relevanter Faktoren \n \nHier ist zum  einen an Faktoren zu denken, die eine m \u00f6gliche Immunsuppression induziert \nhaben k\u00f6nnten, zum  anderen an m \u00f6gliche Koinfektionen mit anderen Erregern. Beide Arten \nvon Faktoren kom men in jedem  Tierheim  mit Gruppenhaltung vor, so dass m an sie in diesem  \nVersuch zur Belastungsprobe des Im pfstoffes unter Tierheim bedingungen dazugeh\u00f6rend \nansehen m u\u00df. Anders als bei dem  Versuch von Hoskins et al. (1994), fand sich kein \nsignifikanter Unterschied in der Gewichtzunahm e zwischen Im pf- und Kontrollgruppe \nzugunsten der vakzinierten Tiere . \n \n  Diskussion 77 \n5.7.1 Psychischer und soz ialer Stre\u00df \n \nIm vorliegenden Versuch waren die Tiere verschiedensten Stre\u00dffaktoren ausgesetzt. Hier sind \nzun\u00e4chst der Abtransport der SPF-Tiere aus steriler Um gebung \u00fcber zwei Tage m it \nnachfolgendem  neuen Um feld, Futterum stellung und dem  Weiterleben in gro\u00dfen Tiergruppen \nzu nennen. Auch die Tierheim katzen waren durch den Wechsel der Um gebung und das \nWeiterleben in neuen Tiergruppen einer vergleichbaren Situation ausgesetzt. Mit dem \nZusam mensetzen aller Tiere begann die zweite Stre\u00dfphase. Massive Rangk\u00e4m pfe lie\u00dfen sich \nnicht verm eiden. Zus\u00e4tzlich f\u00fchrten die Blutentnahm en mit vorherigem  Fangen der Tiere zu \nwiederholtem  Stre\u00df. Wie auch Untersuchungsergebnisse von Rohrer et al. (1993), bei denen \nca. 50 % der FIP-Katzen vor Krankheitsbeginn einer Stre\u00dfsituation wie Besitzerwechsel, \nVerbringen in eine frem de Um gebung oder Tierheim - bzw. Klinikaufenthalt ausgesetzt waren, \nandeuten, k\u00f6nnten diese Stre\u00dfsituationen sowohl die verm ehrte Ausscheidung von FCoV bei \nden bereits infizierten Tierheim katzen als auch die Entwicklung einer FIP bei den neu und den \nbereits l\u00e4nger infizierten Tierheim katzen (vier Tiere starben vor Versuchsbeginn und eines \ndieser Tiere starb w\u00e4hrend des Versuchs an FIP) beg\u00fcnstigt haben. Psy chischer und sozialer \nStre\u00df ist durchaus ein Faktor, der eine zeitweilige Im munsuppression bewirken kann (Weiss \nund Scott, 1981a). \n \n5.7.2 Koinfektionen \n \nWie bereits oben diskutiert, ist aufgrund der aufgetretenen Katzenschnupfensy mptomatik \ndavon auszugehen, dass die SPF-Tiere sich nicht nur m it FCoV auseinandersetzen mu\u00dften, \nsondern auch m it respiratorischen Erregern wie dem  felinen Herpesvirus (FHV) und dem \nfelinen Calicivirus (FCV), ubiquit\u00e4ren Bakterien und Clam ydien. Es w\u00e4re m \u00f6glich, dass diese \nInfektionen die Schleim hautbarriere gegen FCoV geschw\u00e4cht und m\u00f6glicherweise somit den \nnasophary ngealen Infektionsweg des FCoV beg\u00fcnstigt hat. \n \n5.7.3 Immunsuppression durch andere Ursachen \n \nDer Zahnwechsel sowie die Kastration der m \u00e4nnlichen Tiere um  den Zeitraum  des \nVersuchsbeginns k\u00f6nnten neben den oben genannt en psy chischen und sozialen Stre\u00dffaktoren \nsowie m \u00f6glichen Koinfektionen ebenfalls im munsuppressiv gewirkt haben. \nDie Ergebnisse einer experim entellen Infektion von FIV-infizierten Katzen m it FCoV vom \nBioty p FECV lassen verm uten, dass eine Immunsuppression die FIP-Erkrankung von Katzen \n  Diskussion 78 \n\u00fcber eine verm ehrte Bildung und Selektion von FIPV-Mutanten des FCoV beg\u00fcnstigt (Poland \net al., 1996). So zeigten FIV-infizierte Katzen eine hohe FCoV-Replikationsrate m it 100-fach \nst\u00e4rkerer und l\u00e4nger andauernder Virusaussche idung \u00fcber die F\u00e4zes als FIV-negative Tiere \n(Poland et al., 1996). Katzen m it einem  intakten Immunsy stem k\u00f6nnen verm utlich zahlreiche \nFIPV-Mutanten enthalten, ohne FIP zu entwickeln (Pedersen, 1995). Poland et al. (1996) \ngehen davon aus, dass die beobachtete erh\u00f6hte Virusreplikation zusam men m it der \nImmuninkom petenz der FIV-infizierten Tiere die Bedingungen f\u00fcr die Entstehung der FIPV-\nMutanten und die Krankheitsausl\u00f6sung durch FIPV-Mutanten beg\u00fcnstigen. In unserer \nPopulation kam  allerdings keine FIV-Infektion vor. \n \n5.8 Beurteilung der Serologie \n \nWie bereits erw\u00e4hnt, ist der kom petitive ELISA zum  Nachweis FIPV-spezifischer \nImmunkom plexe (Schroo, 1994) f\u00fcr die Selektion FCoV-infizierter Katzen und m\u00f6glicher \nAusscheider des FIPV-Bioty ps geeignet. Man erfa\u00dft Katzen, bei denen h\u00f6chstwahrscheinlich \neine FIPV-Infektion vorliegt (Pfeiffer, 1991). An FIP klinisch erkrankte Tiere zeigten in \ndiesem  ELISA zum  Teil w\u00e4hrend der Erkrankung und auch zum  Todeszeitpunkt, ein negatives \nErgebnis. \u00c4hnliche Ergebnisse erhielt Schroo (1994). Sie sah einen Zusam menhang zwischen \ndem Testergebnis und der Phase der Erkrankung, da offensichtlich nicht st\u00e4ndig \nImmunkom plexe in Serum  und Exsudat vorliegen. Bei von Jacobse-Geels et al. (1982) \ndurchgef\u00fchrten experim entellen Untersuchungen war ein deutlicher Anstieg der \nImmunkom plexkonzentration ab dem  25. Tag post infectionem  zu erkennen. Sie beobachteten \ndie h\u00f6chsten Konzentrationen bei m oribunden Tieren, was in der Arbeit von Schroo (1994) \nnicht best\u00e4tigt wurde. Allerdings wiesen Jacobse-Geels et al. (1982) s\u00e4mtliche im Serum  \nvorhandenen Im munkom plexe nach und nicht nur die FIPV-spezifischen. Nicht zuletzt ist es \nm\u00f6glich, dass das ELISA-Ergebnis bei Vorliegen nur geringer Mengen an FIPV-spezifischen \nImmunkom plexen negativ ausfallen kann, da m it Poly ethylengly kol nur ein relativ geringer \nAnteil der vorhandenen Immunkom plexe ausgef\u00e4llt und som it gewonnen wird (Jones und \nOrlans, 1981). Ein Teil der Tiere, die nicht an FIP erkrankten, zeigten ein positives Ergebnis \nim ELISA. Diese Ergebnisse best\u00e4tigen die Aussage, dass der positive kompetitive ELISA \nkeine Aussage dar\u00fcber zul\u00e4\u00dft, ob ein Tier eine klinisch m anifeste FIP entwickeln wird oder \nnicht (Pfeiffer, 1991; Reinacher, 1994; Schroo, 1994; Kipar et al., 1999b). Es ist davon \nauszugehen, dass solche ELISA-positiven Tiere zum  einen Katzen sein k\u00f6nnen, die die \nInfektion sp\u00e4ter aufgrund einer starken zellul\u00e4ren Im munantwort beenden k\u00f6nnen (Pedersen \nund Black, 1983), zum  anderen in seltenen F\u00e4llen solche Tiere, die lediglich eine Infektion m it \n  Diskussion 79 \ndem FECV-Bioty p des FCoV durchm achen, da auch bei diesen Katzen, wenn auch nach \nexperim enteller Infektion nur einm alig 3 Wochen p.i., ein positives Ergebnis im  ELISA \nbeobachtet werden kann (Pfeiffer, 1991).  \nDie FCoV-Antik\u00f6rpertiter-Verl\u00e4ufe waren sehr unterschiedlich. Es ist bekannt, dass die H\u00f6he \ndes Ak-Titers weder einen diagnostischen noch einen prognostischen Wert hat, weil daraus \nnicht geschlu\u00dffolgert werden kann, da\u00df die Katze eine FIP hat oder entwickeln wird (Rohrer et \nal., 1993; Addie und Jarrett, 1994; Sparkes et al ., 1994; Kipar et al., 1999b; Addie et al., 2000). \nDem entsprechend ist die Ak-Titer-Bestim mung beim  gesunden Tier wenig sinnvoll (Lutz, \n1992). Unsere Ergebnisse best\u00e4tigen die vergleichender Untersuchungen verschiedener \nTestsy stem e zur FIP-Diagnostik, die keine Si gnifikanz f\u00fcr serologische FCoV-Ak-Tests \nfeststellen konnten (Troy  et al., 1996; Kennedy  et al., 1998). Serologische Methoden auf der \nBasis des Ak-Nachweises eignen sich ledig lich f\u00fcr Bestands- und Verlaufsuntersuchungen, \nunabh\u00e4ngig von der Art des FCoV-Bioty ps. \nIm Rahm en unseres Versuches w\u00e4ren zur Untersuchung des FCoV-Antik\u00f6rpertiter-Verlaufs \nk\u00fcrzere Intervalle bei den Blutentnahm en vorteilhaft gewesen. Allerdings h\u00e4tten solche \nBlutentnahm en in einer solch gro\u00dfen frei laufenden Katzengruppe zu anderen Belastungen \n(Fangstre\u00df, gesteigerte H\u00e4m atopoese) gef\u00fchrt, wi e sie bei Tierheim katzen, deren Situation ja \nnachgestellt werden sollte, nicht in diesem  Ausm a\u00df vorkom men. \nIm vorliegenden Versuch \u00fcberlebten Tiere m it einem  FCoV-Antik\u00f6rpertiter von >3200, andere \nKatzen mit einem  solchen Titer entwickelten in unserem  Versuch eine letale FIP. Addie et al. \n(2000) beobachteten eine Korrelation zwischen der Ausscheidung von FCoV m it den F\u00e4zes \nund hohen FCoV-Antik\u00f6rpertitern. Dieser Zusam menhang l\u00e4\u00dft sich in unserem  Versuch nur \nzum Teil best\u00e4tigen (s. Tab. 15-17). \nDie oben genannte Serokonversion bei den SPF-Tieren nach der Im pfung m it Prim ucell\u00aeFIP \nentspricht den beschriebenen Befunden (Christianson et al. 1989; Gerber et al. 1989). \n \n5.9 \u00dcberleben einer klinisch manifesten FIP \n \nLutz et al. (1985) und Lutz (1992) gingen davon aus, da\u00df ein Tier mit den Symptomen einer \nFIP praktisch keine Aussicht auf eine definitive Heilung haben kann. Die verschiedenen \nbeschriebenen Therapieversuche (Lutz et al ., 1985; Kitchen, 1988; Weiss et al., 1993; B\u00f6lcskei \nu. Bilkei 1995a,b) f\u00fchrten nicht zum  \u00dcberleben der Katzen. Berichte \u00fcber die Heilung von \nKatzen sind generell vorsichtig zu werten, da eine eindeutige FIP-Diagnose nicht vorlag \n(Bilkei, 1988).  \n  Diskussion 80 \nDas im  Versuch m it Prim ucell\u00aeFIP vakzinierte Tier H6 1453 zeigte \u00fcber m ehrere Wochen eine \ndeutliche neurologische und ophthalm ologische Sy mptomatik. Hinzu traten Gewichtsverlust, \nInappetenz, und Apathie. Die FCoV-Antik\u00f6rpertiter betrugen zwischenzeitlich >3200 und \nfielen nach der Genesung wieder auf 1:100 ab. Die Augenver\u00e4nderungen und die \nneurologischen Sy mptome traten zeitgleich und gleichartig auf, wie bei anderen Katzen (H6 \n1466, H6 1451, H6 1450), die sp\u00e4ter an FIP starben und die histologisch sowie \nimmunhistologisch FIP-ty pische Augenver\u00e4nderungen aufwiesen (Weber, 2000). Bei der \nKatze H6 1453 verschwanden die Symptome allerdings wieder fast vollst\u00e4ndig, bis auf \ngeringradige Augenver\u00e4nderungen (Irishinterfl\u00e4chenpigm entstrang, Abb. 19). Die ZNS-\nSt\u00f6rungen klangen vollst\u00e4ndig wieder ab. Bei der Sektion konnten keine Granulom e oder \nandere auf FIP deutende Ver\u00e4nderungen festge stellt werden. Die intra vitam -Diagnose FIP \nzum Zeitpunkt der klinischen Manifestation erscheint akzeptabel, da viele \nDifferentialdiagnosen entfallen, es sich nicht um  die Fr\u00fchphase der Erkrankung handelte und \nalle Sy mptome der trockenen Form  der FIP, wie sie auch bei an FIP gestorbenen Tieren \nauftraten, m assiv ausgepr\u00e4gt waren. Daraus ergibt sich die \u00dcberlegung, ob eventuelle \nTherapieerfolge nicht auch auf Spontanheilungen zur\u00fcckzuf\u00fchren sein k\u00f6nnen. M\u00f6glich ist, \ndass das Tier m it einer starken zellverm ittelten und humoralen Immunantwort auf den \nInfektionsdruck, eventuell auch als Folge der Im pfung reagierte, so da\u00df es nach der \n\u00fcrspr\u00fcnglichen Entwicklung von FIP-L\u00e4sionen rekonvaleszierte. \n \n5.10 FIPV-Infektion ohne Entw icklung einer FIP \n \nAuch die Katzen (insgesam t 17%), die nicht klinisch erkrankten, jedoch nachweislich FIPV-\ninfiziert waren (Monozy ten-assoziierte FCoV-Vir\u00e4m ie, FCoV-Ausscheidung, FCoV-\nspezifische sy stem ische Im munantwort [Kipar et al., 1999b ]) sowie die Tierheim katzen \nk\u00f6nnten eine effektive Im munantwort gegen FCoV/FIPV entwickelt und diese \u00fcber die Dauer \ndes Versuchs aufrechterhalten haben (Kipar et al., 1999b). Ungewi\u00df bleibt, ob die \n\u00fcberlebenden Tierheim katzen schon zu Versuchsbeginn eine nat\u00fcrliche Immunit\u00e4t ausgebildet \nhatten, oder ob dieser Status erst im  Laufe des Versuchs erreicht wurde. Eine zwischenzeitliche \nElim inierung der Infektion, das Vorliegen inapparenter Infektionen sowie regelm \u00e4\u00dfige \nReinfektionen, die letztendlich zu einer nat\u00fcrlichen Im munit\u00e4tsausbildung f\u00fchrt, sind \nvorstellbar. In einer Langzeitstudie \u00fcber 10 Jahre wurde \u00e4hnliches beobachtet, wobei nur ein \ngeringer Prozentsatz seropositiver Tiere nach langer Inkubationszeit eine FIP entwickelte \n(Addie et al., 2000). Nach 36 Monaten sind die \u00fcberlebenden Tierheim katzen durchweg \n  Diskussion 81 \nklinisch unauff\u00e4llig. Weitergehende Untersuchungen zum  FCoV-Infektionsstatus sind leider \nnicht m ehr m\u00f6glich, da die Tiere den Untersuchungen nicht m ehr zug\u00e4nglich sind. \nDas \u00dcberleben eines Teils der FCoV-infiziert en SPF-Katzen unabh\u00e4ngig vom  Impfstatus \u00fcber \nden gesam ten Versuchszeitraum  ohne klinische Sy mptomatik deutet darauf hin, da\u00df die \nKonstitution und Kondition des einzelnen Tieres sowie andere Faktoren einen entscheidenden \nEinflu\u00df auf die Disposition f\u00fcr die Entwicklung einer FIP haben. Am  Versuchsende wiesen \ndiese Tiere niedrige FCoV-Antik\u00f6rpertiter auf und zeigten im  kom petitiven ELISA zum  \nNachweis zirkulierender FCoV-Im munkom plexe ein negatives Ergebnis, was auf ein Abflauen \nder Infektion hindeutet (Addie et al., 1996; G unn-Moore et al., 1998). Solche Tiere k\u00f6nnten f\u00fcr \nein Tierheim  ein Problem  darstellen, da sie kaum  als potentielle FCoV-Infektionsquellen zu \nerkennen sind, Virus m it dem  Kot aber noch ausscheiden k\u00f6nnen, wie unser Versuch zeigt (s. \nTab. 15-17). \n \n5.11 Ausw ertbarkeit des Versuches \n \nVersuchaufbau und Versuchsdurchf\u00fchrung erwiesen sich als f\u00fcr die Zielstellung geeignet. Die \nUntersuchungen lieferten eindeutige Ergebnisse. F\u00fcr den Fall von nicht signifikanten \nTendenzen war eine Wiederholung des Versuches unter gleichen Bedingungen unm ittelbar im  \nAnschlu\u00df vorgesehen (2. Versuchsdurchlauf); dies erfolgte aufgrund der eindeutigen \nErgebnisse aber nicht. \nUm der Fragestellung gerecht zu werden, kam en nur nat\u00fcrlich infizierte Katzen aus \nTierheim en als Infektionsquelle in Betracht. Eine Sektion der \u00fcberlebenden Tierheim katzen am  \nEnde des Versuchs erfolgte gem \u00e4\u00df der Tiervers uchsgenehm igung nicht, da diese Tiere an neue \nBesitzer weiterverm ittelt wurden. \n \n5.12 Beurteilung der Wirksamkeit des FIP-Impfstoffes \n \nIm Rahm en dieses Versuchs erwies sich der eingesetzte FIP-Im pfstoff (Prim ucell\u00aeFIP) als \nnicht protektiv. Die hohe Inzidenz der FIP war \u00fcberraschend. Bei \u00e4hnlich aufgebauten \nVersuchen (Hoskins et al., 1994) wurde durch die Vakzination mit Prim ucell\u00aeFIP ein Schutz \nvon 50 % erreicht und die Vakzine m it \u201cGut\u201c bewertet. Fehr et al. (1995) konnten in \nFelduntersuchungen einen gerade noch signifikanten Im pfschutz nachweisen. \nDie Vakzine Prim ucell\u00aeFIP beinhaltet nur einen FIPV-Stam m. (ts-FIPV isoliert aus Norden \nDF 2 wild-type FIPV [Gerber et al., 1990 ]). M\u00f6glich ist, da\u00df unter Feldbedingungen, so wie \neventuell auch in diesem  Versuch, eine viel h\u00f6here Infektionsdosis die Belastungsinfektion \n  Diskussion 82 \ndarstellt, als von den Im pfstoffherstellern bei der Belastungsinfektion dam als verwendet \nwurde. Scott et al. (1992, 1995) stellten fest, da\u00df der Schutz vor experim entellen Infektionen \nentscheidend vom Virusstam m und der Virusdosis abh\u00e4ngig ist. Au\u00dferdem  ist m \u00f6glich, da\u00df \nmehrere FIPV-St\u00e4m me mit unterschiedlichen virulenten und antigenen Eigenschaften durch \ndie Tierheim katzen aus den verschiedenen Tierheim en in den Versuch eingebracht wurden. Es \nist wahrscheinlich, da\u00df in dieser Studie die Belastungsinfektion nicht durch den gleichen \nFIPV-Stam m verursacht wurde, wie bei den Wirksam keitspr\u00fcfungen dam als von SmithKline \nBeecham . Dieser Sachverhalt ist aber auch notwendig, um  einen Schutz unter \nFeldbedingungen beweisen zu k\u00f6nnen. \nDie Wirksam keit der Vakzine soll gew\u00e4hrleistet werden \u00fcber eine starke Im munantwort in der \nNasen-Rachen-Mukosa, vorrangig \u00fcber eine zellverm ittelte Im munit\u00e4t und nicht \u00fcber eine \nhumorale Im munit\u00e4t und durch die Verhinderung der sy stem ischen Ausbreitung des Virus \n(Christianson et al., 1989; Gerber et al., 1989; Gerber et al., 1991). Der Aspekt der zellul\u00e4ren \nImmunit\u00e4t neben der hum oralen Im munit\u00e4t ist interessant, wenn man von der These (Pedersen \nund Boyle, 1980; Walter und Rudolph, 1989; McRey nolds und Macy , 1997) ausgeht, da\u00df \nKatzen mit einer ausgepr\u00e4gten hum oralen und zellul\u00e4ren Im munit\u00e4t keine FIP entwickeln und \nKatzen mit partieller zellul\u00e4rer bzw. ohne zellul\u00e4re Im munit\u00e4t neben der vorhandenen \nhumoralen Im munit\u00e4t eine trockene bzw. effusive FIP entwickeln. \nLetztendlich m u\u00df m an davon ausgehen, da\u00df die Im pfung je nach Situation nicht geeignet ist, \num potentiell empf\u00e4ngliche Tiere in einer gem ischtaltrigen Mehrfachhaltung, wie sie in \nTierheim en im mer wieder vorkom mt, bei hohem  Infektionsdruck vor der FIP zu sch\u00fctzen. \nDa zwischen der Im pf- und der Kontrollgruppe kein signifikanter Unterschied bez\u00fcglich der \nFIP-Erkrankungen im  Versuch auftrat, kann m an also auch bei ung\u00fcnstigen Bedingungen \ndavon ausgehen, da\u00df sich die Vakzine Prim ucell\u00aeFIP nicht nachteilig auf die \nimmunulogischen Prozesse der Katzen auswirkt. Dieses Ergebnis unterst\u00fctzt also ebenfalls \nnicht die von experim entellen Infektion abgeleitete These, da\u00df geim pfte Katzen sensibilisierte \nKatzen sind, die bei Infektion mit dem FIPV sehr schnell an FIP erkranken und hochgradige \nklinische Sy mptome zeigen (ADE) (Hohdatsu et al., 1991; Olsen et al., 1992; Corapi et al., \n1992, 1995; Scott et al., 1995). \nAbschlie\u00dfend seien noch einige Konsequenzen und Em pfehlungen aus den Ergebnissen und \nder Diskussion f\u00fcr Tierheim e zusam mengefa\u00dft: \nAufgrund dieser Studie und der betr\u00e4chtlichen Kosten, die bei der routinem \u00e4\u00dfigen \nkonsequenten Im pfung m it Prim ucell\u00aeFIP f\u00fcr ein Tierheim  anfallen, ist diese Variante der \nPr\u00e4vention in einer Situation, wie sie im  Versuch vorlag, ungeeignet. Man bedenke dabei auch, \nda\u00df Prim ucell\u00aeFIP einer der teuersten veterin\u00e4rm edizinischen Im pfstoffe ist. Um  das Problem  \n  Diskussion 83 \nder FIP in den Tierheim en anzugehen, scheinen die Em pfehlungen von Addie und Jarrett \n(1990, 1995) sowie Pedersen et al. (1995) noch am  effektivsten, die auf einem  konseqenten \nHygieneregim e (minimale f\u00e4kale Kontam ination), der Quarant\u00e4ne sowie dem  fr\u00fchen Absetzen \nder Welpen (mit 4 bis 6 Wochen) basieren. Die Hauptinfektionsquelle der Felinen CoV sind \ndie Faeces infizierter Katzen. Aufgrund des f\u00e4kal-oralen \u00dcbertragungsweges der CoV \n(McRey nolds u. Macy , 1997) wird der Katzentoilette eine Schl\u00fcsselrolle zugeschrieben, weil \nhier die M\u00f6glichkeit besteht, Einflu\u00df auf die f\u00e4kale Kontam ination zu nehm en. Es wird \nempfohlen, eine leicht zu reinigende und gut zu desinfizierende Katzentoilette f\u00fcr nicht mehr \nals zwei Katzen weit ab des Fre\u00df- und Wasserplatzes aufzustellen. Eine Stre\u00dfm inimierung \nsollte auch im  Hinblick auf andere Katzenkrankheiten angestrebt werden. Dem zufolge sollte \ndie Gruppengr\u00f6\u00dfe nicht m ehr als 10 Tiere betragen. Das Trennen von CoV-Ak seronegativen \nund -positiven Tieren erscheint sinnvoll, wird aber unter Praxisbedingungen nur schwer zu \nrealisieren sein. Insgesam t mu\u00df es das Ziel sein, alle f\u00fcr die FIP pr\u00e4disponierenden Faktoren \nauszuschalten. \n \n5.13 Abschlie\u00dfende Bemerkungen \n \nDie angewandten diagnostischen Methoden im  Rahm en eines Feldversuches wurden \nausgesch\u00f6pft. K\u00fcrzere Untersuchungsintervalle w\u00e4ren wissenschaftlich interessant gewesen, \nh\u00e4tten sich aber m it den Kriterien eines Feldversuches bzw. den Bedingungen eines \nTierheim es, dem  Protokoll sowie der Tierversuchsgenehm igung nicht vereinbaren lassen. \nBez\u00fcglich der Infektionsquelle, des Im pfregim es, des Stresses und der Betreuung der Tiere \nlassen sich realit\u00e4tsn\u00e4here Bedingungen zu einem  Tierheim  kaum  schaffen. \nDies ergibt, dass die FIP-Inzidenz dire kt abh\u00e4ngig sein m u\u00df von der FECV/FIPV-\nMutationsrate, die wiederum  beeinflu\u00dft wird von der FECV-Replikationsrate, der \nerworbenen/angeborenen Resistenz der Einzelkatze gegen\u00fcber den FIPV-Mutanten und der \nMutationsrate des jeweiligen FECV-Stam mes (Vennem a et al., 1998). \nUm eine Population vor der FIP zu sch\u00fctzen, m u\u00df m an auch eine Elim ination des FECV \nerreichen, das hei\u00dft, dass m an die chronischen FCoV-Ausscheider erfassen und elim inieren \nmu\u00df (Foley  et al., 1997a). Das sollte ein wichtiger praktischer Ansatzpunkt f\u00fcr Tierheim e und \nandere Mehrfachhaltungen sein, der sicherlich nur \u00fcber ein generelles CoV-Screening zu \nerreichen ist. \n  Zusam menfassung 84 \n6.  Zusammenfassung  \n \nZiel der vorliegenden Arbeit war es, die Wirksamkeit einer Vakzine (Primucell\u00aeFIP) im \nTierversuch unter den Bedingungen eines Tierheimes zu untersuchen. \nZehn Tierheimkatzen, die mit Hilfe des kompetitiven ELISA zum Nachweis l\u00f6slicher FIPV-\nspezifischer Immunkomplexe in Seren und Exsudaten als Virustr\u00e4ger ohne klinische FIP \nidentifiziert wurden, wurden mit 20 geimpften und 20 ungeimpften SPF-Katzen \nzusammengesetzt. \nIm Versuchszeitraum erkrankte der \u00fcberwiegende Teil der SPF-Tiere an FIP. Ein SPF-Tier \u00fcberlebte eine vermutliche FIPV-Infektion mit klinischer Manifestation. Sie genas nach \nabgeklungener Symptomatik vollkommen und blieb klinisch unauff\u00e4llig. Die Sektion am \nVersuchsende ergab keine FIP-spezifischen Befunde. \nSieben SPF-Tiere (17,5 %) zeigten w\u00e4hrend des gesamten Versuchszeitraumes keinerlei Symptome irgendeiner Erkrankung. Keines dieser am Ende des Versuchs euthanasierten SPF-\nTiere wies eine FIP auf. \nDer klinische Status der meisten Tierheimkatzen, die in den Versuch gelangten, blieb \nunver\u00e4ndert. Eines der Tiere entwickelte allerdings eine klinisch manifeste Coronavirus-\nEnteritis, an der es verstarb. \nIm Verlauf des Versuches erkrankten und starben (bzw. wurden im Finalstadium der \nErkrankung euthanasiert) 23 Tiere (45%) an FIP. \n 10 Tiere stammten aus der Kontrollgruppe, \n 12 Tiere aus der Primucell\u00ae-Impfgruppe, \n und ein Tier aus der Tierheimgruppe. \nBez\u00fcglich der Anzahl der an FIP erkrankten Tiere ergab sich kein signifikanter Unterschied (p = 0,53) zwischen der SPF-Primucell\n\u00ae-Impfgruppe und der SPF-Kontrollgruppe. Es gab keinen \nsignifikanten Unterschied in der Geschlechtsverteilung der an FIP erkrankten Tiere. \nIm Versuch ergab sich eine gesch\u00fctzte Fraktion (preventable fraction) von -20 %, also kein Schutz durch die Impfung. \nDie FIP pr\u00e4sentierte sich \u00fcberwiegend in der feuchten (65%), aber auch in der trockenen Form. Die effusive Form lag in den meisten F\u00e4llen in klassischer Auspr\u00e4gung vor. Der \nKrankheitsverlauf war i.a. fulminant bei kurzer Krankheitsdauer. Erstes wahrnehmbares \nSymptom war stets die Aszitesbildung, die rasant voranschritt. Zusam menfassung 85 \nBei den F\u00e4llen der trockenen Form der FIP waren die Symptome \u00fcberwiegend unspezifischer \nNatur. Die trockene Form wurde w\u00e4hrend des gesamten Versuchszeitraums beobachtet. Ein \nTier entwickelte eine ausschlie\u00dflich zentralnerv\u00f6se klinische Symptomatik. \nDurch symptomatische Therapie war eine Beeinflu\u00dfung der Krankheitsdauer und des \nKrankheitsverlaufes nicht feststellbar. \n\u00dcber 80% der Tiere, die an FIP erkrankt waren, hatten zeitgleich oder kurz davor eine Katzen-schnupfenproblematik, w\u00e4hrend dies bei den nicht an FIP erkrankten Katzen nur f\u00fcr 44 % \nzutraf. \nAlle Tiere zeigten im Laufe des Versuchs eine Serokonversion. Die Vakzine Primucell\u00aeFIP \ninduzierte CoV-Antik\u00f6rpertiter von 1:50 bis 1:800. Nach einsetzendem Infektionsdruck stiegen die CoV-Antik\u00f6rpertiter bei einzelnen Tieren bis auf > 3200, sowohl bei den Impf- als auch bei \nden Kontrolltieren. Nicht alle Tiere, die hohe CoV-Antik\u00f6rpertiter aufwiesen oder im ELISA positiv reagierten, erkrankten auch an FIP. \nKatzen, die im kompetitiven ELISA zum Nachweis von l\u00f6slichen Immunkomplexen in Seren und Exsudaten positiv reagieren, auch wenn sie keine klinische Symptomatik aufweisen, \nm\u00fcssen als potentielle Infektionsquelle f\u00fcr empf\u00e4ngliche Tiere betrachtet werden. Die CoV-\nAntik\u00f6rpertiter erlauben keine Aussage dar\u00fcber, ob eine Katze eine FIP entwickeln wird und sind deshalb zur Prognose eines Infektionsverlaufs ungeeignet. \nAm Versuchsende wurde bei fast allen Tieren (20 von 23), die den Versuch \u00fcberlebten, mittels RT-PCR eine Monozyten-assoziierte FCoV-Vir\u00e4mie nachgewiesen. Summa ry 86 \n7.  Summary \n \nThe study aimed at the evaluation of the efficacy of the Primucell\u00aeFIP vaccine in an animal \nexperiment. The experiment was set up under conditions simulating those of an animal shelter. \nThe natural source of FIPV was represented by a group of 10 clinically healthy cats from \nanimal shelters which were tested positive for circulating FCoV immune complexes by means \nof a competitive ELISA. \nDuring the experiment, most of the 40 SPF cats developed FIP. One SPF cat survived a \npresumed FIPV infection with clinical manifestation and remained clinically healthy after the \nsymptoms had resolved. Necropsy at the end of the experiment did not reveal any FIP-specific \nlesions. \nDuring the experiment, seven SPF cats (17.5%) did not show any clinical symptoms. None of \nthese animals who all were necropsied at the end of the experiment, exhibited FIP. \nThe clinical status of most cats originating from animal shelters, remained unaltered throughout the experiment. One of these cats, however, developed and died of coronavirus \nenteritis. \nTwenty-three cats (45%) died of or were euthanatized in the final stage of FIP during the \nexperiment.Ten of these animals were control SPF cats, 12 animals were Primucell\u00aeFIP \nvaccinated SPF cats, and one animal was originating from an animal shelter. \nConcerning the number of cats developing FIP, there was neither a significant difference between Primcell\n\u00ae-vaccinated and control SPF cats (p=0.53) nor with regards to the sex \ndistribution. The experiment yielded a protected/preventable fraction of \u201320%, that is to say, \nno protection by Primcell\u00aeFIP vaccination occurred. \nPathologically, FIP was mainly represented by the effusive form (65%) which mostly appeared \nin the classical form. The clinical course was often fulminant with short duration of disease. In \ngeneral, ascites represented the first symptom and showed fast progression. \nWith the dry form of FIP which occurred throughout the whole experiment, symptoms were \nmainly non-specific. In one animal, clinical signs were restricted to CNS symptoms. \nNeither duration nor the course of disease were affected by symptomatic therapy. \nAt the same time as the clinical signs of FIP or prior to their development, more than 80% of the animals had clinical signs of upper respiratory disease, where as only 44 % of the FIP-\nnegative cats developed such symptoms. \nDuring the experiment, all SPF cats showed seroconversion. The vaccine Primucell\u00aeFIP \ninduced CoV anitbody titres of 1:50 up to 1:800. With the onset of  infectious pressure, CoV antibody titres rised to >3200 in some animals. Animals who developed high CoV antibody Summa ry 87 \ntitres or showed a positive result in the competitive ELISA for circulating FCoV immune \ncomplexes did not necessarily develop FIP. \nRegardless of the presence of clinical symptoms, cats with a positive result in the competitive ELISA for circulating FCoV immune complexes in sera or exudates have to be regarded as \npotential source of FCoV infection for susceptible animals. CoV antibody titres do not allow a \nprognosis concerning the development of FIP. \nAt the end of the experiment, monocyte-associated FCoV viraemia was identified by RT-PCR in nearly all animals who had survived (20 of 23). Literaturverzeichnis 88 \n8.  Literaturverzeichnis \n \nAddie, D. D., O. Jarrett (1990) \n Control of feline coronavirus infection in kitten \n Vet. Rec. 126, 164 \n \nAddie, D. D., O. Jarrett (1992) \n Feline coronavirus antibodies in cats \n Vet. Rec. 131, 202-203 \n \nAddie, D. D., O. Jarrett (1994) \n Die Epidemiologie der Felinen Infekti\u00f6sen Peritonitis \n Proceedings des Symposiums \u201cNeue Perspektiven zur Bek\u00e4mpfung der Felinen \n Infekti\u00f6sen Peritonitis\u201c, Berlin, Dezember 1994, 13-16 \n \nAddie, D. D., O. Jarrett (1995) \n Control of feline coronavirus infections in breeding catteries by serotesting, isolation,  and early weaning \n Feline Pract. 23, 92-95 \n \nAddie, D. D., O. Jarrett (1998) \n Feline Coronavirus Infection \n In: Infectious Diseases of the Dog and Cat, 2nd Ed., Greene, C.E. (Ed.), W.B. Sauners \n Company, Philadelphia, pp. 58-69 \n \nAddie, D. D., S. Toth, G. D. Murray, O. Jarrett (1995a) \n The risk of typical and antibody enhanced feline infectious peritonitis among cats  from feline coronavirus endemic households \n Feline Pract. 23, 24-26 \n \nAddie, D. D., S. Toth, G. D. Murray, O. Jarrett (1995b) \n Risk of feline infectious peritonitis in cats naturally infected with feline coronavirus \n Amer. J. Vet. Res. 56, 429-434 \n \nAddie, D. D., S. Toth, A. A. P. M. Herrewegh, O. Jarrett (1996) \n Feline coronavirus in the intestinal contents of cats with feline infectious peritonitis \n Vet. Rec. 139, 522-523 \n \nAddie, D. D., J. M. Dennis, S. Toth, J. J. Callanan, S. Reid, O. Jarrett (2000) \n Long-term impact on a closed household of pet cat of natural infection with feline  coronavirus, feline leukaemia virus and feline immunodeficiency virus \n Vet. Rec. 146, 419-424 \n \nAugust, J. R. (1984) \n Feline infectious peritonitis: An immune-mediated coronaviral vasculitis \n Vet. Clin. North Am. 14, 971 Literaturverzeichnis 89 \nBae, I., D. J. Jackwood, D. A. Benfield, L.J. Saif, R. D. Wesley, H. Hill (1991) \n Differentiation of transmissible gastroenteritic virus from porcine respiratory \n coronavirus and other antigenically related coronaviruses by using cDNA probes  specific for the 5`-region of the s-glycoprotein gene \n J. Clin. Microbiol. 29, 215-218 \n \nBaldwin, C. A. (1986) \n Immunization studies against feline infectious peritonitis \n Diss. Abstr. Int. B 47, 2791 \n \nBaldwin, C. W., F. W. Scott (1997) \n Attempted immunization of cats with feline infectious peritonitis virus propageted at  reduced temperatures \n Am. J. Vet. Res. 58, 251-256 \n \nBarlough, J. E., J. C. Adsit, F. W. Scott (1982) \n The worldwide occurence of feline infectious peritonitis \n Feline Pract. 12, 26-30 \n \nBarlough, J. E., R. C. Weiss (1983) \n Feline infectious peritonitis \n In: Kirk, R. W. (ed.): Current Vet. Therapy VIII, Philadelphia, W. B. Saunders Co.,  1186-1193 \n \nBarlough, J. E., R. H. Jacobsen, R. C. Weiss (1983a) \n Feline coronaviral serology \n Feline Pract. 13, 25-35 \n \nBarlough J. E., C. A. Stoddart, G. P. Sorresso, R. H. Jacobsen, F. W. Scott (1983b) \n Experimental inoculation of cats with canine coronavirus and subsequent challenge  with feline infectious peritonitis virus \n Ann. Meeting of the Conference of Research Workers in Animal Disease, Chicago, November 1983, 44, 64 \n \nBarlough, J. E. (1984) \n Experimental studies with four coronaviruses in cats (ELISA) \n Diss. Abstr. Int. B 45, 2042 \n \nBarlough J. E., R. H. Jacobsen, C. E. Pepper, F. W. Scott (1984) \n Role of recent vaccination in production of false-positive coronavirus antibody titers in  cats \n J. Clin. Microbiol. 19, 442-445 \n \nBarlough, J. E. (1985) \n Cats, coronaviruses and coronavirus antibody tests \n J. Small Anim. Pract. 26, 353-362 Literaturverzeichnis 90 \nBarlough, J. E., C. M. Johnson-Lussenburg, C. A. Stoddart, R. H. Jacobson, F. W. Scott (1985) \n Experimental inoculation of cats with human coronavirus 229E and subsequent \n challenge with feline infectious peritonitis virus \n Can. J. Comp. Med. 49, 303-307 \n \nBarlough, J. E., C. A. Stoddart (1990) \n Feline coronaviral infections \n Greene CE (ed): Infectious disease of the dog and cat, 2nd ed. Philadelphia: WB  Saunders Co, 300-312 \n \nBarlough, J. E., B. L. Shacklett (1994) \n Antiviral studies of feline infectious peritonitis virus in-vitro \n Vet. Rec. 135, 177-179 \n \nBilkei, G. (1988) \n Beitrag zur Therapie der FIP \n Tier\u00e4rztl. Umschau 43, 192-196 \n \nBlack, J. W. (1980) \n Recovery and in vitro cultivation of a coronavirus from laboratory-induced cases of  feline infectious peritonitis (FIP) \n Vet. Med. Small Anim. Clin. 75, 811-814 \n \nB\u00f6lcskei, A., G. Bilkei (1995a) \n Langzeitstudie \u00fcber behandelte FIP-verd\u00e4chtige Katzen, 1. Mitteilung: \u00dcberlebensrate  der FIP-verd\u00e4chtigen Katzen nach Behandlung mit Ampicillin, Prednisolon und  Cyclophosphamid \n Tier\u00e4rztl. Umschau 50, 590-594 \n \nB\u00f6lcskei, A., G. Bilkei (1995b) \n Langzeitstudie \u00fcber behandelte FIP-verd\u00e4chtige Katzen, 2. Mitteilung: Die  Auswirkungen verschiedener Therapieversuche auf das \u00dcberleben FIP-verd\u00e4chtiger  Katzen \n Tier\u00e4rztl. Umschau 50, 721-728 \n \nB\u00f6lcskei, A., G. Bilkei, O. Biro u. Tak\u00e1cs (1995) \n Retrospektive FIP-Studie, III. Mitteilung: Bericht \u00fcber die Wirksamkeit der Vakzine  Primucell FIP unter Praxisbedingungen und \u00fcber die Akzeptanz dieser Impfung bei  den Katzenhaltern \n Tier\u00e4rztl. Umschau 50, 851-853 \n \nBonaduce, A. (1942) \n Sulla pleurite infettiva de gatto \n Nuova Vet. 21, 32-36 \n \nCammarata Parodi, M., G. Cammarata, S. Paltrinieri, A. Lavazza, F. Ape (1993) \n Using direct immunofluorescence to detect coronaviruses in peritoneal and pleural  effusions \n J. Small Anim. Pract. 34, 609-613 Literaturverzeichnis 91 \nCavanagh, D., D. A. Brian, L. Enjuanes, K. V. Holmes, M. M. C. Lai, H. Laude, S. G. Siddell, \n W. Spaan, F. Taguchi, P. J. Talbot (1990) \n Recommendations of the coronavirus study group for the nomenclature of the  structural proteins mRNA, and genes of coronaviruses \n Virology 176, 306-307 \n \nChristianson, K. K., J. D. Ingersoll, R. M. Landon; N. E. Pfeiffer, J. D. Gerber (1989) Characterization of a temperature sensitive feline infectious peritonitis coronavirus.  Arch. Virol. 109, 185-196 \n \nColly, L. P. (1973) \n Feline infectious peritonitis \n Vet. Clin. 13, 34 \n \nCorapi, W. V., Olsen, C. W., Scott, F. W. (1992) \n Monoclonal antibody analysis of neutralization and antibody-dependent enhancement  of feline infectious peritonitis virus \n J. Virol. 11, 6695-6705 \n \nCorapi W. V., Darteil R. J., Audonnet J. C., Chappuis G. E. (1995) \n Localization of antigenic sites of the S gl ycoprotein of feline infectious peritonitis \n virus involved in neutralization and antibody-dependent enhancement \n J Virol  69, 2858-2862 \n \nCotter, S. M., C. E. Gilmore, C. Rolins (1973) \n Multiple cases of feline leukemia and feline infectious peritonitis \n J. Am. Vet. Med. Assoc. 166, 1054-1058 \n \nDe Groot, R. J.,J. Maduro, J. A. Lenstra, M. C. Horzinek, B. A. M. van der Zeijst, W. J. M.  Spaan (1987) \n cDNA-cloning and sequence analysis of the gene encoding the peplomer protein of  feline infectious peritonitis virus \n J. Gen. Virol. 68, 2639-2646 \n \nDea, S., R. S. Roy, M. A. S. Y. Elazhary (1982) \n Corona-like particles in the feces of cat with diarrhea \n Can. Vet. J. 23, 153-155 \n \nDoherty, M. J. (1971) \n Ocular manifestation of feline infectious peritonitis \n J. Am. Vet. Med. Assoc. 159, 417-424 \n \nEscobar, J. C., S. A. Kochik, E. Skaletsky, J. S. Rosenberg, T. R. Beardsley (1992) \n Immunization of cats against feline infectious peritonitis with anti-idiotypic antibodies \n Viral Immunol. 5, 71-79 \n \nEssex, M., S. M. Cotter, Jr. W. D. Hardy, P. Hess, W. Jarrett, O. Jarrett, L. Mackey (1975) \n Feline oncornavirus-associated cell membrane antigen. IV. antibody titers in cats  with naturally occuring leukemia, lymphoma, and other disease \n J. Natl. Cancer Inst. 55, 463-467 Literaturverzeichnis 92 \nEvermann, J. F., L. Baumgartener, R. L. Ott, E. V. Davis, A. J. McKeirnan (1981) \n Characterization of a feline infectious peritonitis virus isolate \n Vet. Path. 18, 256-265 \n \nEvermann, J. F., J. L. Heeney, M. E. Roelke, A. J. McKeirnan, S. J. O`Brien (1988) \n Biological and pathological consequences of feline infectious peritonitis infection in \n the cheetah \n Arch. Virol. 102, 155-171 \n \nEvermann, J. F., A. J. McKeirnan, R. L. Ott (1991) \n Perspectives on the epizootiology of feline enteritic coronavirus and the  pathogenesis of feline infectious peritonitis \n Vet. Microbiol. 28, 243-255 \n \nFankhauser, R., R. Fatzer (1977) \n Meningitis und Chorioependymitis granulomatosa der Katze; m\u00f6gliche Beziehung  zur felinen infekti\u00f6sen Peritonitis (FIP) \n Kleintierpraxis 22, 19-22 \n \nFanton, R. W. (1991) \n Field safety studies of an intranasal FIPV vaccine \n Proceedings of the symposium: New perspectives on prevention of feline infectious  peritonitis, Orlando, Florida, 47-50 \n \nFatzer, R. (1975) \n Leukodystrophische Erkrankungen im Gehirn junger Katzen \n Schweiz. Arch. Tierheilk. 117, 641-648 \n \nFehr, D., E. Holznagel, S. Bolla, B. Hauser, A. A. P. M. Herrewegh, M. C. Horzinek, H. Lutz  (1995) \n Evaluation of the safety and efficacy of a modified live FIPV vaccine under field  conditions \n Feline Pract. 23, 83-88 \n \nFehr, D., S. Bolla, A. A. P. M. Herrewegh, M. C. Horzinek, H. Lutz (1996) \n Nachweis feliner Coronaviren mittels RT-PCR: Grundlage zum Studium der  Pathogenese der Felinen Infekti\u00f6sen Peritonitis (FIP) \n Schweiz. Arch. Tierheilk. 138, 74-79 \n \nFehr, D., E. Holznagel, S. Bolla, B. Hauser, A. A. P. M. Herrewegh, M. C. Horzinek, H. Lutz  (1997) \n Placebo-controlled evaluation of a modified life virus vaccine against feline infectious  peritonitis: Safety and efficacy under field conditions \n Vaccine 15, 1101-1109 \n \nFeldmann, B. M., B. S. Jortner (1964) \n Clinico-pathologic conference \n J. Am. Vet. Med .Assoc. 144, 1409-1420 Literaturverzeichnis 93 \nFiscus, S. A., Y. A. Teramoto, M. M. Mildbrand, C. V. Knisley, S. E. Winston, N. C. Pedersen \n (1985) \n Competitive enzyme immunoassays for the rapid detection of antibodies to feline  infectious peritonitis virus polypeptides \n J. Clin. Microbiol. 22, 395-401 \n \nFoley, J. E., A. Poland, J. Carlson, N. C. Pedersen (1997a) \n Risk factors for feline infectious peritonitis among cats in multiple-cat environments  with endemic feline enteric coronavirus \n J. Am. Vet. Med .Assoc. 210, 1313-1318 \n \nFoley, J. E., A. Poland, J. Carlson, N. C. Pedersen (1997b) \n Patterns of feline coronavirus infection and fecal shedding from cats in multiple-cat  environments \n J. Am. Vet. Med .Assoc. 210, 1307-1312 \n \nFord, R. B. (1982) \n New information on epidemiology of feline infectious peritonitis \n Norden News 57, 6 \n \nFransen, D. R. (1972) \n Feline infectious peritonitis in an infant jaguar \n Proc. Ann. Meet. Am. Assoc. Zoo Vet. 261-264 \n \nFrost, J. W., W. Lohrbach (1987) \n Der Nachweis von Antik\u00f6rpern gegen das Virus der Felinen Infekti\u00f6sen Peritonitis  (FIP) mittels Indirektem Immunfluoreszenztest \n Tier\u00e4rztl. Praxis 15, 301-304 \n \nGamble, D. A., A. Lobbiani, M. Gramegna, L. E. Moore, G. Colucci (1997) \n Development of a nested PCR assay for detection of feline infectious peritonitis virus  in clinical specimens \n J. Clin. Microbiol. 35, 673-675 \n \nGelatt, K. N. (1973) \n Iridocyclitis-panophthalmitis associated with feline infectious peritonitis \n Vet. Med. Small Anim. Clin. 68, 56-57 \n \nGerber, J. D., J. D. Ingersoll, K. K. Christianson, R. M. Landon, N. L. Selzer, U. E. Pfeiffer  (1989) \n Protection of cats against feline infectious peritonitis (FIP) by intranasal  administration of an FIP virus vaccine \n Immunobiology Suppl. 4, 116 \n \nGerber, J. D., J. D. Ingersoll, A. M. Gast, K. K. Christianson, N. L. Selzer, R. M. Landon; N.  E. Pfeiffer, R. L. Sharpee, W. H. Beckenhauer (1990) \n Protection against feline infectious peritonitis by intranasal inoculation of a  temperature-sensitive FIPV vaccine \n Vaccine 8, 536-542 Literaturverzeichnis 94 \nGerber, J. D., K. K. Christianson, A. M. Gast, N. E. Pfeiffer (1991) \n Lokale IgA und zellvermittelte Immunreaktion in Verbindung mit dem Schutz von \n Katzen, die intranasal mit einem temperatursensitiven Impfstoff gegen die Feline  Infekti\u00f6se Peritonitis immunisiert wurden \n Proceedings (XVI. Weltkongre\u00df in Wien), 07-Immunology, 210-212 \n \nGerber, J. (1994) \n Immunantworten auf Infektionen mit dem felinen infekti\u00f6sen Peritonitis Virus und auf  einen felinen infekti\u00f6sen Peritonitis Impfstoff \n Proceedings Symposium: Neue Perspektiven zur Bek\u00e4mpfung der Felinen Infekti\u00f6sen  Peritonitis; Berlin \n \nGerber, J. D. (1995) \n Overview of the development of a modified live temperature-sensitive FIP virus  vaccine \n Feline Pract. 23, 62-66 \n \nGerbig, T., W. Kraft (1979) \n Zur Klinik der Felinen Infekti\u00f6se Peritonitis \n Kleintierpraxis 24, 5-8 \n \nGierend, M., B. Heppner (1983) \n Diagnostische Untersuchungen bei der Felinen Infekti\u00f6sen Peritonitis \n Kleintierpraxis 28, 103-104, 106 \n \nGoldhorn, W. (1987) \n Das Tierheim - ein Tierschutzproblem? \n Prakt. Tierarzt 9, 23-27 \n \nGrahn, B. J. (1991) \n The feline coronavirus infections - feline infectious peritonitis and feline coronavirus  enteritis \n Vet. Med. 86, 376-393 \n \nGriffiths, G., P. Rottier (1992) \n Cell biology of viruses that assemble along the biosynthetic pathway \n Semin. Cell. Biol. 3, 367-381 \n \nGunn-Moore, D. A. (1997a) \n PCR-based diagnosis of feline infectious peritonitis \n Vet. Rec. 26, 464 \n \nGunn-Moore, D. A. (1997b) \n Molecular characterisation of feline coronavirus infection \n PhD-Thesis, Bristol, UK \n \nGunn-Moore, D. A., T. J. Gruffydd-Jones, D. A. Harbour (1998) \n Detection of FCoV by culture and RT-PCR of blood samples from healthy cats and  cats with clinical FIP \n Vet. Microbiol. 62, 193-205 Literaturverzeichnis 95 \nGunn-Moore, D. A., F. J. Gunn-Moore, T. J. Gruffydd-Jones, D. A. Harbour (1999) \n Detection of FCoV quasispecies using denaturing gradient gel electrophoresis \n Vet. Microbiol. 69, 127-130 \n \nHaagmans, B. L., H. Egberink, V. E. C. J. Schijns, M. C. Horzinek (1996) \n Apoptosis and T-cell depletion during feline infectious peritonitis \n J. Virol.70, 789-793 \n \nHardy, W. D., A. I. Hurvitz (1971) \n Feline infectious peritonitis: experimental studies \n J. Am. Vet. Med .Assoc. 158, 994-1002 \n \nHarpold, L. M., Legendre, A. M., Kennedy, M. A., Plummer, P. J., Millsaps, K., Rohrbach, B. \n (1999) \n Fecal shedding of feline coronavirus in adult cats and kittens in an Abyssinian cattery \n J. Am. Vet. Med. Assoc. 215: 948-951 \n \nHasegawa, T., A. Hasegawa (1991) \n Interleukin 1 alpha mRNA-expressing cells on the local inflammatory response in  feline infectious peritonitis \n J. Vet. Med. Sci. 53, 995-999 \n \nHawkins, E. C. (1991) \n Feline infectious peritonitis: update \n Proc 9th ACVIM Forum, New Orleans, 133-135 \n \nHayashi, T., F. Utsumi, R. Takahashi, K. Fujiwara (1980) \n Pathology of non-effusive type of feline infectious peritonitis and experimental  transmission \n Jpn. J. Vet. Sci. 42, 197-210 \n \nHayashi, T., Y. Watabe, H. Nakayama, K. Fujiwara (1982) \n Enteritis due to feline infectious peritonitis virus \n Jpn. J. Vet. Sci. 44, 97-106 \n \nHayashi, T., K. Doi, K. Fujiwara (1983) \n Role of circulating antibodies and thymus-dependent lymphocytes in production of  effusive type feline infectious peritonitis after oral infection \n Adv. Exp. Med. Biol., 173, 383-384 \n \nHerrewegh, A. A. P. M., H. F. Egberink, M. C. Horzinek, P. J. M. Rottier, R. J. de Groot  (1995a) \n Polymerase chain reaction (PCR) for the diagnosis of naturally occurring feline  coronavirus infections \n Feline Pract. 23, 56-59 Literaturverzeichnis 96 \nHerrewegh, A. A. P. M., R. J. de Groot, A. Cepica, H. F. Egberink, M. C. Horzinek, P. J. M. \nRottier (1995b) \n Detection of feline coronavirus RNA in feces, tissues, and body-fluids of naturally  infected cats by reverse-transcriptase PCR \n J. Clin. Microbiol. 33, 684-689 \n \nHerrewegh, A. A. P. M., Vennema, H., Horzinek, M. C., Rottier, P. J. M., Degroot, R. J.  (1995c) \n The molecular-genetics of feline coronaviruses - comparative sequence-analysis of the  Orf7a/7b transcription unit of different biotypes \n Virology 212, 622-631 \n \nHerrewegh, A. A. P. M., M. M\u00e4hler, H. J. Hedrich, B. L. Haagmans, H. F. Egberink, M. C.  Horzinek, P. J. M. Rottier, R. J. de Groot (1997) \n Persistence and evolution of feline coronavirus in a closed cat-breeding colony \n Virology 234, 349-363 \n \nHerrewegh, A. A. P. M., Smeenk, I., Horzinek, M. C., Rottier, P. J. M., Degroot, R. J. (1998) \n Feline Coronavirus Type-II Strain-79-1683 and Strain-79-1146 Originate from a  Double Recombination Between Feline Coronavirus Type-I and Canine Coronavirus \n J. Virol. 72, 4508-4514 \n \nHickman, M. A., J. G. Morris, Q. R. Rogers (1995) \n Elimination of feline coronavirus infection from a large experimental specific  pathogen-free cat breeding colony by serologic testing and isolation \n Feline Pract. 23, 96 \n \nHirschberger, J., K. Hartmann, N. Wilhelm, J. Frost, H. Lutz, W. Kraft (1995) \n Klinik und Diagnostik der Felinen Infekti\u00f6sen Peritonitis \n Tier\u00e4rztl. Prax. 23, 92-99 \n \nHohdatsu, T., Nakamura, M., Ishizuka, Y., Yamada, H., Koyama, H. (1991) \n A study on the mechanism of antibody-dependent enhancement of feline infectious  peritonitis virus infection in feline macrophages by monoclonal antibodies \n Arch. Virol. 117, 85-89 \n \nHohdatsu, T., S. Okada, Y. Ishizuka, H. Yamada, H. Koyama (1992) \n The prevalence of types I and II feline coronavirus infection in cats \n J. Vet. Med. Sci. 54, 557-562 \n \nH\u00f6k, K. (1990) \n Demonstration of feline coronavirus (FCV) antigen in organs of cats suspected of  feline infectious peritonitis (FIP) disease \n Acta Pathol. Microbiol. Immunol. Scand. 98, 659-664 \n \nH\u00f6k, K. (1991) \n A comparison between immunofluorescence staining on smears from Membrana  nictitans (M3 test), immunohistopathology and routine pathology in cats with  suspected feline infectious peritonitis (FIP) \n Acta Vet. Scand. 32, 171-176 Literaturverzeichnis 97 \nH\u00f6k, K. (1993a) \n Morbidity, mortality and coronavirus antigen in previously coronavirus free kittens \n placed in two catteries with feline infectious peritonitis \n Acta Vet. Scand. 34, 203-210 \n \nH\u00f6k, K. (1993b) \n Development of clinical signs and occurrence of feline coronavirus antigen in naturally  infected barrier reared cats and their offspring \n Acta Vet. Scand. 34, 345-356 \n \nHolmes, K. V., M. M. C. Lai (1996) \n Coronaviridae: The viruses and their replication \n Fields Virology, Third Edition, Lippincott-Raven, Philadelphia, 1075-1090 \n \nHolzworth, J. (1963) \n Some important disorders of cats. \n Cornell Vet. 53, 157-160 \n \nHorchler-Jahn, H., M. Seidel (1993) \n Zwei seltene F\u00e4lle von Ascites abdominalis bei Katze und Hund \n Kleintierpraxis 38, 103-110 \n \nHorzinek, M. C., A. D. M. E. Osterhaus, D. J. Ellens (1977) \n Feline infectious peritonitis virus \n Zbl. Vet. Med. B. 24, 398-405 \n \nHorzinek, M. C., A. D. M. E. Osterhaus (1979a) \n Feline infectious peritonitis: A worldwide serosurvey \n Am. J. Vet. Res. 40, 1487-1492 \n \nHorzinek, M. C., A. D. M. E. Osterhaus (1979b) \n The virology and pathogenesis of feline infectious peritonitis. Brief review \n Arch. Virol. 59, 1-15 \n \nHorzinek, M. C., J. Ederveen, H. Egbering, H. E. L. Jacobse-Geels, T. Niewold, J. Prins  (1986) \n Virion polypeptide specificity of immune complexes and antibodies in cats inoculated  with feline infectious peritonitis virus \n Am. J. Vet. Res. 47, 754-761 \n \nHorzinek, M. C., A. Herrewegh, R. J. de Groot (1995) \n Perspectives on feline coronavirus evolution \n Feline Pract. 23, 34-39 \n \nHoshino, Y., F. W. Scott (1978) \n Brief communication: Replication of feline infectious peritonitis virus in organ  cultures of feline tissue \n Cornell Vet 68, 411-417 Literaturverzeichnis 98 \nHoshino, Y., F. W. Scott (1980) \n Coronavirus-like particles in the feces of normal cats \n Arch. Virol. 63, 147 \n \nHoskins, J. D. (1991) \n Coronavirus infection in cats \n Comp. Cont. Educ. Pract. Vet. 13, 567-585 \n \nHoskins, J. D., H. W. Taylor, T. L. Lomax (1994) \n Challenge trial of an intranasal feline infectious peritonitis vaccine \n Feline Pract. 22, 9-13 \n \nHoskins, J. D., W. G. Henk, J. Storz, M. T. Kearney (1995a) \n The potential use of a modified live FIPV vaccine to prevent experimental FECV \n infection \n Feline Pract. 23, 89-90 \n \nHoskins, J. D., H. W. Taylor, T. L. Lomax (1995b) \n Independent evaluation of a modified live feline infectious peritonitis virus vaccine  under experimental conditions (Louisiana experience) \n Feline Pract. 23, 72-73 \n \nJacobse-Geels H. E. L., M. R. Daha, M. C. Horzinek (1980) \n Isolation and characterization of feline C 3 and evidence for the immune complex \n pathogenesis of feline infectious peritonitis \n J. Immunol. 125, 1606-1610 \n \nJacobse-Geels H. E. L., M. R. Daha, M. C. Horzinek (1982) \n Antibody, immune complexes and complement activity fluctuations in kittens with  experimentelly induced feline infectious peritonitis \n Am. J. Vet. Res. 43, 666-670 \n \nJones, V. E., E. Orlans (1981) \n Isolation of immune complexes and characterisation of their constituent antigens and  antibodies in some human diseases: a review \n J. Immunol. Methods 44, 249-70 \n \nKaas, P. H., T. H. Dent (1995) \n The epidemiology of feline infectious peritonitis in catteries \n Feline Pract. 23, 27-32 \n \nKai, K., Y. Kaneda, N. Goto, M. Kanoe (1987) \n Isolation and characterization of a new and higher titer strain of feline infectious  peritonitis virus \n Jpn. J. Vet. Sci. 49, 1105-1111 \n \nKai, K., M. Yukimune, T. Murata, Y. Uzuka, M. Kanoe, H. Matsumoto (1992) \n Humoral immune response of cats to feline infectious peritonitis virus infection \n J. Vet. Med. Sci. 54, 501-507 Literaturverzeichnis 99 \nKai, K., Y. Akagi, T. Soma, K. Nomura, M. Kanoe (1995) \n Biphasic immune responses of cats under controlled infection with feline enteric \n coronavirus 79-1683 strain \n J. Vet. Med. Sci. 57, 781-783 \n \nKellner, S. J., B. Litschi (1989) \n Augenver\u00e4nderung bei der Felinen Infekti\u00f6sen Peritonitis \n Kleintierpraxis 34, 261-266 \n \nKennedy, M. A., K. Brenneman, R. K. Millsaps, J. Black, L. N. D. Potgieter (1998) \n Correlation of genomic detection of feline coronavirus with various diagnostic assays  for feline infectious peritonitis \n J. Vet. Diagn. Invest. 10, 93-97 \n \nKersten, U. (1985) \n Erg\u00fcsse in K\u00f6rperh\u00f6hlen, Diagnose und Differentialdiagnose \n Effem-Report 21, 1-7 \n \nKipar, A., J. Kremendahl, D. D. Addie, W. Leukert, C. K. Grant, M. Reinacher (1998) \n Fatal enteritis associated with coronavirus infection in cats \n J. Comp. Pathol. 119, 1-14 \n \nKipar, A., K. Koehler, S. Bellmann, M. Reinacher (1999a) \n Feline infectious peritonitis presenting as a tumour in the abdominal cavity \n Vet. Rec. 144, 118-122 \n \nKipar, A., S. Bellmann, D. A. Gunn-Moore, W. Leukert, K. K\u00f6hler, S. Menger, M. Reinacher  (1999b) \n Histopathological alterations of lymphatic tissues in cats without feline infectious  peritonitis after long-term exposure to FIP virus \n Vet. Microbiol. 69, 131-137 \n \nKitchen, L. W. (1988) \n Effect of diethylcarbamazine on serum antibodies to feline infectious peritonitis in  cats \n Vaccine 6, 10-11 \n \nKlumperman, J., J. K. Locker, A. Meijer, M. C. Horzinek, H. J. Geuze, J. M. Rottier (1994) \n Coronavirus M-protein accumulate in the golgi complex beyond the site of virion  budding \n J. Virol. 68, 6523-6534 \n \nK\u00f6lbl, S., W. Schuller (1988) \n Zur Diagnostik von viralen Erkrankungen bei der Katze \n Wiener Tier\u00e4rztl. Mschr. 75, 64-67 \n \nKolb, E. (1982) \n Vom Leben und Verhalten unserer Haustiere \n S. Hirzel Verlag Leipzig, 129-150 Literaturverzeichnis 100 \nKornegay, J. N. (1978) \n Feline infectious peritonitis: The central nervous system form \n J. Am. Anim. Hosp. Assoc. 14, 580-584 \n \nKovacevic, S., A. Kipar, J. Kremendahl, D. Teebken-Schuler, C. G. Grant, M. Reinacher \n (1997) \n Immunhistochemical diagnosis of feline leukemia virus infection in formalin-fixed  tissue \n Eur. J. Vet. Path. 3, 13-19 \n \nKrebiel, J. D., V. L. Langer, A. Ravi (1974) \n Ophthalmic lesions in feline infectious peritonitis: Gross, microscopic and  ultrastructural changes \n Vet. Pathol. 11, 443-444 \n \nKriegleder, H.u. S. Geyer (1984) \n Befunde der Felinen Infekti\u00f6sen Peritonitis \n Tier\u00e4rztl. Umschau 39, 382, 387-389 \n \nKrum, S., K. Johnson, J. Wilson (1975) \n Hydrocephalus associated with the noneffusive form of feline infectious peritonitis \n J. Am. Vet. Med .Assoc. 167, 746-748 \n \nLandes, C., H. Kriegleder, K. D. Lengfelder (1984) \n Todes- und Erkrankungsursachen bei Katzen anhand der Sektionsstatistik 1969- 1982 \n Tier\u00e4rztl. Praxis 12, 369-382 \n \nLange, H., W. Herbst, M. Noack, T. Schliesser (1987) \n Vergleichende Untersuchungen zum Nachweis von Antik\u00f6rpern gegen die Infekti\u00f6se  Peritonitis der Katze (FIP) mittels Immunfluoreszenz und Enzym Immuntest  (ELISA) \n J. Vet. Med. B. 34, 530-537 \n \nLi, X., Scott, F.W., (1994) \n  Detection of feline coronaviruses in cell cultures and in fresh and fixed feline \n tissues using polymerase chain reaction \n  Vet. Microbiol. 42, 65-77 \n \nLiebermann, H. (1992) \n Lehrbuch der veterin\u00e4rmedizinischen Virologie \n G. Fischer Verlag Jena-Stuttgart, 130 \n \nLoeffler, D. G., R. L. Ott, J. F. Evermann, J. E. Alexander (1978) \n The incidence of natural occurring antibodies against feline infectious peritonitis in a  selected cat population \n Feline Pract. 8, 43-45 Literaturverzeichnis 101 \nLutz, H., B. Hauser, M. C. Horzinek (1984) \n Die Diagnostik der felinen infekti\u00f6sen Peritonitis mittels Serologie \n Prakt. Tierarzt 65, 406-408 \n \nLutz, H., B. Hauser, M. C. Horzinek (1985) \n Die Feline Infekti\u00f6se Peritonitis - Wo stehen wir heute? \n Kleintierpraxis 30, 51-59 \n \nLutz, H., B. Hauser, M. C. Horzinek (1986) \n Feline infectious peritonitis (FIP) - the present state of knowledge \n J. Small Anim. Prac. 27, 108-116 \n \nLutz, H., R. Lehmann, G. Winkler, B. Kottwitz, A. Dittmer, C. Wolfensberger, P. Arnold \n (1990) \n Das feline Immunschw\u00e4chevirus in der Schweiz: Klinik und Epidemiologie im  Vergleich mit dem Leuk\u00e4mie- und Coronavirus \n Schw. Arch. Tierheilk. 132, 217-225 \n \nLutz, H. (1992) \n Feline Infekti\u00f6se Peritonitis \n In: Schmidt, V. u. M. C. Horzinek (Hrsg.): Krankheiten der Katze \n G. Fischer Verlag, Jena-Stuttgart, 318-337 \n \nLutz, H., J. Huder, D. Fehr, C. Oehninger, B. Sigrist (1996) \n Neue Methoden zur Diagnose der Katzenvirosen (FeLV, FIV, FIP) \n Referatesammlung zur 27. Jahresversammlung der Schweizerischen Vereinigung f\u00fcr  Kleintiermedizin 9.-11.5.1996 Interlaken /Schweiz, 51-57 \n \nMadron, E. de (1986) \n Pericarditis with cardiac tamponade secondary to feline infectious peritonitis in a cat \n J. Am. Anim. Hosp. Assoc. 22, 65-69 \n \nMaess, J. (1985) \n Feline Infekti\u00f6se Peritonitis (FIP) \n Dtsch. Tier\u00e4rztl. Wschr. 92, 482-483 \n \nMcArdle, F, M. Bennett, R. M. Gaskell, B. Tennant, D. F. Kelly, C. J. Gaskell (1992) \n Induction and enhancement of feline infectious peritonitis by canine coronavirus \n Am. J. Vet. Res 53, 1500-1506 \n \nMcArdle, F, B. Tennant, M. Bennett, D. F. Kelly, C. J. Gaskell, R. M. Gaskell (1995) \n Independent evaluation of a modified live FIPV vaccine under experimental conditions  (university of Liverpool experience) \n Feline Pract. 23, 67-71 \n \nMcKeirnan, A. J., J. F. Evermann, A. Hargis, L. M. Miller, R. L. Ott (1981) \n Isolation of feline coronaviruses from cats with diverse disease manifestations \n Feline Pract. 11,  16-20 Literaturverzeichnis 102 \nMcReynolds, C., D. Macy (1997) \n Feline infectious peritonitis. Part I. Etiology and diagnosis \n Comp. Cont. Educ. Pract. Vet. 19, 1007-1016 \n \nMertens, C. (1994) \n Tiergerechte Katzenhaltung. \n Tierlaboratorium 17, 89-101 \n \nMertens, C., R. Sch\u00e4r (1988) \n Practical Aspects of research on cats. In: The Domestic Cat: The biology of its \n behavior \n ed. Turner D. C. and P. Bateson, pp. 179-190. Cambridge: Cambridge University Press \n \nMorris, D. (1994) \n Catwatching \n Ebury Press Limited, London, 78 \n \nM\u00f6stl, K. (1983) \n Nachweis von Antik\u00f6rpern gegen das Virus der Felinen Infekti\u00f6sen Peritonitis in  Katzenseren und Peritonealexsudaten \n Wiener Tier\u00e4rztl. Mschr. 70, 318-323 \n \nMotokawa, K., Hohdatsu, T., Hashimoto, H., Koyama, H. (1996) \n Comparison of the amino acid sequence and phylogenetic analysis of the peplomer,  integral membrane and nucleocapsid proteins of feline, canine and porcine  coronaviruses \n Microbiol. Immunol. 40, 425-433 \n \nNeu, H., E. G. Pfeifer (1985) \n FIP (Feline Infekti\u00f6se Peritonitis): Klinische Fr\u00fchsymptome und vorausgegangene  Belastungen \n Kleintierpraxis 30, 307-314 \n \nNicolaysen, P., T. Van Winkile, M. Haskuis, H. Rozimiarek (1990) \n Feline coronavirus (feline infectious peritonitis) in a cat breeding colony \n Lab. Animal Science 40, 543 \n \nOlsen, C. W., F. W. Scott (1991) \n Feline infectious peritonitis vaccination - past and present \n Feline Health Topics for Veterinarians 6, 1-8 \n \nOlsen C. W., Corapi W. V., Ngichabe C. K., Baines J. D., Scott F. W. (1992) \n Monoclonal antibodies to the spike protei n of feline infectious peritonitis virus \n mediate antibody-dependent enhancement of infection of feline macrophages \n J. Virol. 66, 956-965 \n \nOlsen, C. W. (1993) \n A review of feline infectious peritonitis virus: molecular biology,  immunopathogenesis, clinical aspects, and vaccination \n Vet. Microbiol. 36, 1-37 Literaturverzeichnis 103 \nO\u00b4Reilly, K. J., B. Fishman, L. M. Hitchcock (1979) \n Feline infectious peritonitis: Isolation of a coronavirus \n Vet. Rec. 104, 348 \n \nOsterhaus, A. D. M. E., M. C. Horzinek, D. J. Ellens (1976) \n Untersuchungen zur \u00c4tiologie der Felinen Infekti\u00f6sen Peritonitis, Vorl\u00e4ufige \n Mitteilung \n Berl. M\u00fcnch. Tier\u00e4rztl. Wschr. 89, 135-137 \n \nOsterhaus, A. D. M. E., M. C. Horzinek, D.J. Reynolds (1977) \n Seroepidemiology of feline infectious peritonitis using transmissible gastroenteritis  virus as antigen \n Zbl. Vet. Med. B 24, 835-841 \n \nOsterhaus, A. (1979) \n Feline Infekti\u00f6se Peritonitis \n Kleintierpraxis 24, 115-120 \n \nPanzero, R. A. (1992) \n An outbreak of feline infectious peritonitis in a colony of cornish rex cats \n Feline Pract. 20, 7-8 \n \nPedersen, N. C. (1976a) \n Serologic studies of naturally occuring feline infectious peritonitis \n Am. J. Vet. Res. 37, 1449-1453 \n \nPedersen, N. C. (1976b) \n Morphologic and physical characteristics of feline infectious peritonitis virus and its  growth in autochthonous peritoneal cell cultures \n Am. J. Vet. Res. 37, 567-572 \n \nPedersen, N. C., J. F. Boyle (1980) \n Immunologic phenomena in the effusive form of feline infectious peritonitis \n Am. J. Vet. Res. 41, 868-876 \n \nPedersen, N. C., Boyle, J. F., Floyd, K. (1981a) \n Infection studies in kittens, using feline infectious peritonitis virus propagated in cell  culture \n Am. J. Vet. Res. 42, 363-367 \n \nPedersen, N. C., J. F. Boyle, K. Floyd, A. Fudge, J. Barker (1981b) \n An enteric coronavirus infection of cats and its relationship to feline infectious  peritonitis. \n Am. J. Vet. Res. 42, 368-377 \n \nPedersen, N. C. (1983a) \n Feline infectious peritonitis and feline enteric coronaviruses infections. Part 2. Feline  infectious peritonitis. \n Feline Pract.  13, 5-20 Literaturverzeichnis 104 \nPedersen, N. C. (1983b) \n Feline infectious peritonitis and feline enteric coronaviruses infections. Part 1. Feline \n enteric coronavirus infections. \n Feline Pract. 13, 13 \n \nPedersen, N. C., J. W. Black (1983) \n Attempted immunization of cats against feline infectious peritonitis using either  avirulent live virus or sublethal amounts of virulent virus \n Am. J. Vet. Res. 44, 229-234 \n \nPedersen, N. C., J. W. Black, J. F. Boyle, J. F. Evermann, A. J. McKeirnan, R. L. Ott (1984a) \n Pathogenic difference between various feline coronavirus isolates \n Adv. Exp. Med. Biol. 173, 365-380 \n \nPedersen, N. C., Evermann, J. F., McKeirnan, A. J., Ott, R. L. (1984b) \n Pathogenicity studies of feline coronavirus isolates 79-1146 and 79-1683 \n Am. J. Vet. Res. 45, 2580-2585 \n \nPedersen, N. C., K. F. Floyd (1985) \n Experimental studies with three new strains of feline infectious peritonitis virus:  FIPV-UCD2, FIPV-UCD3, and FIPV-UCD4 \n Comp. Cont. Educ. Pract. Vet. 7, 1001-1011 \n \nPedersen, N. C. (1987) \n Virologic and immunologic aspects of feline infectious peritonitis infection \n Adv. Exp. Med. Biol. 218, 529-550 \n \nPedersen, N. C. (1989) \n Animal virus infections that defy vaccination: Equine infectious anemia, caprine  arthritis-encephalitis, maedi-visna, and feline infectious peritonitis \n Adv. Vet. Sci. Comp. Med. 33, 413-428 \n \nPedersen, N. C. (1995) \n An overview of feline enteric coronavirus and infectious peritonitis virus infections \n Feline Pract. 23, 7-20 \n \nPedersen, N. C., D. Addie, A. Wolf (1995) \n Recommendations from working groups of the international feline enteritic  coronavirus and feline infectious peritonitis workshop \n Feline Pract. 23, 108-111 \n \nPetterson, R. F. (1991) \n Protein localization and virus assembly at intracellular membranes \n Curr. Top. Microbiol. Immunol. 179, 67-106 \n \nPfeiffer, N.E. (1991) \n Prospects and problems of coronaviral serology \n Proc. Symp. New Perspectives on Prevention of Feline Infectious Peritonitis, 30-34 Literaturverzeichnis 105 \nPfeiffer, M. L., J. F. Evermann, M. E. Roelke, A. M. Gallina, R. L. Ott, A. J. McKeirnan \n (1983) \n Feline infectious peritonitis in a captive cheetah \n J. Am. Vet. Med. Assoc. 183, 1317-1319 \n \nPoelma, F. G., J. C. Peters, W. H. W. Mieog, P. Zwart (1974) \n Infekti\u00f6se Peritonitis bei Karakal (Felis caracal) und Nordluchs (Felis lynx lynx) \n Erkrankungen der Zootiere, 13. Int. Symp. Helsinki, 249-283 \n \nPoland, A., H. Vennema, J. E. Foley, N. C. Pedersen (1996) \n Two related strains of feline infectious peritonitis virus isolated from  immunocompromised cats infected with a feline enteric coronavirus \n J. Clin. Microbiol. 34, 3180-3184 \n \nPorterfield, J. S. (1986) \n Antibody-dependentenhancement of viral infectivity \n Adv. Virus Res. 31, 335-355 \n \nPostorino Reeves, N. C., R. V. H. Pollock, E. T. Thurber (1992) \n Long-term follow-up study of cats vaccinated with a temperature-sensitive feline  infectious peritonitis vaccine \n Cornell Vet. 82, 117-123 \n \nPostorino Reeves, N. C. (1995) \n Vaccination against naturally occurring FIP in a single large cat shelter \n Feline Pract. 23, 81-82 \n \nReinacher, M. (1993a) \n Pathologie der Infektion mit dem Felinen Immundefizienzvirus (FIV) bei der Katze \n Prakt. Tierarzt 74, 80-81 \n \nReinacher, M. (1993b) \n Pathologie der Infektion mit dem Felinen Leuk\u00e4mievirus (FeLV) bei der Katze \n Prakt. Tierarzt 74, 82-83 \n \nReinacher, M. (1994) \n Pathogenese und Diagnose von nat\u00fcrlich auftretenden Infektionen mit dem Felinen  Infekti\u00f6sen Peritonitis Virus \n Proceedings des Symposiums \u201cNeue Perspektiven zur Bek\u00e4mpfung der Felinen  Infekti\u00f6sen Peritonitis\u201c, Berlin, Dezember 1994, 9-12 \n \nReubel, G. H. (1987) \n FIP Problematik der Serodiagnose \n Veterin\u00e4rmedizin 9, 6-8 \n \nRichter, M., Schinkinger, M. F., M\u00f6stl, K., (1996) \n Nachweis von Infektionen mit felinen Coronaviren Typ II im Blut von Katzen \n mittels Reverser Transkriptase Polymerase-Kettenreaktion (RT-PCR) \n Wiener Tier\u00e4rztl. Mschr. 83, 263-268 Literaturverzeichnis 106 \nRobinson, R. L., J. Holzworth, C. E. Gilmore (1971) \n Naturally occurring feline infectious peritonitis: signs and clinical diagnosis \n J. Am. Vet. Med .Assoc. 158, 981-986 \n \nRohrer, C. (1992) \n Die Diagnostik der Felinen Infekti\u00f6sen Peritonitis (FIP): eine retrospektive Studie \n Vet. Med. Diss. Z\u00fcrich, 1992 \n \nRohrer, C., P. F. Suter, H. Lutz (1993) \n Die Diagnostik der Felinen Infekti\u00f6sen Peritonitis (FIP): Retrospektive und \n prospektive Untersuchungen \n Kleintierpraxis 6, 379-389 \n \nRoikjo, J. L., M. L. Perdzock, C. M. Cheney, G. J. Kociba (1985) \n The effects of concurrent viruses on the susceptibility of cats to the feline leukemia  virus and disease \n Feline Pract. 15, 30-31 \n \nSch\u00e4r, R. (1989) \n Die Hauskatze. Lebensweise und Anspr\u00fcche. \n Ulmer Verlag, Stuttgart, 3. Auflage, 45-58 \n \nSch\u00e4r, R. (1991) \n Ursachen von Verhaltensproblemen bei Katzen \n Dtsch. Tier\u00e4rztl. Wschr. 98, 13-15 \n \nSch\u00e4r, R. (1996) \n Some frequent occuring behavioral disorders of cats \n Hungarian Vet. J. 51, 664-665 \n \nSch\u00e4r, R. (1997) \n Ethologie der Katze: Grundlagen und Bedeutung f\u00fcr die Versuchstierhaltung. \n Der Tierschutzbeauftragte 1, 10-13 \n \nSch\u00e4r, R. (1998a) \n Ethologie der Katze: Grundlagen und Bedeutung f\u00fcr den Tierarzt \n Kleintiermedizin 6, 7-8 \n \nSch\u00e4r, R. (1998b) \n Verhaltenstherapie bei der Katze \n Kleintiermedizin 6, 9-11 \n \nSchalm, O. W. (1971) \n Feline infectious peritonitis. Vital statistics and laboratory findings \n Calif. Vet. 25, 6-9 \n \nSchmidt, V. (1998) \n Reihe FIP: Typische Augenbefunde \n Kleintier Konkret 2, 21-22 Literaturverzeichnis 107 \nSchmitz, J. (1990) \n M\u00f6glichkeiten besserer Haltung von Versuchstieren - Empfehlungen aus \n ethologischer Sicht. \n Brosch\u00fcre Hessisches Sozialministerium, Wiesbaden \n \nSchroo, S. (1994) \n Kompetitiver ELISA zum Nachweis von l\u00f6slichen Immunkomplexen in Seren und  Exsudaten FIP-verd\u00e4chtiger Katzen \n Vet. Med. Diss., Gie\u00dfen \n \nSchwendenwein, I., S. Koelbl (1991) \n Evaluation of a commercially available CELISA testkit for the detection of antibodies  against feline infectious peritonitis \n Wiener Tier\u00e4rztl. Mschr. 78, 177-180 \n \nScott, F. W. (1987) \n Immunization against feline coronaviruses. \n Adv. Exp. Med. Biol. 218, 569-576 \n \nScott, F. W., W. V. Corapi, C. W. Olsen (1992) \n Evaluation of the safety and efficacy of Primucell FIPV Vaccine \n Feline Health Topic 7, 6-8 \n \nScott, F. W. (1993) \n Feline infectious peritonitis: Transmission and epidemiology \n In: Feline Infekti\u00f6se Peritonitis, Wissenschaftliche Basisinformation, SmithKline  Beecham, M\u00fcnchen, 7-12 \n \nScott, F. W., W. V. Corapi, C. W. Olsen (1995a) \n Independent evaluation of a modified live FIPV vaccine under experimental conditions  (cornell experience) \n Feline Pract. 23, 74-76 \n \nScott, F. W., W. V. Corapi, C. W. Olsen (1995b) \n Antibody-dependent enhancement of feline infectious peritonitis virus infection \n Feline Pract. 23, 77-79 \n \nShell, L. G. (1997) \n Feline infectious peritonitis viral meningoencephalomyelitis \n Feline Pract. 25, 24 \n \nSiddell, S., H. Wege, V. Ter Meulen (1982) \n The structure and replication of coronaviruses \n Curr. Top. Microbiol. Immunol. 99, 131-161 \n \nSiddell, S. G., R. Anderson, D. Cavanagh, K. Fujiwara, H. D. Klenk, M. R. Macnaughton, M.  Pensaert, S. A. Stohlman, L Sturman, B. A. M. van der Zeijst (1983) \n Coronaviridae \n Intervirology 20, 181-189 Literaturverzeichnis 108 \nSlauson, D. O., J. P. Finn (1972) \n Meningoencephalitis and panophthalmitis in feline infectious peritonitis \n J. Am. Vet. Med. Assoc. 160, 729-734 \n \nSnijder, E. J., J. A. Den Boon, M. C. Horzinek, W. J. M. Spaan (1991) \n Comparison of the genome organization of toro- and coronaviruses: evidence for \n two nonhomologous RNA recombination events during Berne virus evolution \n Virology 180, 448-452 \n \nSparkes, A. H., T. J. Gruffydd-Jones, D. A. Harbour, C. D. Hopper, T. N. Smerdon (1990) \n Blood tests for FIP \n Vet. Rec. 126, 225 \n \nSparkes, A. H., T. J. Gruffydd-Jones, P. E. Howard, D. A. Harbour (1992) \n Coronavirus serology in healthy pedigree cats \n Vet. Rec.11, 35-36 \n \nSparkes, A. H., T. J. Gruffydd-Jones, D. A. Harbour (1994) \n An appraisal of the value of laboratory tests in diagnosis of feline infectious peritonitis \n J. Am. Anim. Hospit. Assoc. 30, 345-350 \n \nStoddart, C. A., J. E. Barlough, F. W. Scott (1984) \n Experimental studies of a coronavirus and coronavirus-like agent in a barrier  maintained feline breeding colony \n Arch. Virol. 79, 85-94 \n \nStoddart, C. A., J. E. Barlough, C. A. Baldwin, F. W. Scott (1988a) \n Attempted immunization of cats against feline infectious peritonitis using canine  coronavirus \n Res. Vet. Sci. 45, 383-388 \n \nStoddart, M. E., Gaskell, R. M., Harbour, D. A., Gaskell, C. J. (1988b) \n Virus shedding and immune response in cats inoculated with cell culture-adapted  feline infectious peritonitis virus \n Vet. Microbiol. 16, 145-158 \n \nStoddart, C. A, F. W. Scott (1989) \n Intrinsic resistance of feline peritoneal macrophages to coronavirus infection correlates  with in vivo virulence \n J. Virol. 63, 436-440 \n \nSt\u00fcnzi, H., V. Grevel (1973) \n Die ansteckende fibrin\u00f6se Peritonitis der Katze. Vorl\u00e4ufige Mitteilungen \u00fcber die  ersten spontanen F\u00e4lle in der Schweiz \n Schw. Arch. Tierheilk. 115, 579-586 \n \nSuter, P. F., C. Rohrer, H. Lutz (1993) \n Zur Problematik der FIPV-Infektion \n Kleintierpraxis 38, 373-378 Literaturverzeichnis 109 \nTamke, P. G., M. G. Petersen, A. E. Dietze, A. de Lahunta, (1988) \n Acquired hydrocephalus and hydromyelia in a cat with feline infectious peritonitis: a \n case report and brief review \n Can. Vet. J. 29, 997-1000 \n \nTammer, R., O. Evensen, H. Lutz, M. Reinacher (1995) \n Immunohistological demonstration of feline infectious peritonitis virus antigen in  paraffin-embedded tissues using feline ascites or murine monoclonal antibodies. \n Vet. Immunol. Immunopathol. 49, 177-182 \n \nTammer, R. (1996) \n Immunhistologischer Nachweis von Antigen des Virus der Felinen Infekti\u00f6sen  Peritonitis bei Sektionskatzen. \n Vet. Med. Diss., Gie\u00dfen, 73-76 \n \nTheobald, J. (1978) \n Felidae \n In: Fowler, M. E. (ed): Zoo and wild animal medicine, W. B. Saunders Co.,  Philadelphia, 650-667 \n \nTimoney, J. F. (1976) \n Feline infectious peritonitis \n Vet. Clin. North Am. 6, 391-394 \n \nToma, B., C. Duret, G. Chappius, B. Pellerin (1979) \n Echec de l\u00b4immunisation contre la peritonite infectieuse feline par infection de virus de  la gastroenterite transmissible du porc \n Rec. Med. Vet. 155, 799 \n \nToolan, D. P. (1993) \n Peritoneal form of feline infectious peritonitis (FIP) \n Irish Vet. J. 46, 102-103 \n \nTroy, G. C., M. J. Becker, R. T. Greene (1996) \n Proficiency testing of selected antigen and antibody tests for use in dogs and cats \n J. Am. Vet. Med .Assoc. 209, 914-917 \n \nTuch, K., K. H. Witte, H. W\u00fcller (1974) \n Feststellung der Felinen Infekti\u00f6sen Peritonitis (FIP) bei Hauskatzen und Leoparden in  Deutschland \n Zbl. Vet. Med. B 21, 426-441 \n \nTupper, G. T., J. F. Evermann, R. G. Russel, M. E. Thouless (1987) \n Antigenic and biological diversity of feline coronaviruses: Feline infectious peritonitis  and feline enteritis virus \n Arch. Virol. 96, 29-38 \n \nVacirca, G., F. Mantelli, E. Ferro, P. G. Brambilla (1989) \n Pericardial effusion with feline infectious peritonitis \n Comp. Anim. Pract. 19, 25-27 Literaturverzeichnis 110 \nVanden Bossche, G. (1990a) \n Zur epizootiologischen Interpretation der Coronavirus-Serologie bei gesunden und \n non-FIP (Feline Infekti\u00f6se Peritonitis) kranken Katzen mittels der indirekten  Immunfluoreszenz (IF) \n Kleintierpraxis 35, 189-191 \n \nVanden Bossche, G. (1990b) \n Zur Serodiagnose der Feline Infekti\u00f6se Peritonitis (FIP) mittels eines indirekten  Immunfluoreszenz-Tests (IFT): Eine statistische Bewertung der diagnostischen  Treffsicherheit \n Kleintierpraxis 35, 201-213 \n \nVennema, H. (1999) \n Genetic drift and genetic shift during feline coronavirus evolution \n Vet. Microbiol. 69, 139-141 \n \nVennema, H., R. de Groot, D. A. Harbour, M. Dalderup, T. Gruffydd-Jones, M. C. Horzinek,  W. J. M. Spaan (1990) \n Early death after feline infectious peritonitis virus challenge due to recombinant  vaccinia virus immunization \n J. Virol. 64, 1407-1409 \n \nVennema, H., R. de Groot, D. A. Harbour, M. C. Horzinek, W. J. M. Spaan (1991) \n Primary structure of the membrane and nucleocapsid protein genes of feline infectious  peritonitis virus and immunogenicity of recombinant vaccinia viruses in kittens \n Virology 181, 327-335 \n \nVennema, H., A. Poland, K Floyd Hawkins, N. C. Pedersen (1995) \n A comparison of the genomes of FECVs and FIPVs and what they tell us about the  relationships between feline coronaviruses and their evolution \n Feline Pract. 23, 40-44 \n \nVennema, H., A. Poland, J. Foley, N. C. Pedersen (1998) \n Feline infectious peritonitis viruses arise by mutation from endemic feline enteritic  coronaviruses \n Virology 243, 150-157 \n \nViefhues, G., O. Uysal, A. Heusinger (1990) \n Der Nachweis von Antik\u00f6rpern gegen das Virus der Felinen Infekti\u00f6sen Peritonitis \n (FIPV) mit dem Diasystem\u2122FIP Test Kit im Vergleich zur direkten  Immunfluoreszenz \n Tier\u00e4rztl. Umschau 45, 490-492 \n \nVieler, E., Herbst, W., (1995) \n  Detection of viruses in faeces of diarrhoeic dogs by electron microscopy. \n  Tier\u00e4rztl. Praxis 23, 66-69 \n \nWallach, J. D., W. J. Boever (1983) \n Diseases of exotic animals. Medical and surgical managment \n Saunders Verlag Philadelphia, 369-370 Literaturverzeichnis 111 \nWalter, J. H., R. Rudolph (1989) \n Untersuchungen zur H\u00e4ufigkeit und Pathogenese der Feline Infekti\u00f6se Peritonitis \n (FIP) \n Dtsch. tier\u00e4rztl. Wschr. 96, 194-201 \n \nWard, J. M. (1970) \n Morphogenesis of a virus in cats with experimental feline infectious peritonitis \n Virology 41, 191-194 \n \nWard, J. M., R. J. Munn, D. H. Gribble, D. L. Dungworth (1968) \n An observation of feline infectious peritonitis \n Vet. Rec. 83, 416-417 \n \nWeber, M. (2000) \n Pathologische und immunhistologische Untersuchungen am Auge von Katzen mit  Feliner Infekti\u00f6ser Peritonitis \n Vet. Med. Diss., Leipzig \n \nWeiss, R. C., F. W. Scott (1980) \n Laboratory diagnosis of feline infectious peritonitis \n Feline Pract. 10, 16-22 \n \nWeiss, R. C., F. W. Scott (1981a) \n Pathogenesis of feline infectious peritonitis. Nature and development of viremia \n Am. J. Vet. Res. 42, 382-390 \n \nWeiss, R. C., F. W. Scott (1981b) \n Antibody-mediated enhancement of disease in feline infectious peritonitis:  comparisons with dengue-haemorrhagic-fever \n Comp. Immunol. Microbiol. Infect. Diseases 4, 175-189 \n \nWeiss, R. C. und T. Oostrom-Ram (1989) \n Inhibitory effects of ribavirin alone or combined with human alpha interferon on  feline infectious peritonitis virus replication in vitro \n Vet. Microbiol. 20, 255-265 \n \nWeiss, R. C. (1991) \n The diagnosis and clinical managment of feline infectious peritonitis \n Vet. Med. 86, 308-319 \n \nWeiss, R. C., N. R. Cox, M. L. Martinez (1993) \n Evaluation of free or liposome-encapsulated ribavirin for antiviral therapy of  experimentally induced feline infectious peritonitis  \n Res. Vet. Sci. 55, 162-172 \n \nWeiss, R. C. (1995) \n Treatment of feline infectious peritonitis with immunomodulating agents and antiviral  drugs: A review \n Feline Pract. 23, 103-106 Literaturverzeichnis 112 \nWisser, J. (1984) \n Feline Infekti\u00f6se Peritonitis - Sektionsbild bei einer L\u00f6win (Panthera leo) \n Verhandlungsbericht des Internationalen Symposiums \u00fcber Erkrankungen der Zootiere \n 26, 341-348 \n \nWitte, K. H., K. Tuch, H. Dubenkropp, C. Walter (1977) \n Untersuchungen \u00fcber die Antigenverwandtschaft der Viren der Felinen Infekti\u00f6sen  Peritonitis (FIP) und der Transmissiblen Gastroenteritis (TGE) des Schweines \n Berl. M\u00fcnch. Tier\u00e4rztl. Wschr. 90, 396-401 \n \nWolf, A. (1997) \n Feline infectious peritonitis, Part I \n Feline Pract. 25, 26-29 \n \nWolfe, L. G., R. A. Griesemer (1966) \n Feline infectious peritonitis \n Path. Vet. 3, 255-270 \n \nWolfe, L. G., R. A. Griesemer (1971) \n Feline infectious peritonitis: Review of gross and histopathologic lesions \n J. Am. Vet. Med. Assoc. 158, 987-993 \n \nWoods, R. D., N. C. Pedersen (1979) \n Cross-protection studies between feline infectious peritonitis and porcine  transmissible gastroenteritis viruses \n Vet. Microbiol. 4, 11-16 \n \nYaling, Z., J. Ederveen, H. Egberink, M. Pensaert, M. C. Horzinek (1988) \n Porcine epidemic diarrhea virus (CV 777) and feline infectious peritonitis virus  (FIPV) are antigenically related \n Arch. Virol. 102, 63-71 \n \nZook, B. C., N. W King, R. L Robinson, H. L. McCombs (1968) \n Ultrastructural evidence for the viral etiology of feline infectious peritonitis \n Path. Vet. 5, 91-95 Anhang 113 \n9.  Anhang \n \n9.1  Abbildungen \n \n  Abb. 1: Geschlechtsverteilung der SPF-Tiere nach randomisierter  \n    Einteilung in T1 und T2 ( 3.2.1; S. 35) \n  Abb. 2: FCoV und Glycerinaldehyd-3-Phosphat-Dehydrogenase  \n    (GAPDH) Primer ( 3.5.3.5; S. 52) \n  Abb. 3: Gewichtsentwicklung aller SPF-Katzen im Versuchzeitraum \n    ( 4.1; S. 58) \n  Abb. 4: Chronologische \u00dcbersicht der Todesf\u00e4lle (aller Ursachen) im \n    Versuchszeitraum ( 4.5; S. 60) \n  Abb. 5: chronologische \u00dcbersicht \u00fcber das Auftreten der einzelnen  \n    Formen der FIP bei den SPF-Katzen ( 4.6; S. 62) \n  Abb. 6: Geschlechtsverteilung der an FIP erkrankten SPF-Tiere \n    ( 4.6; S. 62) \n  Abb. 7: Verteilung der FIP-Formen bei den 23 aufgetretenen F\u00e4llen  \n    (alle Gruppen) im Versuchszeitraum ( 4.8; S. 64) \n  Abb.  8: H\u00e4ufigkeit von Katzenschnupfen bei den 22 an FIP   \n    erkrankten SPF-Katzen (4.9; S. 67) \n  Abb. 9: H\u00e4ufigkeit von Katzenschnupfen bei den 18 nicht an FIP  \n    erkranken Katzen (4.9; S. 67) Anhang 114 \nAbb. 10, 11: \neffusive Form  der FIP bei \neiner SPF-Katze m it \nausgepr\u00e4gter Aszitesbildung \nohne Beeitr\u00e4chtigung des \nAllgem einbefindens \nAbb. 12: \nVergleich SPF-FIP-Katze \nmit Aszites m it SPF-Katze \nohne Sy mptomatik                    \n \n \n \n \n \n \n \n       \n  Anhang 115 \nAbb. 13: Vergleich SPF-FIP-Katze m it Aszites m it SPF-Katze ohne Sym ptomatik \nAbb. 14, 15: ungest\u00f6rtes Fre\u00df- und Trinkverhalten bei SPF-FIP-Katzen m it Aszites \n                          \n  \n                          \n  \n                          \n   Anhang 116 \nAbb. 16:  SPF-Katze (Prim ucell\u00ae-Gruppe, H 6 1453) m it Symptomatik der nichteffusiven \n  FIP \nAbb. 17: gleiche Katze wie Abb. 16 m it Nickhautvorfall und Augenver\u00e4nderungen \n    \n  \n \nAbb. 18:  gleiche Katze wie Abb. 16 m it frei schwebenden Fibrinpr\u00e4zipitaten in der  \n  vorderen Augenkam mer \nAbb. 19: gleiche Katze wie Abb. 16 nach \u00fcberstandener FIP-Sy mptomatik m it  \n  bleibendem  Irishinterfl\u00e4chenpigm entstrang \n     \n  Anhang 117 \nAbb. 20: SPF-Katze (Prim ucell\u00ae-Gruppe, H 6 1466) vor der FIP-Erkrankung \n                        \n  \nAbb. 21: gleiche Katze wie Abb. 20 m it Augenver\u00e4nderungen \n                        \n  \nAbb. 22: gleiche Katze wie Abb. 20 m it Irisverf\u00e4rbungen und streuenden    \n  Gef\u00e4\u00dfinjektionen \n                        \nAnhang 118 \nAbb. 23: SPF-Katze (Kontroll-Gruppe, H 6 1448) m it Anisokorie \n                     \n  \n \n \nAbb. 24: gleiche Katze wie Abb. 23 m it Rubiosis iridis \n                     \n  Anhang 119 \nAbb. 25: gleiche Katze wie Abb. 23 m it Neovaskularisationen \n                    \n  \n \n \nAbb. 26: gleiche Katze wie Abb. 23: Fundus: Hy poreflexien, subretinale Infiltrate \n                    \n  \n Anhang: Ak-Titer- und ELISA-Verl\u00e4ufe 120 \n9.2  Diagramme \n  Titerverl\u00e4ufe CoV-Ak und ELISA (> 25% Hem mung = positiv) \n  FIP-Vakzine: 1. Im pfung 7. Woche, 2. Im pfung (Boosterung) 10. Woche \n  Zusam mensetzen m it Tierheim katzen 12. Woche \nTierheimkatze Nr. 41\nzeitweise Enteritis, Tier am Versuchsende vermittelt, derzeit wohlauf0 12 223 24 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\n \nTierheimkatze Nr. 42\nniemals Symptomatik, Tier am Versuchsende vermittelt0 122 23 24 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\n \nTierheimkatze Nr. 43\nniemals Symptomatik, Tier am Versuchsende vermittelt0 122 23 2 4202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISAAnhang: Ak-Titer- und ELISA-Verl\u00e4ufe 121 \nTierheimkatze Nr. 44\nTier verendet, Diagnose: Coronavirus-Enteritis01 2 22 32 4202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\n \nTierheimkatze Nr. 45\nTier euthanasiert, Diagnose: FIP0 122 23 24 201234\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\nTierheimkatze Nr. 46\nrapider Krankheitsverlauf, Tier verendet, Diagnose: FIP01 2 22 32 4201234567\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA \n \n Anhang: Ak-Titer- und ELISA-Verl\u00e4ufe 122 \nTierheimkatze Nr. 47\nzeitweise Symptomatik, Tier am Versuchsende vermittelt, derzeit wohlauf0 12 223 24 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\n \nTierheimkatze Nr. 48\nniemals Symptomatik, Tier am Versuchsende vermittelt0 122 2 324 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\nTierheimkatze Nr. 49\nniemals Symptomatik, Tier am Versuchsende vermittelt0 122 23 2 4202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA \n Anhang: Ak-Titer- und ELISA-Verl\u00e4ufe 123 \nTierheimkatze Nr. 50\nkeine Symptomatik, Tier am Versuchsende vermittelt0 122 23 24 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\n \nTierheimkatze Nr. 51\nniemals Symptomatik, Tier am Versuchsende vermittelt0 122 2 324 201234\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\nTierheimkatze Nr. 52\nkeine Symptomatik, Tier am Versuchsende vermittelt0 122 2 324 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA \n \n Anhang: Ak-Titer- und ELISA-Verl\u00e4ufe 124 \nSPF-\"Primucell\u00ae\"-Katze Nr. H6 1408\nTier verendet, Diagnose: keine FIP, Pneumonie0 122 2 324 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\n \nSPF-\"Primucell\u00ae\"-Katze Nr. H6 1451\nTier euthanasiert, Diagnose: FIP0 122 2 324 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\nSPF-\"Primucell\u00ae\"-Katze Nr. H6 1410\nTier verendet, Diagnose: FIP0 122 23 24 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA \n \n Anhang: Ak-Titer- und ELISA-Verl\u00e4ufe 125 \nSPF-\"Primucell\u00ae\"-Katze Nr. H6 1411\nTier euthanasiert, Diagnose: FIP0 12 223 24 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\n \nSPF-\"Primucell\u00ae\"-Katze Nr. H6 1400\nTier euthanasiert, Diagnose: FIP0 122 2 324 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\nSPF-\"Primucell\u00ae\"-Katze Nr. 1446\nTier verendet, Diagnose: FIP0 122 23 2 4202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA \n \n Anhang: Ak-Titer- und ELISA-Verl\u00e4ufe 126 \nSPF-\"Primucell\u00ae\"-Katze Nr. 1464\nTier euthanasiert, Diagnose: FIP01 2 22 32 4202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\n \nSPF-\"Primucell\u00ae\"-Katze Nr. 1434\nTier verendet, Diagnose: FIP0 122 23 24 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\nSPF-\"Primucell\u00ae\"-Katze Nr. 1395\nTier verendet, Diagnose: FIP0 12 223 24 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA Anhang: Ak-Titer- und ELISA-Verl\u00e4ufe 127 \nSPF-\"Primucell\u00ae\"-Katze Nr. 1404\nTier euthanasiert, Diagnose: FIP0 122 2 324 202004006008001000\n0255075100ELISA\nAk-Titer ELISA\n \nSPF-\"Primucell\u00ae\"-Katze Nr. H6 1440\nTod bei Narkosezwischenfall (ophthalmologische OP), keine FIP 0 122 23 24 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\nSPF-\"Primucell\u00ae\"-Katze Nr. H6 1450\n0 122 23 24 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA \nTier euthanasiert, Diagnose: FIPAnhang: Ak-Titer- und ELISA-Verl\u00e4ufe 128 \nSPF-\"Primucell\u00ae\"-Katze Nr. H6 1466\nTier euthanasiert, Diagnose: FIP0 12 223 24 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\n \nSPF-\"Primucell\u00ae\"-Katze Nr. 1444\nTier euthanasiert, Diagnose: FIP0 122 2 324 201234\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\nSPF-\"Primucell\u00ae\"-Katze Nr. H6 1443\nTier am Versuchsende euthanasiert, keine FIP0 122 23 24 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA Anhang: Ak-Titer- und ELISA-Verl\u00e4ufe 129 \nSPF-\"Primucell\u00ae\"-Katze Nr. H6 1436 \nTier am Versuchsende euthanasiert, keine FIP0 122 23 2 4202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\n \nSPF-\"Primucell\u00ae\"-Katze Nr. H6 1449\nTier am Versuchsende euthanasiert, keine FIP0 122 23 24 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\nSPF-\"Primucell\u00ae\"-Katze Nr. H6 1427\n0 12 223 24 201234\n0255075100ELISA (% Hemmung) \nTier am Versuchsende euthanasiert, keine FIPAk-Titer ELISAAnhang: Ak-Titer- und ELISA-Verl\u00e4ufe 130 \nSPF-\"Primucell\u00ae\"-Katze Nr. H6 1433\nTier am Versuchsende euthanasiert, keine FIP0 122 23 24 201234\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\n \nSPF-\"Primucell\u00ae\"-Katze Nr. H6 1453\nZNS), Diagnose: keine FIP0 122 23 24 201234\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\nSPF-Kontroll-Katze Nr. H6 1402\nTier euthanasiert, Diagnose: FIP0 122 2 324 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA \n Anhang: Ak-Titer- und ELISA-Verl\u00e4ufe 131 \nSPF-Kontroll-Katze Nr. H6 1452\nTier euthanasiert, Diagnose: FIP0 122 23 24 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\n \nSPF-Kontroll-Katze Nr. H6 1401\nTier verendet, Diagnose: FIP0 122 2 324 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\n \nSPF-Kontroll-Katze Nr. H6 1397\nTier verendet, Diagnose: FIP0 122 2 324 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISAAnhang: Ak-Titer- und ELISA-Verl\u00e4ufe 132 \nSPF-Kontroll-Katze Nr. H6 1391\nTier verendet, Diagnose: FIP0 12 223 24 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\n \nSPF-Kontroll-Katze Nr. H6 1437\nTier verendet, Diagnose: FIP0 122 23 24 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\nSPF-Kontroll-Katze Nr. H6 1430\n01 2 22 32 4202004006008001000\n0255075100ELISA (% Hemmung) \nTier pl\u00f6tzlich verendet, Diagnose: keine FIP, Pleuritis (Nocardiose)Ak-Titer ELISAAnhang: Ak-Titer- und ELISA-Verl\u00e4ufe 133 \nSPF-Kontroll-Katze Nr. H6 1399\nTier verendet, Diagnose: FIP01 2 22 32 4201234\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\n \nSPF-Kontroll-Katze Nr. H6 1409\nTier verendet, Diagnose: FIP0 122 23 24 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\nSPF-Kontroll-Katze Nr. H6 1431\nTier euthanasiert, Diagnose: FIP0 122 23 24 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA Anhang: Ak-Titer- und ELISA-Verl\u00e4ufe 134 \nSPF-Kontroll-Katze Nr. 1424\nTier euthanasiert, Diagnose: FIP01 2 22 32 4201234\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\n \nSPF-Kontroll-Katze Nr. 1405\nTier am Versuchsende euthanasiert, keine FIP0 122 23 24 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\nSPF-Kontroll-Katze Nr. H6 1441\n0 12 223 24 202004006008001000\n0255075100ELISA (% Hemmung) \nTier am Versuchsende euthanasiert, keine FIPAk-Titer ELISAAnhang: Ak-Titer- und ELISA-Verl\u00e4ufe 135 \nSPF-Kontroll-Katze Nr. H6 1448\n0 122 23 2 4202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\n \nSPF-Kontroll-Katze Nr. H6 1456\nTier am Versuchsende euthanasiert, keine FIP0 122 2 324 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\nSPF-Kontroll-Katze Nr. H6 1432\n0 122 23 2 4202004006008001000\n0255075100ELISA (% Hemmung)\nTier am Versuchsende euthanasiert, keine FIPAk-Titer ELISAAnhang: Ak-Titer- und ELISA-Verl\u00e4ufe 136 \nSPF-Kontroll-Katze Nr. H6 1425\nTier am Versuchsende euthanasiert, keine FIP0 12 223 24 201234\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\n \nSPF-Kontroll-Katze Nr. H6 1442\nTier am Versuchsende euthanasiert, keine FIP0 12 223 24 201234\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA\nSPF-Kontroll-Katze Nr. H6 1455\nTier am Versuchsende euthanasiert, keine FIP0 122 23 24 202004006008001000\n0255075100ELISA (% Hemmung)\nAk-Titer ELISA \n Anhang 137 \n9.3  L\u00f6sungen, Puffer und Bezugsquellen \n \n9.3.1  ELISA \n \nF\u00fcr den ELISA ben\u00f6tigte L\u00f6sungen, Seren und Antik\u00f6rper \n \nCoatingBuffer  (f\u00fcr die Verd\u00fcnnung des FIP-Antigens; pH 9,4) \nNatriumtetraborat x 10 H 2O      38,12 g \nAqua bidest.           ad 1000,00 ml \nDie L\u00f6sung ist mehrere Wochen bei Raumtemperatur haltbar. \n \nPr\u00e4zipitationsreagenz (zur Ausf\u00e4llung der Immunkomplexe, pH 8,3-8,5) \nPolyethylenglykol (PEG; MW 8000)     25,00 g \nBors\u00e4ure        6,18 g \nNatriumtetraborat x 10       9,54 g \nNaCl         0,49 g \nAqua bidest.         ad 1000,00 ml \n \nPhosphate-buffered saline (PBS, pH 7,2) \nNaCl         7,50 g \nKCl         0,20 g \nKH 2PO 4         0,20 g \nNa2HPO 4 x 2 H 2O       1,40 g \nAqua bidest.         ad 1000,00 ml \n \nBlockierungsl\u00f6sung (pH 7,1-7,2) \nPolyvinyl-Alkohol (PVA; MW 13000-23000)    10,00 g \nPBS                 1000,00 ml \nZum L\u00f6sen des PVA empfiehlt sich eine konstante Erw\u00e4rmung auf einem beheizbaren \nMagnetr\u00fchrer. Die L\u00f6sung wird anschlie\u00dfend durch einen 0,45 \u00b5m Filter filtriert. Anhang 138 \nVerd\u00fcnnungsl\u00f6sung \n(Verd\u00fcnnung von pr\u00e4zipierten Serum- bzw. Exsudatproben und Antik\u00f6rperl\u00f6sungen) \nBlockierungsl\u00f6sung       950 ml \nFetales K\u00e4lberserum (FKS)      50 ml \n \nWaschl\u00f6sung (10 x) \nNaCl         75,00 g \nKCl         2,00 g \nKH 2PO 4         2,00 g \nNa2HPO 4 x 2 H 2O       14,40 g \nTween 20        5,00 g \nAqua bidest         ad 1000,00 ml \nVerd\u00fcnnte Waschl\u00f6sung sollte einen pH-Wert von 7,2 aufweisen. \n \nFIPV-Antigen  (FIP-Virus gereinigt von W. Herbst, Gie\u00dfen)  \nVerd\u00fcnnung 1:300 \n \nPositiv-Kontrollserum \nDie Positiv-Kontrollseren wurden von Katzen gewonnen, die an FIP erkrankt waren \n(Hemmung > 25 %) und wurde vom Institut f\u00fcr Veterin\u00e4r-Pathologie der Universit\u00e4t Leipzig \nzur Verf\u00fcgung gestellt. \n \nNegativ-Kontrollserum  \nAls Negativ-Kontrollserum diente gepooltes Pferdeserum. \n \nMonoklonaler Antik\u00f6rper  (mAk) gerichtet gegen das E1-Protein des FIPV (IgG1) \nDer monoklonale Antik\u00f6rper sollte bei \u2264 -20\u00b0C gelagert werden. \n \nPeroxidase-gekoppeltes Ziege anti Maus-IgG  \nDas Enzymkonjugat sollte bei \u2264 -20\u00b0C gelagert werden. Anhang 139 \nABTS/H 2O2-L\u00f6sung  (Peroxidase-Substrat f\u00fcr ELISA) \nZitronens\u00e4ure        1,15 g \nAqua bidest             ad 38,00 ml \nDer pH-Wert wird mittels 40%iger NaOH auf 4,2 eingestellt. \nABTS (2`,2`-Azino-bis-(3-Ethylbenz-Thiazolin-Sulfons\u00e4ure)) 4,4 mg \nUnmittelbar vor Gebrauch 5,6 \u00b5l 30%iges H 2O2 zugeben \n \nStop-L\u00f6sung \nZitronens\u00e4ure        1,92 g \nNaN 3          0,01 g \nAqua bidest        100,00 ml \nTween 20        0,10 ml \n \n9.3.2  PCR \n \n50 x TAE \nTris         242 g \nEssigs\u00e4ure conc. (Eisessig)      57,1 ml \nEDTA         37,2 g \nad 1 l Aqua bidest \nF\u00fcr den Gebrauch 1 : 50 in Aqua bidest verd\u00fcnnen. \n \n9.3.4  Bezugsquellen \n \nAldrich GmbH & Co. KG, Steinheim \nPolyethylenglycol (PEG) MW 8000 \nPolyvinylalkohol (PVA) MW 13000-23000 \n \nAmerican National Can\u2122, Greenwich, C.T. 06836, USA  \nParafilm, Laboratory film \n \nBinding-site, Heidelberg  \nFluoreszein-Isothyocyanat [FITC]-markiertes Anti-Katzen-IgG \n \n Anhang 140 \nCarl Roth KG Chemische Fabrik, Karlsruhe \nRoti-Histol\u00ae \nCitronens\u00e4ure \n \nCustoms Monoclonals International, Sacramento, USA \nMaus anti-felines Coronavirus (clone FCV 3-70) \n \nDIANOVA GmbH, Hamburg \nMaus Peroxidase anti-Peroxidase \nRatte anti-Maus IgG \nTarget unmasking fluid \n \nE. Merck, Darmstadt \nBors\u00e4ure krist., reinst \n \nFluka Feinchemikalien, Neu Ulm  \nHaematoxylin \nKaliumdihydrogenphosphat (KH 2PO 4) \nNaCl \n \nKABE Labortechnik GmbH, N\u00fcmbrecht-Elsenroth \nKabevette\u00ae \n \nLife Science International, Frankfurt/Main  \nCoverplates\u2122 \n \nMenzel Gl\u00e4ser, Braunschweig \nSuperFrost*/Plus-Objekttr\u00e4ger \n \nNunc GmbH, Wiesbaden \nImmunoplatten Anhang 141 \nSARSTEDT AG & Co., N\u00fcmbrecht \nMonovette\u00ae, Multivette\u00ae \n \nServa Feinbiochemica GmbH & Co. KG, Heidelberg  \nTween 20 \n \nSigma-Aldrich Vertriebs GmbH, Deisenhofen \nABTS, kristallin \n \nVogel GmbH & Co KG,Gie\u00dfen \nVogel-Histo-Comp\u00ae Anhang 142 \n9.5  Abk\u00fcrzungen  \n \nADE  Antibody-dependent enhancement \n  (Antik\u00f6rpervermittelte Verst\u00e4rkung) \nAg  Antigen \nAk  Antik\u00f6rper \nBCV  Bovines Coronavirus \nCCV  Canines Coronavirus \nCV  Coronavirus \nDIC  disseminierte intravasale Koagulopathie \nDNase  Desoxyribonuklease \nFECV  Felines enterales Coronavirus \nFeLV  Felines Leuk\u00e4mievirus \nFIV  Felines Immundefizienzvirus \nFIPV  Felines Infekti\u00f6ses Peritonitisvirus \nGCPV  Good Clinical Practice for Conduct of Clinical Trials for Veterinary Medicinal \n  Products \nHCV  Humanes Coronavirus \nHEV  H\u00e4magglutinierendes Enzephalomyelitisvirus \nIBV  Infekti\u00f6se Bronchitisvirus \nMHV  M\u00e4usehepatitisvirus \nRbCV  Kaninchen Coronavirus \nRECV  Enterales Kaninchen Coronavirus \nSDAV  Sialodakryadenitisvirus \nTCV  Turkey Coronavirus \nTGEV  Transmissibles Gastroenteritisvirus des Schweines \nPFU  plaque forming units \n  \n \n \nDanksagung \n \n \nIch danke Herrn Prof. Dr. M. Reinacher f\u00fcr die \u00dcberlassung des Themas, sowie f\u00fcr seine \nBetreuung. Ohne seine grenzenlose Geduld w\u00e4re eine Fertigstellung der Arbeit ganz sicher nicht m\u00f6glich gewesen. \nDer Firma Pfizer danke ich f\u00fcr die M\u00f6glichkeit der Bearbeitung des Projektes und die materielle Unterst\u00fctzung. \nGanz besonderer Dank gilt meinen Eltern, die mir in jeder Phase dieser Zeit R\u00fcckhalt und Unterst\u00fctzung gaben. \nIch danke Frau Dr. Anja Kipar f\u00fcr ihre stetige freundliche Unterst\u00fctzung, ihre konstruktive Kritik und Diskussionsbereitschaft. Ich danke der ganzen Belegschaft der damaligen Lehr- und Versuchsstation Liebertwolkwitz, dem kleinen und dem gro\u00dfen Labor der Veterin\u00e4r-Pathologie der Universit\u00e4t Leipzig, insbesondere Frau Wipplinger. Ich danke aus der Veterin\u00e4r-Pathologie J\u00fcrgen, Kernt, Steffi, Cora, Matthias, Isabell, Falk und all`den anderen nicht namentlich genannten Kollegen und Mitarbeitern. \nIch danke allen meinen Freunden, die mich tatkr\u00e4ftig unterst\u00fctzt haben, auch wenn sie nicht alle namentlich hier erw\u00e4hnt sind. \nIch danke meinem langj\u00e4hrigen Freund und derzeitigen Mitstreiter Stephan ganz herzlich. \nIch bedanke mich f\u00fcr die unkomplizierte Zusammenarbeit beim Tierheim Bitterfeld, besonders bei Herrn Dr. Schreier, beim Tierheim Dresden, hier besonders bei Frau Meyer. \n \nMein herzlichster Dank gilt meiner liebsten Daniela, ihrem Verst\u00e4ndnis, das sie jederzeit f\u00fcr mich hatte und f\u00fcr die Zeit, die sie mir immer und immer wieder f\u00fcr diese Arbeit einr\u00e4umte. \n ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}